P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009598] u d y   O v er vi e  w  - P h as e I/II   D os e  Es c al ati o n  Tri al  ...........................................  [ADDRESS_1009599] t o  F oll o  w- u p ...............................................................................  3 4 4. 3. 3. 6    D e at h   ....................................................................................................  3 4 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009600] ati n .........................................................................................................  3 6   6. 3    R a di ati o n  T h er a p y   ..............................................................................................  3 7 
6. 3. 1    A d v ers e  E v e nts   R e p ort e d   wit h   R a di ati o n  T h er a p y ............................................  3 7   
6. 4    C o n c o  mit a nt  T h er a pi [INVESTIGATOR_014]  a n d   M e di c ati o ns ...........................................................  3 9   6. 5     G ui d eli n es f or   D os e   D el a y  a n d   D os e   M o difi c ati o n ...........................................  4 0  
6. 5. 1    C o n c urr e nt   C h e  m or a di ati o n  a n d   BI  O  3 0 0  Tr e at  m e nt ........................................  4 0   
6. 5. 1. 1    C h e  m ot h er a p y/  BI  O  3 0 0/  R T   D os e   M o difi c ati o n f or   H e  m at ol o gi c 
T o xi cit y  ........................................................................................................  4 0 
6. 5. 1. 2    C h e  m ot h er a p y/  BI  O 3 0 0   D os e   M o difi  c ati o ns f or  N o  n- H e  m at ol o g  ic 
T o xi cit y ........................................................................................................  4 1  
6. 5. 1. 3    C h e  m ot h er a p y/  R T      D os e    M odifi c ati o ns   f or  R T    Fi el d,     N o n-
H e  m at o  l o gi c  T o xi cit y     D urin g C o n c urr e nt  T h e  r a p y  ...................................  [ADDRESS_1009601] ati n   f or N e  u r op at h y  ...............................................................................  4 7 
6. 5. 6   M a n a g e  m e nt  of   Q T c  pr ol o n g ati o n .......................................................................  4 7  
6. 5. 6. 1   A b n or  m al   Q T c i nt er v al  of  ≥  5 0 0   ms e c  or  b as eli n e  c h a n g e  of  >  6 0   ms e c .  4 7  
6. 5. 6. 2   A b n or  m al   Q T c i nt er v al  of  4 8 0- 4 9 9   ms e c .................................................  4 7  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009602] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
6  6. 5. 7   D os e   M o difi c ati o n  d u e t o   G astr oi nt esti n al (  GI)  T o xi cit y ....................................  [ADDRESS_1009603]   Bl o o d   V ol u  m e   R e q uir e  m e nts ................................................................  5 7  
7. 5    S p e ci  m e n   C oll e cti o n  S u  m  m ar y  ..........................................................................  5 8 
7. 6    H e alt h  -R el at e d   Q u alit y  of  Lif e (  H  R  Q  O L)   A n al ysis   ..........................................  [ADDRESS_1009604] e d   A d v ers e  E v e nts...............................................................................  5 9   
8. 2    D o c u  m e nti n g   A d v ers e  E v e nts ............................................................................  5 9   
8. 2. 1    A d v ers e  E v e nt   D at a  El e  m e nts   ............................................................................  5 9 
8. 2. 2    S e v erit y  of   A Es  ..................................................................................................  6 0 
8. 2. 3    Ass ess  m e nt  of   R el ati o ns hi p  of   A E t o  Tr e at  m e nt ...............................................  6 0   8. 2. 4    F oll o  w- u p  of   A Es ...............................................................................................  6 0  
8. 3    R e p orti n g   A Es t o I  R  B ........................................................................................  6 0   
8. 4    E x p e dit e d r e p orti n g  of  a d v ers e  e v e nts ...............................................................  6 1  8. 5    D os e  Li  miti n g  T o xi citi es (  D L Ts)   .......................................................................  [ADDRESS_1009605] u d y ...............................................................................  6 5  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009606] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
7  1 0. 5    Pr ot o c ol  a  m e n d  m e nts .........................................................................................  6 6  
1 0. 6    M o nit ori n g ..........................................................................................................  6 6   
1 0. 6. 1  O n  -sit e   M o nit ori n g .............................................................................................  6 6 
1 0. 6. 2  S af et y   D at a   M o nit ori n g  a n d   R e p orti n g ..............................................................  6 6  1 0. 6. 3  Pr ot o c ol   D e vi ati o ns ............................................................................................  6 7  
1 0. 7    R e c or ds r et e nti o n  ................................................................................................ 6 8  
1 1. 0    R E F E  R E  N  C E S   ...............................................................................................  6 9 
1 2. 0    A P P E  N  DI C E S   ................................................................................................  7 1 
A p p e n di x  1:   C o nt a ct list ...............................................................................................  7 1   
A p p e n di x  2:   Dr u gs t h at   m a y  pr ol o n g   Q T c ...................................................................  8 0   
A p p e n di x  3:   N e  w   Y or k   H e art   Ass o ci ati o n  F u n cti o n al   Cl assifi c ati o n ..........................  8 1   
A p p e n di x  4:   R E  CI S T   Crit eri a .......................................................................................  8 2   A p p e n di x  5:   C T  C  A E  v ersi o n  4. 0 3 ................................................................................  8 3   
A p p e n di x  6:  E  C  O  G  P erf or  m a n c e st at us .......................................................................  8 4   
A p p e n di x  7:   Dr u gs t o  a v oi d   wit h   BI  O  3 0 0   Or al  S us p e nsi o n........................................  8 5   A p p e n di x  8:  S o y   Ri c h  F o o ds ........................................................................................  8 6   
A p p e n di x  9:  S u  m  m ar y  of  bl o o d  dr a  ws f or s af et y,  P  K,  a n d  P  D  ass ess  m e nt .................  8 7   
A p p e n di x  1 0:   Crit eri a f or  P at h ol o gi c   R es p o ns e  of  T ar g et  L esi o ns  a n d  E xt e nt  of 
S ur gi c al   R es e cti o n  ........................................................................................................  8 8 
A p p e n di x  1 1:   R a di ati o n  P n e u  m o nitis  q u a ntifi c ati o n  vi a   C T  c h a n g es ..........................  8 9   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009607] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8  LI S  T   O F  FI  G  U  R  E S   
Fi g ur e  3. 3. 1  S c h e  m a  of  Tri al   D esi g n  ................................................................................  2 9 
Fi g ur e  6. 5. 6. 1   M a n a g e  m e nt  of   Q T c  pr ol o n g ati o n  or  a b n or  miti es  ....................................  4 8 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009608] ei n:   C  m a x  a n d   A  U  C fr o  m  p h ar  m a c o ki n eti c st u di es  ...................  [ADDRESS_1009609] e  m ........................................................................  3 8  T a bl e  6. 3. 1. 2  S u g g esti o ns f or   m a n a g e  m e nt  of r a di ati o n  es o p h a gitis ...............................  3 8   T a bl e  6. 5. 1. 1. 1    D os e   M o difi c ati o n f or   H e  m at ol o gi c  T o xi cit y   .....................................  4 0 T a bl e  6. 5. 1. 2. 1    D os e   M o difi c ati o n f or   N o n-  H e  m at ol o gi c  T o xi cit y   .............................  4 1 T a bl e  6. 5. 1. 3. 1   D os e   M o difi c ati o n f or I n-fi el d  n o n- H e  m at ol o gi c  T o xi cit y   .....................  4 3 T a bl e  6. 5. 2. 1. 1   C o ns oli d ati o n   D os e   M o difi c ati o n f or   H e  m at ol o gi c  T o xi cit y ..................  4 5   T a bl e  6. 5. 2. 2. 1   C o ns oli d ati o n   D os e   M o difi c ati o n f or  n o n- H e  m at ol  o gi c  T o xi cit y  ...........  4 6 T a bl e  7. 1. 1  Ti  m e t o  E v e nt f or  n o n s ur gi c al s u bj e cts ........................................................  4 9  T a bl e  7. 1. 2  Ti  m e t o  E v e nt f or s ur gi c al s u bj e cts ...............................................................  5 0  T a bl e  7. 1. 3   Visit   Wi n d o  w  T a bl e .......................................................................................  5 2  T a bl e  7. 4. 1   Bl o o d  v ol u  m e, s u bj e cts  e nr oll e d f or  P  K  a n d  P  D  a n al ysis .............................  5 7   T a bl e  7. 4. 2   Bl o o d  v ol u  m e, s u bj e cts  e nr oll e d f or  P  D  a n al ysis ..........................................  5 7  T a bl e  7. 5. 1  S p e ci  m e n   C oll e cti o n  S u  m  m ar y .....................................................................  5 8  T a bl e  8. 2. 2. 1   Gr a di n g  a n d   D es cri pti o n  of   A d v ers e  E v e nts ..............................................  6 0  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009610] et e   Bl o o d   C o u nt 
c c c u bi c  c e nti  m et ers  
C F  R C o d e  of  F e d er al   R e g ul ati o ns   
C  G E C o b alt   Gr a y  E q ui v al e nt 
C  m a x M a xi  m u  m ( p e a k)  pl as  m a  c o n c e ntr ati o n   
C  O P  D C hr o ni c   O bstr u cti v e  P ul  m o n ar  y   Dis e as e  
C  R F C as e   R e p ort  F or  m   
C T C o  m p ut e d  T o  m o gr a p h y 
C T  C  A E C o  m  m o n  T er  mi n ol o g y   Crit eri a f or   A d v ers e  E v e nts 
C T  V Cli ni c al  T ar g et   V ol u  m e   
D( d) D a y   
D L T D os e  Li  miti n g  T o xi cit y   
E  C  G El e ctr o c ar di o gr a  m  
E  C  O  G E ast er n   C o o p er ati v e   O n c ol o g y   Gr o u p 
E  R Estr o g e n   R e c e pt or  
F F a hr e n h eit  
F  A  C T -T  OI  F u n cti o n al   Ass ess  m e nt  of   C a n c er  T h er a p y  –  Tri al   O ut c o  m e I n d e x  
F  D  A F o o d  a n d   Dr u g   A d  mi nistr ati o n 
F  D  G Fl u d e o x y gl u c os e 
F E  V 1 F or c e d  E x pir ati o n   V ol u  m e i n  1 s e c o n d 
F  V  C F or c e d   Vit al   C a p a cit y  
G  C P G o o d   Cli ni c al  Pr a cti  c e  
G T  V Gr oss  T u  m or   V ol u  m e 
G y Gr a y   
H( h) H o ur 
H  G  B H e  m o gl o bi n 
HI P  A  A H e alt h I ns ur a n c e  P ort a bilit y  a n d   A c c o u nt a bilit y   A ct 
HI  V H u  m a n I  m  m u n o d efi ci e n c y   Vir us   
H  R  Q  O L H e alt h  -R el at e d   Q u alit y  of  Lif e   
I L I nt erl e u ki n 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009611] or  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009612] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 2  T  m a x  Ti  m e t o   m a xi  m u  m ( p e a k)  pl as  m a  c o n c e ntr ati o n  
T  N F T u  m or   N e cr osis  F a ct or 
U  C S  D  -S  O  B    U ni v ersit y   of     C alif or ni a,    S a n     Di e g o   –   S h ort n ess   of     Br e at h 
Q u esti o n n air e 
U L  N   U p p er  Li  mit  of   N or  m al   
V #   Visit   N u  m b er   
W  B  C   W hit e   Bl o o d   C ell 
β  h  C  G B et a   H u  m a n   C h ori o ni c   G o n a d otr o pi n 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009613] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 3  P  R  O  T  O  C  O  L  S  Y  N  O P S I S  
P r ot o c ol   Titl e  A   P  h as e   I/II    Cli ni c al   St u d y    E v al u ati n g   t h e   S af et y   a n d 
Eff e cti v e n ess   of     BI  O   3 0 0     Or al   S us p e nsi o n   i n   P ati e nts R e c ei vi n g   C h e  m or a di ati o n  T h er a p y f or   N o n  -S  m all   C ell  L u n g C a n c er (  N S  C L C)   
P r ot o c ol   N u  m b e r  C L - [ADDRESS_1009614] u d y  P h as e  P h as e I/II  
N a  m e  of  St u d y   D r u g   BI  O  3 0 0   Or al  S us p e nsi o n ( 3 2 5   m g/  m L) 
I n v esti g ati o n al  Sit es M  ulti pl e  sit es wit hi n t h e   U nit e d  St at es   
St u d y   O bj e cti v es  Pri  m ar y   O bj e cti v e  
T h e   pri  m ar y   o bj e cti v e   is   t o   d es cri b e   a n y   d os e   li  m  iti n g 
t o xi citi es    of    t h e    c o  m bi n ati o n    of     BI  O    3 0 0     wit h c h e  m or a di ot h er a p y i n s u bj e cts   wit h   N S  C L C  a n d t o  d et er  mi n e t h e r e c o  m  m e n d e d  d os e (t h e  o pti  m al  d os e)  of t his c o  m bi n ati o n. 
S e c o n d ar y   O bj e cti v es  
•T o  d es cri b e t h e  o v er all  a d v ers e  e v e nt  pr ofil e  of t h e
c o  m bi n ati o n  of   BI  O  3 0 0  a n d  c h e  m or a di ot h er a p y i nt h e t ar g et  p ati e nt  p o p ul ati o n
•T o  d et er  mi n e t h e  p h ar  m a c o ki n eti cs  of   BI  O  3 0 0  a n dt h e  c h e  m ot h er a p y  c o  m p o n e nts  of t h e r e gi  m e n
( p a clit a x el  a n d  c ar b o pl ati n)   w h e n  gi v e n i n
c o  m bi n ati o n
•T o  d et er  mi n e t h e  p h ar  m a c o d y n a  mi c  eff e cts  of   BI  O3 0 0 i n  c o  m bi n ati o n   wit h  c h e  m or a di ot h er a p y  b y t h ed et er  mi n ati o n  of  c ert ai n s er u  m  pr ot ei n  a n d  c yt o ki n el e v els
•T o r e p ort l o c al  pr o gr essi o n r at e  as  d efi n e d  p erR E  CI S T ( 1. 1)  crit eri a   (s e e   A p p e n di x  4). S ur gi c alp ati e nts  p at h ol o gi c al r es p o ns e   will  b e  e v al u at e d  asd efi n e d i n   A p p e n di x  1 0.
•P ul  m o n ar y f u n cti o n t est ( P F T )  a n d q u alit y  of lif e(Q  O L  ) m e as ur es ( F  A  C T  -T  OI,   U S  C  D -S  O  B,  a n ds  w all o  wi n g  di ar y)
•T o  st u d y t h e  eff e ct  of   BI  O  3 0 0  o n t h e i n ci d e n c e  ofp ul  m o n ar y fi br osis f oll o  wi n g  c h e  m or a di ot h er a p y i nt h e t ar g et  p o p ul ati o n  as  ass ess e d  b y  4  D   C T s c a n ni n g
•T o  d et er  mi n e  o v er all s ur vi v al (  O S)  a n d  pr o gr essi o nfr e e s ur vi v al ( P F S) i n t h e st u d y  p o p ul ati o n
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009615] u d y   D esi g n  T his is  a n  o p e n -l a b el,  si n gl e-ar  m,  as c e n di n g  d os e   P h as e  I/II 
st u d y    of     BI  O    3 0 0    gi v e n    or all y   i n   c o  m bi n ati o n     wit h  p a clit a x el/ c ar b o pl ati n  a n d r a di ot h er a p y i n  s u bj e cts   wit h  st a g e II,  III,   or  I  V    N S  C L C    w h o   ar e   c a n di d at es  f or   c o  m bi n e d c h e  m or a di ot h er a p y. 
P h as e I/II  –  As c e n di n g   D os e   E v al u ati o n  of   BI  O  3 0 0 ( 3  d os e 
l e v els) 
A   mi ni  m u  m   of  [ADDRESS_1009616] er e d  d ail y f or  t h e e ntir e  c o urs e  of  c o n c urr e nt  c h e  m or a di ot h er a p y,  a   mi ni  m u  m  of 6   w e e ks  ;  c h e  m ot h er a p y    will  b e  a d  mi nist er e d    w e e kl y   f or  [ADDRESS_1009617] er e d  d ail y (  M-F) f or a p pr o xi  m at el y  6- 7  w e e ks  .   T h e i niti al  d os e  of  BI  O  3 0 0   will  b e 5 0 0    m g/ d;  s u bs e q u e nt  d os es    will  b e  1 0 0 0    m g/ d  a n d   1 5 0 0 m g/ d  .      P a clit a x el   a n d   c ar b o pl ati n     will   b e   a d  mi nist er e d i ntr a v e n o usl y   w e e kl y,  p a clit a x el i n  a  d os e  of  4 5   m g/  m
[ADDRESS_1009618] ati n  i n  a  d os e  s uffi ci e nt  t o  a c hi e v e  a n    A  U  C   of   2  m g *  mi n/  m L  .    R a di ot h er a p y    will  b e  a d  mi nist er e d  5  d a ys  a w e e k  (  M  -F)  f or  a p pr o xi  m at el y   6- [ADDRESS_1009619] er e d  o n   D a y   1, 
Visit  2, i n   w hi c h   s af et y  d at a ( a d v ers e  e v e nts,  E  C  Gs, r es ults  of s af et y l a b or at or y  d et er  mi n ati o ns),  p h ar  m a c o ki n eti c ( P  K ) a n d p h ar  m a c o d y n a  mi c ( P  D ) d at a   will  b e  c oll e ct e d.   P  K  d at a   will b e  c oll e ct e d  fr o  m  a    mi ni  m u  m  of  si x  ( 6)  st u d y   p arti ci p a nts fr o  m  e a c h st u d y  c o h ort.   Bl o o d s a  m pl es f or  P  D  d at a  c oll e cti o n will  b e  c oll e ct e d  pri or t o  a n d  p ost   BI  O  3 0 0  d osi n g (  2  hr) fr o  m all s u bj e cts i n  e a c h st u d y  c o h ort.  
D a y  [ADDRESS_1009620] er e d    i n    c o  m bi n ati o n    wit h    t h e    c h e  m ot h er a p y c o  m p o n e nts    of   t h e   pr ot o c ol    t h er a p y    ( p a clit a x el    a n d c ar b o pl ati n).     D uri n g   t h e   first    or   s e c o n d   c h e  m ot h er a p y 
i nf usi o n, as  b ef or e,  a d diti o n al s af et y,  P  K  a n d  P  D  d at a   will  b e 
c oll e ct e d.   Bl o o d   s a  m pl es  f or   P  D   d at a   c oll e cti o n    will   b e c oll e ct e d  pri or  t o  a n d  p ost   BI  O  3 0 0  d osi n g  ( 2  hr)  fr o  m  all s u bj e cts i n  e a c h st u d y  c o h ort.  
D a y  1  of   r a di ati o n  t h er a p y  (  R T)  m a y  b e  s c h e d ul e d  at  t h e 
dis cr eti o n   of   t h e   i n v esti g at or   pr o vi d e d   t h e   s u bj e ct   h as c o m pl et e d  a   mi ni  m u  m  of  [ADDRESS_1009621] er e d   d ail y;   p a clit a x el   a n d c ar b o pl ati n   will  b e  a d  mi nist er e d   w e e kl y  a n d r a di ot h er a p y   will  b e  a d  mi nist er e d  d ail y  as  d es cri b e d  a b o v e  u ntil  a t ot al  d os e  of [ADDRESS_1009622] er e d.      D uri n g  t h e   p eri o d   of
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009623] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 5  c o  m bi n e d  BI  O  3 0 0  a n d  c h e  m or a di ot h er a p y  (a p pr o xi  m at el y  6 -
7  w e e ks  ),  a d diti o n al s af et y,  P  K  a n d  P  D  d at a   will  b e  c oll e ct e d w e e kl y.   Tr o u g h   l e v els    f or     BI  O    [ADDRESS_1009624]   pri or  t o  t h at    w e e k’s  c h e  m ot h er a p y tr e at  m e nt  a n d t h at  d a ys’   BI  O  [ADDRESS_1009625] et e d c o n c urr e nt  c h e  m or a di ot h er a p y    wit h  f e  w er  t h a n   3 3  %    D L Ts  attri b ut e d t o   BI  O  [ADDRESS_1009626] u d y,  d at a   will  b e  a n al y z e d fr o  m  all 
c o h orts  t o  d et er  mi n e  t h e  o n c ol o gi c  r es p o ns e,  s af et y  of   BI O 3 0 0,  a n d  a  r e c o  m  m e n d e d   BI  O  3 0 0  d os e.   R e p orti n g  of  l o c al pr o gr essi o n r at e  as  d efi n e d  p er   R E  CI S T ( 1. 1)  crit eri a  will  b e d o n e f or  all  s u bj e cts i n  e a c h  of t h e  c o h orts  (s e e   A p p e n di x  4). S ur gi c al  p ati e nts  p at h ol o gi c al  r es p o ns e   will  b e  e v al u at e d  as d efi n e d i n   A p p e n di x  1 0.
    I n  a d diti o n,  q u alit y  of lif e   will  b e 
ass ess e d  usi n g t h e  F u n cti o n al   Ass ess  m e nt  of   C a n c er  T h er a p y –  Tri al   O ut c o  m e I n d e x ( F  A  C T -T  OI).  T h e r at e  of  F  A  C T -T  OId e cli n e  at  [ADDRESS_1009627] eti o n    will   b e    m e as ur e d.    A d d iti o n al   q u alit y   of  lif em e as ur es   will  als o  b e  us e d, i n cl u di n g  a s  w all o  wi n g  di ar y  a n dt h e   U ni v ersit y  of  C alif or ni a –  S a n   Di e g o (  U  C S  D) s h ort n ess  of
br e at h ( S  O  B)  q u esti o n n air e.  S u bj e cts   will  u n d er g o l o n g -t er  m
f oll o  w-u p  aft er t h e  c o  m pl eti o n  of t h er a p y t o  d et er mi n e  o v er alls ur vi v al (  O S),  pr o gr essi o n fr e e  s ur vi v al ( P F S),  a n d t h e  eff e ctof   BI  O  [ADDRESS_1009628] f ulfill  all  of t h e f oll o  wi n g i n cl usi o n  crit eri a:  
1)  A g e   >  1 82)  Hist ol o gi c al  or  c yt ol o gi c al  c o nfir  m ati o n  of
N S  C L C (s p  ut u  m  c yt ol o g y   will  n ot  b e  a d e q u at ee vi d e n c e  of   m ali g n a n c y)
3)   S u bj e cts  di a g n os e d   wit h st a g e II, III,  or I  V
( oli g o  m et ast ati c) N S  C L  C f or   w h o  m r a di ati o n
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009629] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 6  t h er a p y of  6 0 -7 0  G y  a n d  c o n c urr e nt   w e e kl y   
p a clit a x el/ c ar b o pl ati n  is r e c o  m  m e n d e d  as  p art  of p ot e nti all y  c ur ati v e t h er a p y  eit h er  al o n e  or pr e o p er ati v el y .  
4)  U p t o t hr e e s  m all   ( ≤ 3  c  m  e a c h) l u n g
oli g o  m et ast as es   will  b e  all o  w e d   a n d/ or  o n eoli g o  m et ast asis  at  a n y   ot h er/ or sit e i n t h e  b o d y.T h es e  c o ul d  b e tr e at e d   wit h f o c us e d  S  B  R T( St er e ot a cti c   B o d y   R T).
5)    E  C  O  G  P S  of  0  or  1 (  A p p e n di x  6)6)  F E  V 1:   b est  v al u e  o bt ai n e d  pr e-  or  p ost-
br o n c h o dil at or   m ust  b e  ≥  1. 0  lit ers/s e c o n d or  >5 0  %  pr e di ct e d  v al u e
7)  A d e q u at e  b o n e   m arr o  w r es er v e  b as e d  o n
a.  W  B  C   >  3, 0 0 0/ µ Lb.  A  N  C   >  1, 5 0 0/ µ Lc.  P L T  >  1 0 0, 0 0 0/ µ Ld.  H  G  B   >  9  g/ d L
8)  A d e q u at e  h e p ati c r es er v e  as  e vi d e n c e d   b y
A L T/  A S T   <  3  X   U L  N f or t h e r ef er e n c e l a b  a n dbilir u bi n  <  1. 5   m g/ d L ( e x c e pt i n s u bj e cts   wit hk n o  w n   Gil b ert’s s y n dr o  m e,   w h er e t h e  bilir u bi nm a y  b e   <  2. 0   m g/ d L)
9)    A d e q u at e r e n al f u n cti o n  as  e vi d e n c e d  b y  a s er u  m
cr e ati ni n e  ≤   1. 5 X   U L  N f or t h e r ef er e n c el a b or at or y   O  R  a  c al c ul at e d  cr e ati ni n e  cl e ar a n c e  of≥  6 0   m L/  mi n  b y t h e   C o c kr oft- G a ult  e q u ati o n
1 0)  F e  m al e s u bj e cts  of  c hil d b e ari n g  p ot e nti al   m ust
h a v e  a  n e g ati v e  pr e g n a n c y t est   wit hi n  [ADDRESS_1009630] art  of tr e at  m e nt
1 1)  F e  m al e s u bj e cts  of  c hil d b e ari n g  p ot e nti al  a n d
m al e s u bj e cts   wit h f e  m al e s e x u al  p art n ers  ofc hil d b e ari n g  p ot e nti al   m ust  a gr e e t o  us e  a neff e cti v e   m et h o d  of  c o ntr a c e pti o n ( e. g.,  or alc o ntr a c e pti v es,  d o u bl e- b arri er   m et h o ds s u c h  as  ac o n d o  m  a n d  a  di a p hr a g  m, i ntr a ut eri n e  d e vi c e)d uri n g t h e st u d y  a n d f or  [ADDRESS_1009631] ai n fr o  ms e x u al i nt er c o urs e f or t his ti  m e;  a   w o  m a n  n ot  ofc hil d b e ari n g  p ot e nti al is  o n e   w h o  h as  u n d er g o n ebil at er al  o o p h or e ct o  mi es  or   w h o is  p ost-m e n o p a us al,  d efi n e d  as  n o   m e nstr u al  p eri o ds f or1 2  c o ns e c uti v e   m o nt hs
1 2)   A bilit y t o r e a d  a n d  pr o vi d e   writt e n i nf or  m e d
c o ns e nt
E x cl usi o n   C rit e ri a   S u bj e cts   m a y  n ot  h a v e  a n y  of t h e f oll o  wi n g  e x cl usi o n  crit eri a:  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009632] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 7  1)  W ei g ht l oss  gr e at er t h a n  1 0  % i n  pri or   4   w e e ks
2)   Pri or   m ali g n a n c y i n   w hi c h t h e y r e c ei v e d  a n y
t h or a ci c r a di ot h er a p y u nl ess t h e tr e ati n gp h ysi ci a n  c o nsi d ers it  u nli k el y t o i  m p a ct t h ecli ni c al  o ut c o  m e  of t h e  p ati e nt.
3)   P ati e nts   wit h  c o n c urr e nt i n v asi v e
m ali g n a n c y    ot h er t h a n  n o n-m el a n o  m a s ki n  c a n c eror  c er vi c al i ntr a e pit h eli al  n e o pl asi a   u nl ess t h etr e ati n g  p h ysi ci a n  c o nsi d ers it  u nli k el y t o i  m p a ctt h e  cli ni c al  o ut c o  m e  of t h e  p ati e nt.
4)    A n  a cti v e i nf e cti o n  or   wit h  a f e v er  ≥  3 8. 5°  C
wit hi n  [ADDRESS_1009633] s c h e d ul e d  d a y  of  d osi n g
5)   P o orl y  c o ntr oll e d i nt er c urr e nt ill n ess es, s u c h  as
u n c o ntr oll e d  h y p ert e nsi o n;  p o orl y  c o ntr oll e ddi a b et es   m ellit us,  d efi n e d  as t h e  n e e d f orh os pit ali z ati o n  [ADDRESS_1009634] u d y  e ntr y:u nst a bl e  a n gi n a;  hist or y  of   m y o c ar di al i nf ar cti o n,a c ut e  c or o n a r y s y n dr o  m e;  hist or y  of  c o n g esti v eh e art f ail ur e;  c ar di a c  arr h yt h  mi as r e q uiri n gm e di c al t h er a p y  or  a  p a c e  m a k er  ; c er e br o v as c ul are v e nts .
6)  P at ie nts  wit h  a    pri or t h or a c ot o  m y wit hi n   [ADDRESS_1009635] u d y r e gistr ati o n .
7)    C hr o ni c   O bstr u cti v e  P ul  m o n ar y  Dis e as e
(  C  O  P  D )  e x a c er b ati o n   or  ot h er r es pir at or yill n ess  r e q uiri n g  h os pit ali z ati o n  or  pr e cl u di n gst u d y t h er a p y wit hi n  3 0  d a ys  b ef or e   r e gistr ati o n
8)  P ati e nts  wit h  a n y  of t h e f oll o  wi n g  ar e  n ot
eli gi bl e;
a.  Pr e vi o us  hist or y  of   Q T c  pr ol o n g ati o n   r es ulti n g  fr o  m
m e di c ati o n   t h at   r e q uir e  d    dis c o nti n u ati o n    of   t h atm e di c ati o n;
b.  C o n g e nit al l o n g   Q T  s y n dr o  m e,  or  [ADDRESS_1009636] ai n e d s u d d e n  d e at h  u n d er  4 0  y e ars  of  a g e;
c.  Pr es e n c e  of l eft  b u n dl e  br a n c h  bl o c k ( L  B  B  B);d.  Q T c   wit h   Fri d eri ci a’s  c orr e cti o n t h at is  u n  m e as ur a bl e,
or  ≥  4 8 0   ms e c  o n  s cr e e ni n g   E  C  G.   T h e  a v er a g e   Q T cfr o  m t h e s cr e e ni n g  E  C  G ( c o  m pl et e d i n tri pli c at e) m ust
b e  <  [ADDRESS_1009637] u d y;
e.  S u bj e cts t a ki n g  a n y  c o n c o  mit a nt   m e di c ati o n t h at   m a y
c a us e   Q T c  pr ol o n g ati o n, i n d u c e   T ors a d es  d e  P oi nt es(s e e   A p p e n di x  2)  ar e  n ot  eli gi bl e if   Q T c  ≥ 4 6 0  ms e c.
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009638] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
1 8  9)  P ati e nts  m ust  n ot  h a v e  h a d  a  cli ni c all y si g nifi c a nt
c ar di a c  e v e nt s u c h  as   m y o c ar di al i nf ar cti o n
(  wit hi n  [ADDRESS_1009639] u d y tr e at  m e nt);  u n c o ntr oll e d/s y  m pt o  m ati cc o n g esti v e  h e art f ail ur e ( N e  w   Y or k   H e artAss o ci ati o n (  N  Y  H  A)  cl assifi c ati o n  of  h e artdis e as e ,   Cl ass III  or I  V, s e e   A p p e n di x  3)   wit hi n  6m o nt hs  b ef or e  e ntr y;  or t h e  pr es e n c e  of   a n y  ot h eru n c o ntr oll e d  c ar di o v as c ul ar  c o n diti o ns( h y p ert e nsi o n  or  arr h yt h  mi a,  u nst a bl e  a n gi n ap e ct oris,  or s e v er e  v al v ul ar  h e art  dis e as e,  et c.)t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, i n cr e as est h e ris k  of  v e ntri c ul ar  arr h yt h  mi a.
1 0)  P ati e nts   wit h  a  hist or y  of  arr h yt h  mi a (  m ultif o c al
pr e  m at ur e  v e ntri c ul ar  c o ntr a cti o ns ( P  V  Cs),bi g e mi n y, tri g  e mi n y,  v e ntri c ul ar t a c h y c ar di a,  oru n c o ntr oll e d  atri al fi brill ati o n)   w hi c h iss y  m pt o  m ati c  or r e q uir es tr e at  m e nt (  C T  C  A EGr a d e  3)  or  as y  m pt o  m ati c s ust ai n e d  v e ntri c ul art a c h y c ar di a  ar e  n ot  eli gi bl e.   P ati e nts   wit h  atri alfi brill ati o n wit h   w ell  - c o ntr oll e d  v e ntri c ul ar r at eo n   m e di c ati o n,  ar e  eli gi bl e.
1 1) Ps y c hi atri c  c o n diti o ns, s o ci al sit u ati o ns  or
s u bst a n c e  a b us e t h at  pr e cl u d es t h e  a bilit y  of t h es u bj e ct t o  c o o p er at e   wit h t h e r e q uir e  m e nts  of t h etri al  a n d  pr ot o c ol t h er a p y
1 2)  Gr a d e  2  or  hi g h er  p eri p h er al  n e ur o p at h y1 3)   K n o  w n  hist or y  of   HI  V /  AI  D S,  h e p atitis   B  or   C.
N  ot e,   h o  w e v er, t h at HI  V   or  h e p atitis  t esti n g isn ot  r e q uir e d f or e ntr y  i nt o t his  pr ot o c ol. T h en e e d  t o  e x cl u d e p ati e nts  wit h   AI  D S  ,  h e p atitis   Bor   C  fr o  m t his  pr ot o c ol is n e c ess ar y  b e c a us e  t h etr e at  m e nts i n v ol v e d i n t his  pr ot o c ol m a y    b esi g nifi c a ntl y i  m  m u n os u p pr essi v e.   Pr ot o c ol-s p e cifi c r e q uir e  m e nts m a y   als o  e x cl u d e  i  m  m u n o-c o  m pr o  mis e d  p ati e nts.
1 4)  Pr e g n a n c y   or  w o  m e n    of   c hil d b e ari n g   p ot e nti al
a n d   m e n    w h o    ar e   s e x u all y  a cti v e   a n d   n otwilli n g/ a bl e    t o  us e  m e di c all y    a c c e pt a bl e   f or  msof  c o ntr a c e pti o n;   t his  e x cl usi o n  is  n e c ess ar yb e c a us e  t h e tr e at  m e nt i n v ol v e d i n t his st u d y   m a yb e t er at o g e ni c.
1 5)  W o  m e n   w h o  ar e  br e astf e e di n g  ar e  n ot  eli gi bl e f or
t his st u d y.
N u  m b e r  of  S u bj e cts   U p  t o  t  hirt y -si x  (3 6 )    m al e  a n d  f e  m al e  s u bj e cts    w h o   gi v e i nf or  m e d  c o ns e nt  a n d  f ulfill  t h e  s el e cti o n  crit eri a    will  b e 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009640] et e d 
s e q u e nti all y; e a c h   will  a c cr u e  a   mi ni  m u  m  of  [ADDRESS_1009641] et e d  c o n c urr e nt c h e  m or a di ot h er a p y   wit h  l ess t h a n 3 3  %   D L Ts  attri b ut a bl e t o BI  O  3 0 0   Or al   S us p e nsi o n  . If  o n e  or  f e  w er   D L Ts  o c c ur,  t h e d os e   will  b e  es c al at e d  t o t h e  n e xt  c o h ort  of  6  s u bj e cts.  If  2 D L Ts  o c c ur  ( 2/ 6  s u bj e cts),  a n  a d diti o n al  2  s u bj e cts   will  b e tr e at e d   wit h t h e  s a  m e  d os e. If  n o  a d diti o n al   D L Ts  o c c ur ( 2/ 8 s u bj e cts),  d os e  es c al ati o n   m a y  pr o c e e d.  If  1  a d diti o n al  D L T o c c urs ( 3/ 8  s u bj e cts),  a n  a d diti o n al  2  s u bj e cts   will  b e tr e at e d at t h e  s a  m e  d os e  f or  a t ot al  of  1 0  s u bj e cts.   If  n o  a d diti o n al D L Ts  o c c ur ( 3/ 1 0 s u bj e cts),  d os e es c al ati o n   m a y  pr o c e e d.   T h e st u d y    s p o ns or     will   t e  m p or aril y    c e as e    e nr oll  m e nt    f or e v al u ati o n if i n  a n y  gi v e n  c o h ort  4  s u bj e cts ( o ut  of  a t ot al  of 1 0)  e x p eri e n c e   D L Ts  attri b ut a bl e t o  BI  O  [ADDRESS_1009642] er e d i ntr a v e n o usl y   w e e kl y  d uri n g 
r a di ot h er a p y i n  a d os e  of  4 5   m g/  m
2. 
C ar b o pl ati n   will  b e  a d  mi nist er e d i ntr a v e n o usl y   w e e kl y  d uri n g r a di ot h er a p y  i n  a  d os e  d esi g n e d  t o  a c hi e v e  a n    A  U  C  of  2 m g *  mi n/  m L  . 
R a di ot h er a p y   will  b e  a d  mi nist er e d  5  d a ys  a   w e e k  (  M  -F)  i n 
fr a cti o ns   of   1. 8- 2. [ADDRESS_1009643] a bl e/  m e di c all y i n o p er a bl e  dis e as e will   r e c ei v e  c o ns oli d ati o n  c h e  m ot h er a p y c o nsisti n g  of  a n  a d diti o n al  2  c y cl es  of  p a clit a x el  2 0 0   m g/  m
[ADDRESS_1009644] er e d   t o   a c hi e v e   a n     A  U  C   of   6 m g *  mi n/  m L    o n    D a y   [ADDRESS_1009645] u d y T r e at  m e nt   BI  O    3 0 0  tr e at  m e nt   will   b e   a p pr o xi  m at el y    6- 7  w e e ks  i n d ur ati o n , i n  c o  m bi n ati o n   wit h c h e  m or a di ot h er a p y.    BI  O  3 0 0 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009646] u d y s u bj e cts;  b y  fi n di n gs  o n  p h ysi c al  e x a  m;  b y  d et er  mi n ati o n  of vit al si g ns ( bl o o d  pr ess ur e,  p uls e, t e  m p er at ur e, r es pir at or y r at e a n d   w ei g ht);  b y  fi n di n gs  o n   E  C  Gs;  a n d t h e  r es ults  of  s af et y l a b or at or y  t ests  ( c o  m pl et e  bl o o d  c o u nts,  s er u  m  c h e  mistri es, uri n al ys es).  
P h ar  m a c o ki n eti cs T h e   p h ar  m a c o ki n eti cs   of    BI  O   3 0 0  a n d  t h e  c h e  m ot h er a p y 
a g e nts   t h at    c o  m p os e    pr ot o c ol   t h er a p y    ( p a clit a x el    a n d c ar b o pl ati n)    will  b e  d et er  mi n e d  b y    m e as ur es  of  t h e  s er u  m l e v els   of   t ot al   g e nist ei n,   fr e e   g e nist ei n,   p a clit a x el   a n d c ar b o pl ati n.    St a n d ar d  p h ar  m a c o ki n eti c  p ar a  m et ers  (  C  m a x, T  m a x,    A  U  C,  h alf -lif e,    V d,  et c.)    will  t h e n  b e  d eri v e d  fr o  m t h es e   m e as ur e d s er u  m l e v els. 
P h ar  m a c o d y n a  mi cs 
T h e   p h ar  m a c o d y n a  mi c   eff e ct   of    BI  O   [ADDRESS_1009647] or (  G-C S F),   C  -r e a cti v e  pr ot ei n,  a n d  pr ost a gl a n di n  E 2.  
Effi c a c y  
T h e  l o c al  pr o gr essi o n  r at e  as  d efi n e d  p er  t h e    R E  CI S T  1. 1 
crit eri a  (  A p p e n di x  4)  will  b e  us e d  t o  ass ess  t h e  n e ar  -t er  m e ffi c a c y    of    t h e    c o  m bi n ati o n    of     BI  O    3 0 0    a n d c h e  m or a di ot h er a p y.  S ur gi c al  p ati e nts  p at h ol o gi c al  r es p o ns e will  b e e v al u at e d as  d efi n e d i n   A p p e n di x  1 0. I n a d diti o n,  P F Ts a n d  a  s  w all o  wi n g  di ar y   will  b e  us e d t o  ass ess  s af et y  of   BI  O 3 0 0    Or al   S us p e nsi o n.      T h e  l o n g er -t er  m   effi c a c y   of  t his c o  m bi n ati o n   will  b e  b as e d  f or t h e  d et er  mi n ati o n  of o v er all a n d pr o gr essi o n- fr e e  s ur vi v al  a n d f or t h e i n ci d e n c e  of  p ul  m o n ar y fi br osis  as  d et er  mi n e d  b y  4  D   C T  s c a n ni n g.     Q u alit y  of  lif e 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009648] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   3 0  4. 0   S  U  B J  E  C  T S  
4. 1   N u  m b e r  of   S u bj e cts  
U p   t o thirt y -si x ( 3 6)   m al e  a n d f e  m al e  s u bj e cts   w h o  gi v e i nf or  m e d  c o ns e nt  a n d f ulfill t h e 
s el e cti o n  crit eri a    will  b e  r e cr uit e d  a n d   e nr oll e d   i nt o  t h e  tri al.    T hr ee  c o h orts    will  b e c o  m pl et e d  s e q u e nti all y ; e a c h   will  a c cr u e  a   mi ni  m u  m  of  [ADDRESS_1009649] et e d  c h e  m or a di ati o n  t h er a p y  a n d  i nt eri  m   d at a  a n al ysis   h as   d et er  mi n e d   t h e o pti  m al  bi ol o gi c al  BI  O  3 0 0   d os e,  t h er e   will  b e  a n o pti o n t o  e nr oll  u p t o  a n  a d diti o n al  1 2 s u bj e cts  at t h at  d os e (s e e s e cti o n  9. 4 f or s el e cti o n  of  o pti  m al  d os e) .  
4. [ADDRESS_1009650]’s eli gi bilit y,  t h e  s p o ns or   will  c o nt a ct  t h e    M e di c al    M o nit or  t o  r e vi e  w  a n d  t o    m a k e  a  fi n al d et er  mi n ati o n  of  eli gi bilit y.   
4. 2. 1   I n cl usi o n C  rit e ri a  
1)    A g  e  ≥  1 8. 
2)    Hist ol o gi c al  or  c yt ol o gi c al  c o nfir  m ati o n  of   N S  C L  C (s p ut u  m  c yt ol o g y   will  n ot  b e 
a d e q u at e  e vi d e n c e  of   m ali g n a n c y) . 
3)    P ati e nts  di a g n os e d   wit h st a g e II, III,  or I  V ( oli g o  m et ast ati c)   N S  C L C f or   w h o  m 
r a di ati o n t h er a p y of  6 0- 7 0    G y  a n d  c o n c urr e nt w e e kl y   p a clit a x el/ c ar b o pl ati n  is 
r e c o  m  m e n d e d  as  p art  of  p ot e nti all y  c ur ati v e t h er a p y  eit h er  al o n e  or  pr e o p er ati v el y. If   a  pl e ur al   eff usi o n   is  pr es e nt,   t h e  f oll o  wi n g  crit eri a     m ust   b e  m et    t o   e x cl u d e   
m ali g n a nt    i n v ol v e  m e nt (i n c ur a bl e   M 1 a dis e as e):  
a)    W h e n    pl e ur al   fl ui d  is  visi bl e  o n  b ot h  t h e  C T    s c a n  a n d   o n  a  c h est   x-r a y,  a 
pl e ur a c e nt esis   is  r e q uir e d  t o  c o nfir  m   t h at  t h e  pl e ur al   fl ui d  is  c yt ol o gi c all y 
n e g ati v e ,  u nl ess t h e  eff usi o n is   mi ni  m al  a n d/ or t o o s  m all t o s af el y t a p. 
4)    P ati e nts  m a y   h a v e  ≤  [ADDRESS_1009651] as es ( e a c h  ≤  3 c  m)  a n d/ or  [ADDRESS_1009652] as  is at 
a n y  ot h er  sit e i n t h e  b o d y,  b as e d  u p o n t h e f oll o  wi n g   mi ni  m u  m  a c c e pt a bl e  di a g n osti c w or k u p: 
a)    Hist or y/ p h ysi c al  e x a  mi n ati o n   wit hi n  1 0   w e e ks  pri or t o r e gistr ati o n   b)    C o  m p ut e d t o  m o gr a p hi c (  C T)/  M  RI i  m a gi n g  of t h e l u n g   wit hi n  1 0   w e e ks  pri or 
t o r e gistr ati o n (  N  O T E: If  a w h ol e  b o d y   P E T/  C T   w as  d o n e,  a s e p ar at e   C T  s c a n of t h e  c h est is  n ot r e q uir e d) 
c)    W h ol e-  b o d y  F  D  G -P E T  or  P E T/  C T ; or if  n o  P E T is  a v ail a bl e,  a  b o n e  s c a n is 
r e q uir e d   wit hi n  1 0   w e e ks  pri or t o  r e gistr ati o n ( a n d   C T  or   M  RI   m ust i n cl u d e t h e li v er) 
d)    M  RI ( or   C T) i  m a gi n g  of t h e  br ai n   wit hi n  [ADDRESS_1009653] as es   m a y  b e tr e at e d  at t h e   dis cr eti o n  of t h e tr e ati n g  p h ysi ci a n .  
5)    E  C  O  G  P erf or  m a n c e  St at us   0- 1 (  A p p e n di x  6). 
6)    F E  V 1:  b est  v al u e  o bt ai n e d  pr e-  or  p ost- br o n c h o dil at or   m ust   b e ≥  1. 0  lit ers/s e c o n d or  >  
5 0  %  pr e di ct e d  v al u e . 
7)    C  B  C/ diff er e nti al    o bt ai n e d wit hi n    [ADDRESS_1009654] arti n g tr e at  m e nt , wit h   a d e q u at e  
b o n e   m arr o  w f u n cti o n  d efi n e d  as  f oll o  ws: 
a)    W  B  C   ≥  3, 0 0 0/  µ L 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009655] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   3 1  b)    A bs ol ut e  n e utr o p hil  c  o u nt (  A  N  C)   ≥  1, 5 0 0  c ells/µ L 
c)    Pl at el ets   ≥  1 0 0, 0 0 0  c ells/µ L 
d)    H e  m o gl o bi n  ≥  9. 0   g/ d L   (  N ot e:  T h e   us e  of  tr a nsf usi o n  or  ot h er   i nt er v e nti o n  t o 
a c hi e v e    HG  B    ≥  9. 0  g/ d L is  a c c e pt a bl e.) 
8)    A d e q u at e  h e p ati c r es er v e  as  e vi d e n c e d  b y   A L T/  A S T   <  3  X   U L  N f or t h e r ef er e n c e l a b 
a n d   bilir u bi n  ≤  1. 5   m g/ d L ( e x c e pt i n s u bj e cts   wit h  k n o  w n   Gil b ert’s s y n dr o  m e,   w h er e t h e  bilir u bi n   m a y  b e  <  2. 0   m g/ d L) 
9)    A d e q u at e r e n al f u n cti o n  as  e vi d e n  c e d  b y  a s er u  m  cr e ati ni n e  ≤  1. 5 X   U L  N f or t h e 
r ef er e n c e l a b or at or y   O  R  a  c al c ul at e d  cr e ati ni n e  cl e ar a n c e  of  ≥  6 0 m L/  mi n  b y t h e C o c kr oft-  G a ult  e q u ati o n  . 
1 0)  F e  m al e s u bj e cts  of  c hil d b e ari n g  p ot e nti al  m ust  h a v e  a  n e g ati v e  pr e g n a n c y t est   wit hi n   [ADDRESS_1009656] art  of tr e at  m e nt.  
1 1)  F e  m al e s u bj e cts  of  c hil d b e ari n g  p ot e nti al  a n d   m al e s u bj e cts   wit h f e  m al e s e x u al  p art n ers 
of  c hi l d b e ari n g  p ot e nti al   m ust  a gr e e t o  us e  a n  eff e cti v e   m et h o d  of  c o ntr a c e pti o n ( e. g., 
or al   c o ntr a c e pti v es,   d o u bl e -b arri er    m et h o ds  s u c h   as   a   c o n d o  m   a n d   a   di a p hr a g  m, i ntr a ut eri n e  d e vi c e) d uri n g t h e st u d y  a n d f or  [ADDRESS_1009657] ai n  fr o  m  s e x u al  i nt er c o urs e  f or  t his  ti  m e;   a    w o  m a n   n ot   of 
c hil d b e ari n g  p ot e nti al  is  o n e   w h o  h as  u n d er g o n e  bil at er al  o o p h or e ct o  mi es  or   w h o  is 
p ost-  m e n o p a us al,  d efi n e d  as  n o   m e nstr u al  p eri o ds f or  1 2  c o ns e c uti v e   m o nt hs. 
1 2)  P ati e nt   m ust  b e  a bl e t o  r e a d  a n d si g n t h e st u d y s p e cifi c i nf or  m e d  c o ns e nt  pri or t o st u d y 
e ntr y.  
 
4. 2. 2   E x cl usi o n   C rit e ri a   
1)    W ei g ht l oss  gr e at er t h a n  1 0  % i n t h e  pri or  4   w e e ks. 
2)    Pri or   m ali g n a n c y i n   w hi c h t h e y r e c ei v e d  a n y t h or a ci c r a di ot h er a p y  u nl ess t h e tr e ati n g 
p h ysi ci a n  c o nsi d ers  it  u nli k el y t o i  m p a ct t h e  cli ni c al  o ut c o  m e  of t h e  p ati e nt.  
3)    P ati e nts   wit h  c o n c urr e nt i n v asi v e   m ali g n a n c y   ot h er t h a n  n o n-m el a n o  m a s ki n  c a n c er 
or  c er vi c al i ntr a e pit h eli al  n e o pl asi a   u nl ess t h e tr e ati n g  p h ysi ci a n  c o nsi d ers it  u nli k el y 
t o i  m p a ct t h e  cli ni c al  out c o  m e  of t h e  p ati e nt
. 
4)    A n  a cti v e i nf e cti o n  or   wit h  a f e v er  ≥  3 8. 5°  C   wit hi n  [ADDRESS_1009658] s c h e d ul e d  d a y 
of  d osi n g. 
5)    P o orl y  c o ntr oll e d  i nt er c urr e nt ill n ess es, s u c h  as; 
a)    u n c o ntr oll e d  h y p ert e nsi o n;   
b)    p o orl y  c o ntr oll e d  di a b et es    m ellit us,  d efi n e d  as  t h e  n e e d  f or  h os pit ali z ati o n  2  or 
m or e ti  m es i n t h e  pr e c e di n g  1 2   m o nt hs. 
c)    u nst a bl e  a n gi n a;  hist or y  of    m y o c ar di al  i nf ar cti o n  or  a c ut e  c or o n ar y  s y n dr o  m e 
wit hi n  [ADDRESS_1009659] u d y  e ntr y;  
d)    hist or y  of  c o n g esti v e  h e art f ail ur e   wit hi n  [ADDRESS_1009660] u d y  e ntr y ;  e)    c ar di a c   arr h yt h  mi as  r e q uiri n g    m e di c al  t h er a p y  or  a  p a c e  m a k er;  c er e br o v as c ul ar 
e v e nts   wit hi n  [ADDRESS_1009661] u d y  e ntr y;  
6)    P at ie nts  wit h  a    pri or t h or a c ot o  m y wit hi n   [ADDRESS_1009662] u d y  r e gistr ati o n. 7)    C hr o ni c   O bstr u cti v e  P ul  m o n ar y   Dis e as e   (  C  O  P  D )  e x a c er b ati o n   or  ot h er 
res pir at or y  ill n ess  r e q uiri n g  h os pit ali z ati o n  or  pr e cl u di n g st u d y t h er a p y wit hi n  [ADDRESS_1009663] arti n g tr e at  m e nt. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009664] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   3 2  8)    P ati e nts   wit h  a n y  of t h e f oll o  wi n g  ar e  n ot  eli gi bl e;  
a)    Pr e vi o us  hist or y  of    Q T c  pr ol o n g ati o n  r es ulti n g  fr o  m    m e di c ati o n  t h at  r e q uir e d 
dis c o nti n u a ti o n  of t h at   m e di c ati o n;  
b)    C o n g e nit al l o n g   Q T s y n dr o  m e,  or  1st d e gr e e r el ati v e   wit h  u n e x pl ai n e d s u d d e n  d e at h 
u n d er  4 0  y e ars  of  a g e;  
c)    Pr es e n c e  of l eft  b u n dl e  br a n c h  bl o c k ( L  B  B  B);  
d)    Q T c   wit h   Fri d eri ci a’s  c orr e cti o n t h at is  u n  m e as ur a bl e,  or  ≥  4 8 0   ms e c  o n s cr e e ni n g 
E  C  G.  T h e  a v er a g e   Q T c fr o  m t h e s cr e e ni n g  E  C  Gs ( c o  m pl et e d i n tri pli c at e)   m ust  b e 
<   [ADDRESS_1009665] u d y;  
e)    S u bj e cts  t a ki n g  a n y  c o n c o  mit a nt    m e di c ati o n  t h at    m a y  c a us e    Q T c  pr ol o n g ati o n, 
i n d u c e  T ors a d es  d e  P oi nt es (s e e   A p p e n di x  2)  ar e  n ot  eli gi bl e if   Q T c  ≥  4 6 0   ms e c.   
9)    P ati e nts   m ust  n ot  h a v e  h a d  a  cli ni c all y si g nifi c a nt  c ar di a c  e v e nt s u c h  as   m y o c ar di al 
i nf ar cti o n (  wit hi n  [ADDRESS_1009666] u dy tr e at  m e nt); 
u n c o ntr oll e d/s y  m pt o  m ati c  c o n g esti v e  h e art f ail ur e (  N e  w   Y or k   H e art   Ass o ci ati o n (  N  Y  H  A)  cl assifi c ati o n  of  h e art  dis e as e,   Cl ass III  or I  V, s e e   A p p e n di x  3)   wit hi n  6 m o nt hs  b ef or e  e ntr y;  or t h e  pr es e n c e  of  a n y  ot h er  u n c o ntr oll e d  c ar di o v as c ul ar c o n diti o ns ( h y p ert e nsi o n  or  arr h yt h  mi a,  u nst a bl e  a n gi n a  p e ct oris,  or s e v er e  v al v ul ar h e art  dis e as e,  et c.) t h at, i n t h e  o pi [INVESTIGATOR_9384] o n  of t h e I n v esti g at or, i n cr e as es t h e ris k  of v e ntri c ul ar  arr h yt h  mi a.  
1 0)  P ati e nts   wit h  a  hist or y  of  arr h yt h  mi a (  m ultif o c al  pr e  m at ur e  v e ntri c ul ar  c o ntr a cti o ns 
( P  V  Cs),  bi g e  mi n y, tri g e  mi n y,  v e ntri c ul ar t a c h y c ar di a,  or  u n c o ntr oll e d  atri al fi brill ati o n)   w hi c h is s y  m pt o  m ati c  or r e q uir es tr e at  m e nt (  C T  C  A E   Gr a d e  3)  or as y  m pt o  m ati c s ust ai n e d  v e ntri c ul ar t a c h y c ar di a  ar e  n ot  eli gi bl e.   P ati e nts   wit h  atri al fi brill ati o n   wit h   w ell-c o ntr oll e d  v e ntri c ul ar r at e  o n   m e di c ati o n,  ar e  eli gi bl e.  
1 1)  Ps y c hi atri c  c o n diti o ns, s o ci al sit u ati o ns  or s u bst a n c e  a b us e t h at  pr e cl u d es t h e  a bilit y 
of t h e s u bj e ct t o  c o o p er at e   wit h t h e r e q uir e  m e nts  of t h e tri al  a n d  pr ot o c ol t h er a p y 
1 2)  G  r a d e  2  or  hi g h er  p eri p h er al  n e ur o p at h y 1 3)  K n o  w n  hist or y  of   HI  V  /  AI  D S,  h e p atitis   B  or   C.   Not e,   h o  w e v er, t h at HI  V   o r 
h e p atiti s  t esti n g is  n ot r e q uir e d f or e ntr y  i nt o t his  pr ot o c ol. T h e  n e e d  t o  e x cl u d e p ati e nts  wit h   AI  D S    or  h e p atitis   B  or   C fr o  m t his pr ot o c ol  is n e c ess ar y  b e c a us e  t h e tr e at  m e nts i n v ol v e d i n t his  pr ot o c ol m a y    b e si g nifi c a ntl y i  m  m u n os u p pr essi v e. Pr ot o c ol- s p e cifi c r e q uir e  m e nts m a y   als o  e x cl u d e  i  m  m u n o- c o  m pr o  mis e d  p ati e nts. 
1 4)  Pr e g n a n c y   or  w o  m e n    of   c hil d b e ari n g   p ot e nti al  a n d   m e n    w h o    ar e   s e x u all y  a cti v e  
a n d   n ot   willi n g/ a bl e   t o  us e  m e di c all y    a c c e pt a bl e   f or  ms  of  c o ntr a c e pti o n;  t his e x cl usi o n   is  n e c ess ar y  b e c a us e  t h e tr e at  m e nt i n v ol v e d i n t his st u d y   m a y  b e t er at o g e ni c. 
1 5)  W o  m e n   w h o  ar e  br e astf e e di n g  ar e  n ot  eli gi bl e f or t his st u d y. 
4. [ADDRESS_1009667] u d y  pr ot o c ol  (t his  n u  m b er    will  i n cl u d e  s u bj e cts    w h o  h a v e  i n a d v ert e nt  pr ot o c ol d e vi ati o ns) .   S u bj e cts,   w h o  dr o p  o ut,  ar e l ost t o f oll o  w  u p,  or   w h o  n e e d t o  b e   wit h dr a  w n fr o  m t h e st u d y,   will  b e i d e ntifi e d  a n d t h e r e as o n   will  b e  c o d e d i n t h e  c as e r e p ort f or  m. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009668] a c e  m e nt  
S u bj e cts  t h at   pr es e nt    wit h   a n   u nr el at e d    m e di c al   c o n diti o n   ( e. g.   str o k e,    m y o c ar di al 
i nf ar cti o n) t h at is  n ot  attri b ut a bl e t o t h e i n v esti g ati o n al  dr u g   will  b e r e pl a c e d.  S u bj e cts t h at ar e  u n a bl e  or  u n  willi n g t o  c o  m pl et e  at l e ast  [ADDRESS_1009669] et e d  t hr o u g h  t h e  BI  O  3 0 0  +    C h e  m o  P  K    visit ,  t h e  r e pl a c e  m e nt  s u bj e cts    will  b e assi g n e d t o t h e  n o n -P  K  s u b gr o u p.  A d diti o n al  s u bj e cts   will  b e  e nr oll e d  as  n e e d e d t o f ulfill d os e  es c al ati o n  crit eri a (s e e s e cti o n  5. 5   D os e  Es c al ati o n   Crit eri a).  
4. 3. [ADDRESS_1009670] u d y   m e as ur e  m e nts   will  b e  p erf or  m e d  at 
t h e ti  m e  of  d e p art ur e ( or  as s h ortl y t h er e aft er  as  p ossi bl e). 
4. 3. 3. 1  D r u g  -R el at e d   R e as o ns   
1)    S u bj e ct  e x p eri e n c es  a n  a d v ers e r e a cti o n  a n d  d o es  n ot   wis h t o r e  m ai n i n t h e tri al.  
2)    S u bj e ct  e x p eri e n c es  a  s eri o us  a d v ers e  r e a cti o n  or  a  s p e cifi c  a d v ers e  r e a cti o n 
t h at  r e q uir es  dis c o nti n u ati o n  a c c or di n g  t o  t h e  pr ot o c ol  as  d et er  mi n e d  b y  t h e i n v esti g at or. 
3)    Cli ni c al tri al is t er  mi n at e d  pr e  m at ur el y  b e c  a us e  of  u n a c c e pt a bl e s af et y c o n c er ns 
(ris ks)  of t h e s u p pl e  m e nt  b ei n g t est e d. 
4. 3. 3. 2  Cli ni c al  -T ri al  -R el at e d   R e as o ns   
1)    S u bj e ct i n di c at es t h e r e q uir e  m e nts ar e t o o  o n er o us,  or t o o l o n g,  or l os es i nt er est; 
or r ef us es t o  p arti ci p at e.  
2)    Cli ni c al tri al is t er  mi n at e d  at  a  pr es et  d at e  a n d s o  m e s u bj e cts  ar e  n ot  c o  m pl et e d.  
4. 3. 3. [ADDRESS_1009671] -  R el at e d   R e as o ns   D et e r  mi n e d  b y t h e I n v esti g at o r 
1)    S u bj e ct f ails t o   m ai nt ai n  a d e q u at e  c o  m pli a n c e   wit h  o n e  or   m or e  as p e cts  of t h e 
pr ot o c ol  or s u bj e ct f ails t o  c o o p er at e  a d e q u at el y  d uri n g  cli n i c al  visits. 
2)    S u bj e ct f o u n d  n ot t o   m e et  or  n o l o n g er   m e ets t h e  ori gi n al  e ntr y r e q uir e  m e nts. 3)    S u bj e ct  h as  us e d  a  n o n- a p pr o v e d   m e di ci n e  or tr e at  m e nt  d uri n g t h e tri al. 4)    S u bj e ct  w h o  at t h e  I n v esti g at or’s  dis cr eti o n  f e els t h at  c o nti n ui n g i n t h e  st u d y 
w o ul d  n ot  b e   i n t h eir  b est i nt er est.  
5)    S u bj e ct  b e c o  m es  pr e g n a nt  ( o bs er v ati o n  a n d  f oll o  w -u p  pr o c e d ur es    m ust  b e 
i niti at e d). 
6)    S u bj e ct   wit h dr a  ws i nf or  m e d  c o ns e nt. 
4. 3. 3. 4  Ot h e r   R e as o ns   
1)    S u bj e ct r ef us es t o st at e r e as o ns f or  dr o p pi n g  o ut. 2)    S u bj e ct  d e v el o ps  a n i nt er c urr e nt ill n ess  a n d is  u n a bl e  or  u n  willi n g t o  c o nti n u e 
i n  a  cli ni c al tri al;  h o  w e v er, I n v esti g at or  di d  n ot   wis h t o  dis c o nti n u e t h e s u bj e ct. 
3)    S u bj e ct’s  p ers o n al  sit u ati o n  c h a n g es:   e. g.  m or e   w or k  r es p o nsi bilit y/tr a v el  or 
h o  m e  c h a n g es (  m o v es,   m arri es, f a  mil y)  a n d s u bj e ct  h as  l ess ti  m e/  m oti v ati o n t o p arti ci p at e.  
4)    Ot h er iss u es r e q uiri n g   wit h dr a  w al  of t h e s u bj e ct fr o  m t h e tri al.   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009672] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   3 7  •    Us e  of  c ar b o pl ati n i n  c o  m bi n ati o n   wit h  ot h er  b o n e   m arr o  w s u p pr essi n g t h er a pi [INVESTIGATOR_014] 
m ust  b e  c ar ef ull y   m a n a g e d   wit h r es p e ct t o  d os a g e  a n d ti  mi n g i n  or d er t o   mi ni  mi z e 
a d diti v e  eff e cts  
•    R e n al  eff e cts  of  n e p hr ot o xi c  c o  m p o u n ds   m a y  b e  p ot e nti at e d  b y  c ar b o pl ati n  
•    C o n c o  mit a nt tr e at  m e nt   wit h  a  mi n o gl y c osi d es  h as r es ult e d i n i n cr e as e d r e n al 
a n d/ or  a u di ol o gi c t o xi cit y,  a n d  c a uti o n   m ust  b e  e x e r cis e d   w h e n  a  p ati e nt r e c ei v es 
b ot h  dr u gs 
•    C ar b o pl ati n  c a n i n d u c e  e  m esis,   w hi c h  c a n  b e   m or e s e v er e i n  p ati e nts  pr e vi o usl y 
r e c ei vi n g  e  m et o g e ni c t h er a p y 
•    I n ci d e n c e  of  p eri p h er al  n e ur ot o xi cit y is i n cr e as e d i n  p ati e nts  ol d er t h a n  [ADDRESS_1009673] ati n  
•    I n cr e as e d ris k  of  all er gi c r e a cti o ns i n cl u di n g  a n a p h yl a xis i n  p ati e nts  pr e vi o usl y 
e x p os e d t o  pl ati n u  m t h er a p y ( pl ati ns).   
R ef er  t o  t h e   p a c k a g e  i ns ert  f or   d et ail e d   p h ar  m a c ol o gi c,   d osi n g,  st or a g e,   a n d  s af et y i nf or  m ati o n. 
6. [ADDRESS_1009674] u d y  a n d  aft er  a   mi ni  m u  m  of  2  d a ys  of 
BI  O  3 0 0  d osi n g.   T h e t y p e  of r a di ati o n t h er a p y  (3  D  C o nf or  m al  R a di ati o n  T h er a p y, I nt e nsit y M o d ul at e d  R a di ati o n  T h er a p y  or  Pr ot o n   B e a  m  R a di ati o n  T h er a p y)  wi  ll  b e at t h e  dis cr eti o n of t h e  tr e ati n g i n v esti g at or. P ati e nts   will  r e c ei v e   R T   tr e at  m e nt  5  d a ys  p er   w e ek, i n  o n c e d ail y  fr a cti o ns,   1. 8- 2. 0    G y  p er  fr a cti o n.    T h e  t ot al  d os e    will  b e  6 0 - 7 0  G y    (c o b alt    G y e q ui v al e nt  ( C  G E  ))  i n  [ADDRESS_1009675] e d  si d e  eff e cts  of  r a di ati o n  t h er a p y.   R a di ati o n  i n d u c e d    m y o c ar ditis  or  tr a ns v ers e m y elitis r ar el y  o c c ur.   R a di o gr a p hi c  e vi d e n c e  of r a di ati o n  c h a n g e  a n d  s u bs e q u e nt fi br osis of t h e l u n g   will  o c c ur   wit hi n l u n g  v ol u  m e  of s o  m e  p ati e nts  r e c ei vi n g  ≥ [ADDRESS_1009676]  si x    m o nt hs  aft er  i niti ati o n   of  tr e at  m e nt;  t h e  i n ci d e n c e   of  r a di ati o n  i n d u c e d p n e u  m o nitis is  a b o ut  1 5 - 2 0  %.  It is  ess enti al t o  s p ar e  as   m u c h  n or  m al l u n g  as  p ossi bl e i n or d er t o  a v oi d s y  m pt o  m ati c l u n g i nj ur y. 
R  a d i ati o n  p n e u  m o nitis is  a l u n g t o xi cit y t h at is  a si d e  eff e ct  of  c h e  m or a di ot h er a p y f or l u n g 
c a n c er.  It  is  c h ar a ct eri z e d   b y   e d e  m a,   diff us e  al v e ol ar   d a  m a g e,   d es q u a  m ati o n   of  t h e c a pi[INVESTIGATOR_54276] y  e n d ot h eli u  m,  a n d  t h e  d e v el o p  m e nt  of  h y ali n e    m e  m br a n es.  S y  m pt o  ms  i n cl u d e s h ort n ess  of  br e at h,  c o u g h,  f ati g u e,  a n d  l oss  of  a p p etit e.    T h e  i n ci d e n c e  of  r a di ati o n p n e u  m o nitis  t y pi c all y   p e a ks   b et  w e e n   [ADDRESS_1009677] eti o n   of  r a di ot h er a p y.   T h e  l u n g    m a y  r e c o v er,  b ut  p n e u  m o nitis  i n cr e as es  t h e  ris k  of  d e v el o pi n g s u bs e q u e nt  p ul  m o n ar y  c o  m pli c ati o ns, i n cl u di n g  p er  m a n e nt s c ari n g  of t h e l u n gs (fi br osis). A    C T  s c a n  is  us e d  t o  d et e ct  t his  t y p e  of  r a di ati o n  -i n d u c e d  l u n g  i nj ur y.    C o  m  m o n    C T 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009678] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   3 9  6. 4   C o n c o  mit a nt   T h e r a pi [INVESTIGATOR_014]  a n d   M e di c ati o ns   
T h o u g h  n o  d at a  h a v e s h o  w n t h at  a n y  c o n c o  mit a nt   m e di c ati o ns   will i nt erf er e   wit h   BI  O  3 0 0 
Or al  S us p e nsi o n, it is  a d vis a bl e t h at  p ati e nts  n ot t a k e  a n y  ot h er   m e di c ati o n(s)  [ADDRESS_1009679] e d f or all  s u bj e cts  fr o  m  t h e  s cr e e ni n g  visit   t hr o u g h  c o ns oli d ati o n  c h e  m ot h er a p y.  P ati e nts  o n c o n c o  mit a nt  m e di c ati o ns   (s e e   A p p e n di x  2) t h at   m a y  pr ol o n g Q T c   ar e   pr o hi bit e d if   Q T c  ≥ [ADDRESS_1009680] a nti al  e vi d e n c e,  s h o ul d  b e  a v oi d e d  if  p ossi bl e  (s e e A p p e n di x  2).    H o  w e v er, t h es e  dr u gs   will  b e  all o  w e d,  at t h e  dis cr eti o n  of t h e i n v esti g at or, if  c o nsi d er e d  a bs ol ut el y  n e c ess ar y.  I n  s u c h  c as es, t h e  p ati e nt   m ust  b e  cl os el y   m o nit or e d i n cl u di n g  r e g ul ar  c h e c ks  of   Q T c  a n d  el e ctr ol yt es.   T h e   E  C  G   m ust  b e  c h e c k e d   wit hi n  [ADDRESS_1009681] t  w o ( 2) w e e ks of  c o -a d  mi nistr ati o n  of  a  dr u g  t h at    m a y  c a us e    Q T c  pr ol o n g ati o n  (s e e    A p p e n di x  2).    El e ctr ol yt es s h o ul d  b e   m ai nt ai n e d   wit hi n t h e  n or  m al r a n g e  usi n g s u p pl e  m e nts if  n e c ess ar y.     P er  mitt e d s u p p orti v e t h er a p y All  s u p p orti v e t h er a p y  f or  o pti  m al   m e di c al  c ar e   will  b e  gi v e n  d uri n g t h e  st u d y  p eri o d  at t h e  dis cr eti o n  of  t h e  att e n di n g  p h ysi ci a n(s)    wit hi n  t h e  p ar a  m et ers  of  t h e  pr ot o c ol  a n d d o c u  m e nt e d  o n  e a c h sit e’s s o ur c e  d o c u  m e nts  as  c o n c o  mit a nt   m e di c ati o n.  N a us e a,  v o  miti n g  or  b ot h   m a y  b e  c o ntr oll e d   wit h  a nti e  m eti c t h er a p y.   [ADDRESS_1009682] ors (  G  -C S F/  G  M  -C S F)   will  n ot  b e  p er  mitt e d  d uri n g r a di ati o n. If  a  p ati e nt r e c ei v es   W  B  C  gr o  wt h f a ct ors  d uri n g r a di ati o n, t his  c o nstit ut es  a   m aj or  pr ot o c ol  vi ol ati o n. W  B  C  gr o  wt h f a ct ors   m a y  b e  us e d  d uri n g  c o ns oli d ati o n  c h e  m ot h er a p y i n  a c c or d a n c e   wit h A S  C  O  g ui d eli n es,  b ut  s h o ul d  n ot  b e  gi v e n  pr o p h yl a cti c all y.  Er yt hr o p oi eti n   m a y  b e  gi v e n at t h e tr e ati n g  p h ysi ci a n’s  dis cr eti o n i n  a c c or d a n c e   wit h  a c c e pt e d  g ui d eli n es.  
Hi g h  d os es  of  gl u c o c orti c oi ds  ( e. g.,   >   2 0    m g  of  Pr e d nis o n e/ d a y  or  e q ui v al e n c e)  a n d 
i  m  m u n os u p pr ess a nts s h o ul d  n ot  b e  us e d.  I  m  m u n ot h er a p y I  m  m u n ot h er a pi [INVESTIGATOR_014] (e. g .,  d ur v al u  m a b, p e  m br oli z u  m a b  or  ni v ol u  m a b ) m a y  b e i nit at e d  aft er t h e  c o  m pl eti o n  of  c o n c urr e nt  ch e  m or a di ot h er a p y  at t h e  dis cr eti o n  of t h e  tr e ati n g  p h ysi ci a n.  I  m  m u n ot h er a p e uti cs    will  b e  n ot  b e  c oll e ct e d  o n  t h e   C o nc o  mit a nt    M e di c ati o n   C  R F  b ut i nst e a d   will  b e  d o c u  m e nt e d s e p ar at el y  o n t h e I  m  m u n ot h er p y  C  R F.    D at a fr o  m t h e  C  R F   will b e  v erifi e d  a g ai nst t h e  s u bje ct   m e di c al  c h art f or  a c c ur a c y.    S o y  pr o d u cts, s u p pl e  m e nts,  a n d  di et 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009683] a di ati  o n  t h er a p y s ho ul d  c o nti n u e  t o  b e d eli v er e d  f or  ≤  Gr a d e    3  no n - he  m at o l o gi c t o xi citi es i n or  o uts id e 
t h e r a di atio n  tr e at  me nt  fi el d. R T   s ho ul d   b e h el d  f or  all   Gr ad e  4  n o n- h e  m at ol o gi c  to xi cit y  a n d r es u  m e d  o nl y 
w h  e n t o xi cit y is  ≤  Gr a d e  2.   
 
  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009684] ati n  D os e     M odifi c at i o ns f o r R e  n al   T o xi cit y 
A  >  1 0  %  c h a n g e i n s er u  m  cr e ati ni n e,  b as e d  o n   w e e kl y  c al c ul at e d  cr e ati ni n e  cl e ar a n c e,   will 
w arr a nt  a r e c al c ul ati o n  of t h e  c ar b o pl ati n  d os e. 
6. 5. 1. [ADDRESS_1009685]  e r e d  (  A p p e n di x   6).   R e  -e v al u at e    pati e nt   aft er   o n e    w e e k   f or   r es u  m pti o n   of r a di ot h er a p y. 
6. 5. 1. [ADDRESS_1009686] 
h a v e r es ol v e d t o  <  gr a d e  2,   C T  C  A E,  v 4. 0 3. 
  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009687] ati n,  b ut  r at h er t h e   m or e t o xi c c h e  m ot h er a p e uti c  p a clit a x el.   
6. 5. 6   M a n a g e  m e nt  of   Q  T c  p r ol o n g ati o n 
P ati e nts   will  h a v e  E  C  Gs  p erf or  m e d t o   m o nit or   Q T c i nt er v al  usi n g  Fri d eri ci a’s  c orr e cti o n.   
 F or t his  st u d y,   Q T c  pr ol o n g ati o n is  d efi n e d  as:   A  si n gl e   Q T c i nt er v al  of  ≥  4 8 0   ms e c.  T h e Q T c  pr ol o n g ati o n t hr es h ol d f or  h ol di n g   BI  O  3 0 0  h as  b e e n  d efi n e d  as  a   Q T c i nt er v al  of  ≥   5 0 0   ms e c or  a n i n cr e as e  of  >  6 0   ms e c fr o  m  b as eli n e.   T h e  b as eli n e   will  b e t h e  a v er a g e  of t h e s cr e e ni n g  d a y  a n d t h e  pr e  -BI  O  3 0 0   Or al  S us p e nsi o n d os e   Q T c i nt er v al  v al u es.  
6. 5. 6. 1   A b n o r  m al   Q  T c i nt e r v al  of  ≥  5 0 0   ms e c  o r  b as eli n e  c h a n g e  of  >  6 0   ms e c 
If t h e   Q T c i nt er v al is ≥  5 0 0   ms e c  or  a n i n cr e as e  of  >  [ADDRESS_1009688] a c e  m e nt eit h er t hr o u g h  I  V  or  P  O  s h o ul d  b e  att e  m pt e d t o   m ai nt ai n  a l e v el  of  p ot assi u  m  ≥  4. 0   m  m ol/ d L a n d/ or   m a g n esi u  m  ≥  2. 0   m g/ d L.  E  C  Gs  a n d  el e ctr ol yt es s h o ul d  b e f oll o  w e d  3 ti  m es  a   w e e k u ntil   Q T c i nt er v al f alls  b el o  w  4 8 0   ms e c.     
Aft er t h e   Q T c i nt er v al r e c o v ers t o   <  [ADDRESS_1009689]  b e 
wit h h e  l d f or >  3   w e e ks t o  all o  w f or   Q T c  pr ol o n g ati o n t o r e c o v er t o  <  [ADDRESS_1009690]  b e  o bt ai n e d   wit hi n  4 8  h o urs.  If t h e E  C  G 
r e  m ai ns a b n or  m al it   will  b e  r e p e ate d t  wi c e,  5   mi n ut es  a p art . If t h e   Q T c i nt er v al is <   4 8 0 
ms e c t h e  p ati e nt   will  c o nti n u e tr e at  m e nt  a n d r es u  m e t  h e  E  C  G  s c h e d ul e  as  o utli n e d i n t h e S c h e d ul e  of   Ass ess  m e nts (s e e  T a bl e  7. 1. 1). If t h e   Q T c  i nt er v al is  ≥  4 8 0   ms e c,  BI  O  3 0 0   will b e  h el d  a n d  t h e  pr o c ess  f or    m o nit ori n g  a n  a b n or  m al   Q T c  i nt er v al  d es cri b e d  i n  s e cti o n 6. 5. 6. 1   will  b e f oll o  w e d.     
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009691] r oi n t esti n al (  GI)   T o xi cit y 
N a us e a,   v o  miti n g,   or   b ot h     m a y   b e   c o ntr oll e d     wit h   a nti e  m eti c   t h er a p y.       R o uti n e 
pr e  m e di c ati o n    f or    c h e  m ot h er a p y    i n    a c c or d a n c e    t o    st a n d ar ds    is    r e c o  m  m e n d e d.  S y  m pt o  m ati c  p ati e nts  s h o ul d  pr o -a cti v el y  b e tr e at e d   wit h  st a n d ar d  a nti n a us e a/ a nt i e  m eti c t h er a p y  as  n e c ess ar y  t o  pr e v e nt  d os e    m o difi c ati o n  or  i nt err u pti o n.      H o  w e v er,  [ADDRESS_1009692] e d.   
7. 0      S  C  H  E  D  U  L  E   O F   A S S  E S S  M  E  N  T S  7. 1   Ti  m e t o   E v e nt   
T h e  Ti  m e t o  E v e nt t a bl e ( T a bl e  7. 1. 1  f or  n o n s ur gi c al s u bj e cts a n d  T a bl e  7. 1. 2 f or c a n di d at e  
s ur gi c al  s u bj e cts ) is  a  r ef er e n c e  of   w h at  st u d y  ass ess  m e nts  n e e d t o  b e  c o  m pl et e d  at  e a c h s p e cifi e d  visit.  A    w e e k  is  d efi n e d  as  5  c o ns e c uti v e  b usi n ess  d a ys  e. g.,    W e d n es d a y, T h urs d a y,  Fri d a y,   M o n d a y,  T u es d a y.  S e e  T a bl e  7. 1. 3 f or  visit   wi n d o  w  d es cri pti o ns.  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009693] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   4 9  T a bl e  7. 1. 1   Ti  m e t o   E v e nt   f o r  n o n s u r gi c al s u bj e cts 
VI SI  T  #   [ADDRESS_1009694] eti o n   3   m o  6   m o  
9   m o  
1 1   m o  
1 3  m o   
I nf or  m e d   C o ns e nt X                              
R e vi e  w I/ E   Crit eri a   X   X                           
M e di c al   Hist or y   X                              
P h ysi c al  E x a  m1  X Xb Xb Xb X   X X X   X X  X 
E  C  O  G  S c or e  X Xb Xb   Xb X   X   X   X   X   X      X 
Vit al  Si g ns X Xb Xb   Xb X   X   X   X   X   X      X 
W ei g ht   X Xb Xb   Xb X   X   X   X   X   X      X 
H ei g ht   X                              
E  C  G X2 X3   X4 b X4 c                     
C  B  C X   X   Xb   Xb    X   X   X         
S er u  m   C h e  mistr y5 X   X   Xb   Xb    X   X   X         
Uri n al ysis6 X                                
Pr e g n a n c y  T est7 X   X                             
E xt e nt  of   Dis e a s e  X         Xd X      X   X   X   X   X   X 
P  K s a  m pli n g     X X Xf X Xb                     
P  D s a  m pli n g    X  Xf X Xb       X   X   X        
BI  O  [ADDRESS_1009695]  X     
         X            X         X 
Di a g.   C T  S c a n   X              X         X   X      X    
4  D -C T  S c a n   X         Xd       X       X    X 
S  w all o  wi n g   Di ar y  X Xb Xb   Xb          X   X      
Di et   C o u ns eli n g8 X Xb Xb   Xb                   
aO pti o n al  visit  5 b   as  n e e d e d,  bw e e kl y, cbi -w e e kl y   ( e v er y  ot h er   w e e k), dvisit  2 0  o nl y;  visit   wi n d o  w  all o  w a n c e 
of  +/ - [ADDRESS_1009696] is   m e di c all y fit f or  s ur g er y us e t a bl e  7. 1. 2 , f BI  O 3 0 0 
+ c h e  m o  P  K s c h e d uli n g  all o  w e d   w e e k  1  or  2,  S e e  T a bl e  7. 1. 3 f or  d et ails  
 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009697] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   5 0  T a bl e  7. 1. 2   Ti  m e t o   E v e nt f o r s u r gi c al s u bj e cts   
VI SI  T  #   [ADDRESS_1009698]  C o ns oli d ati o n   3   m o  
6   m o  
9   m o  
1 2  m o   
I nf or  m e d   C o ns e nt X                           
R e vi e  w I/ E   Crit eri a   X   X                        
M e di c al   Hist or y   X                           
P h ysi c al  E x a  m1  X Xb Xb Xb X   X X X   X X   X 
E  C  O  G  S c or e  X Xb Xb   Xb X   X   X   X   X   X   X 
Vit al  Si g ns X Xb Xb   Xb X   X   X   X   X   X   X 
W ei g ht   X Xb Xb   Xb X   X   X   X   X   X   X 
H ei g ht   X                           
E  C  G X2 X3   X4 b X4 c                  
C  B  C X   X   Xb   Xb    X   X   X      
S er u  m   C h e  mistr y5 X   X   Xb   Xb    X   X   X      
Uri n al ysis6 X                             
Pr e g n a n c y  T est7 X   X                          
E xt e nt  of   Dis e a s e  X         Xd X          X   X   X   X 
P  K s a  m pli n g     X X Xf X Xb                  
P  D s a  m pli n g    X  Xf X Xb       X   X   X     
BI  O  [ADDRESS_1009699]  X     
         X            X      X 
Di a g.   C T  S c a n   X              X         X   X   X   X 
4  D -C T  S c a n   X                             
S  w all o  wi n g   Di ar y  X Xb Xb   Xb          X   X   
Di et   C o u ns eli n g8 X Xb Xb   Xb                
aO pti o n al  visit  5 b   as  n e e d e d,  bw e e kl y, cbi -w e e kl y   ( e v er y  ot h er   w e e k), dvisit  2 0  o nl y;  visit   wi n d o  w  all o  w a n c e 
of  +/ - 7  d a ys , f BI  O 3 0 0  + c  h e  m o  P  K s c h e d uli n g  all o  w e d   w e e k  1  o r  2,  S e e  T a bl e  7. 1. 3 f or  d et ails 
 
 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009700]  .  
5.    T o i n cl u d e s o di u  m,  p ot assi u  m,  c hl ori d e,  bi c ar b o n at e,   B  U  N,  cr e ati ni n e,  gl u c os e, 
A S T,   A L T,  al k ali n e  p h os p h at as e, t ot al  bilir u bi n,  al b u  mi n, t ot al  pr ot ei n, m a g n esi u  m,  c al ci u  m,    p h os p h or o us  a n d  uri c  a ci d.   A n al ysis  of  p a n cr e ati c  e n z y  m es als o t o  b e i n cl u d e d i n  p a n el ( a  m yl as e  a n d li p as e). 
6.    Uri n al ysis t o i n cl u d e  p  H, s p e cifi c  gr a vit y,  di psti c k  d et er  mi n ati o ns  of  gl u c os e, 
k et o n es,  pr ot ei n,  h e  m o gl o bi n,  bilir u bi n. 
7.    Pr e g n a n c y t est   m a y  b e  uri n e  or s er u  m  d et er  mi n ati o n  of  β- H  C  G.   Visit  [ADDRESS_1009701]   will  h a v e  a  mi ni  m u  m  of   3 2  visits t hr o u g h t h e  c o n cl usi o n of  c o n c urr e nt  c h e  m or a di ot h er a p y ( a p pr o xi  m at el y   6- 7   w e e ks  of  c h e  m ot h er a p y  a n d d ail y   R T fr a cti o n s of  1. 8- 2. 0   G y, t ot al  d os e  of  6 0- 7 0  G y)  . 
[ADDRESS_1009702]  a d  mi nistr ati o n  of   BI  O  3 0 0.  Aft er t his ti  m e  ,  a d v ers e  e v e nt  ass ess  m e nt   will  o c c ur  at  e a c h  visit   b ut  o nl y t h os e  e v e nts t h at  ar e c o nsi d er e d s eri o us  a n d  p ossi bl y,  pr o b a bl y  or  d efi nit el y r el at e d t o   BI  O  3 0 0   will  b e d o c u  m e nt e d  a n d  r e p ort e d t o t h e s p o ns or   wit hi n  2 4  h o urs  of  a  w ar e n ess (s e e s e cti o n  8. 0  S af et y   R e p orti n g f or  d et ails).  
  
 
 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009703] a n d ar d  of 
c ar e s h o ul d  b e 
f oll o  w e d. 
BI  O  3 0 0  + 
C h e  m o  P  K   BI  O  3 0 0  +   C h e  m o  p h ar  m a c o ki n eti c s   m a y  b e s c h e d ul e d w e e k  [ADDRESS_1009704] e d   wit hi n  ±  [ADDRESS_1009705] e d   wit hi n  ±  [ADDRESS_1009706] er e d   
Visit  S,  S ur gi c al E v al u ati o n  +/ - 7 d   
Visit  3 6  -3 7 , 
C o ns oli d ati o n C h e  m ot h er a p y
 +/ - 7 d  +/ - 1 4 d f or   C T  
Visit  3 8  -3 9 ,  3 a n d  6   m o nt h f oll o  w  u p +/ - 1 4 d   
Visit  4 0  -4 2 ,  9-1 3 
m o nt h f oll o  w  u p   +/ - 2 1 d  F or s ur gi c al  s u bj e cts 
vi sit  4 1,  1 2   m o nt h 
f oll o  w  u p ( e n d  of st u d y)  
 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009707] u d y  a n d  e n c o ur a g e d t o   m ai nt ai n t h eir  di et   wit hi n  a n  a c c e pt a bl e r a n g e. I n  pr e p ar ati o n f or t h e   Visit  2 (  D a y  1)  P  K/ P  D st u di es,  all s u bj e cts   will  arri v e  at t h e  cli ni c  aft er  a n o v er ni g ht (8  h o ur ) f ast.   T h e first  bl o o d s a  m pl e f or t h es e st u di es   will  b e t a k e n  pri or t o t h e i niti al  d os e of   BI  O  3 0 0. (s e e  s e cti o n  7. 3 f or  d et ails  o n  bl o o d  s a  m pli n g f or  P  K/ P  D).    T h e  s u bj e ct   will b e  as k e d t o r e  m ai n f asti n g f or  [ADDRESS_1009708] a n d ar d   m e al .   Dri n ki n g  of  cl e ar fl ui ds ( pr ef er a bl y   w at er  o nl y,  8  o u n c es)   will  b e  e n c o ur a g e d f oll o  wi n g  a d  mi nistr ati o n  of   BI  O  [ADDRESS_1009709]  arti cl e   will  b e  c o ns u  m e d  at t h e  b e gi n ni n g  of t h e  d a y i  m  m e di at el y aft er t h e i n iti al (ti  m e  0)  bl o o d  s a  m pli n g  o n t h e  d a ys t h at r e q uir e  a  bl o o d  dr a  w.  F oll o  wi n g t h e  p h ar  m a c o ki n eti c  p orti o n  of t h e tri al,  a n d t hr o u g h o ut t h e  e ntir e  st u d y,  s u bj e cts will  b e e n c o ur a g e d t o t a k e t h e  d ail y  d os e  of   BI  O  [ADDRESS_1009710] e, if t h eir r a di ati o n s essi o ns  ar e s c h e d ul e d f or  1 1: 0 0   A  M, t h e y s h o ul d t a k e t h eir d ail y  d os e  of   BI  O  3 0 0   Or al  S us p e nsi o n  at  1 0: [ADDRESS_1009711] et e d  o n  c o h ort 4  ( o pti  m al  bi ol o gi c al  d os e).  At  e a c h  visit   w h er e  bl o o d  s a  m pli n g  o c c urs,  bl o o d   will  b e  c oll e ct e d  pri or t o  a n y tr e at  m e nt a d  mi nistr ati o n i n cl u di n g t h e  d ail y   BI  O  [ADDRESS_1009712] a  ws f or  s af et y,  P  K,  a n d  P  D   ass ess  m e nt  c a n  b e f o u n d i n   A p p e n di x  9.  B el o  w   is  a n  o v er vi e  w  of t h e  d et ails  of t h e  bl o o d  c oll e cti o n s u  m  m ari z e d  b y  visit.   Visit  1 ( S c r e e ni n g)   At t h e s cr e e ni n g  visit,  bl o o d   will  b e  c oll e ct e d f or  a   C  B  C  a n d  bl o o d  c h e  mistri es t o  e v al u at e t h e  s u bj ect’s  b o n e   m arr o  w  a n d  h e p ati c  r es er v e  a n d  r e n al  f u n cti o n.  If  a  pr e g n a n c y t est is r e q uir e d f or t h e  s u bj e ct,  eit h er  a  s er u  m  or  uri n e t est   will  b e  d o n e  at t his ti  m e.   T h es e t est r es ults   will  assist i n  d et er  mi ni n g t h e s u bj e ct’s  a bilit y t o  b e i n cl u d e d i n t h e tri al (s e e s e cti o n 4. 2. 1 I n cl usi o n   Crit eri a).   Visit  2 (  D a y  1)   F or  s u bj e cts i n t h e  P  K  gr o u p ,  aft er  a n  8-h o ur f ast  a n d  pri or t o t h e i niti al  d os e  of   BI  O  [ADDRESS_1009713] e d  f or  C  B  C,   bl o o d  c h e  mistri es  a n d   BI  O  3 0 0 p h ar  m a c o d y n a  mi c ( P  K)  a n d  p h ar  m a c o d y n a  mi c  ( P  D)  b as eli n e v al u e s.   T h e   C  B  C  a n d  bl o o d c h e  mistri es   m a y  b e  dr a  w n  u p t o  [ADDRESS_1009714] is r e q uir e d.  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009715] a  w n   f or   p h ar  m a c o ki n eti c   a n d p h ar  m a c o d y n a  mi c  s a  m pli n g  of   BI  O  3 0 0  at t h e  f oll o  wi n g ti  m es:  pr e -d os e,  0. 5,  1,  2,  3,  4, a n d at [ADDRESS_1009716] e d   wit hi n  ±  [ADDRESS_1009717] e d   wit hi n  ±  [ADDRESS_1009718] u g.   F or  e a c h   BI  O  3 0 0 ti  m e  p oi nt ( P  K  or  P  K  a n d  P  D),  a  [ADDRESS_1009719] a  w (  BI  O  3 0 0  P  K  a n d  P  D), t h e  s er u  m  fr o  m t h e  si n gl e  bl o o d  c oll e cti o n t u b e will  b e s e p ar at e d   i nt o t  w o  ali q u ots ( 0. 3  m L f or   BI  O  3 0 0  P  D  a n al ysis  a n d t h e r e  m ai n d er f or 
BI  O  3 0 0  P  K  a n al ysis)  a n d  fr o z e n    at  - 8 0°C  .   T h e  t u b e  f or   BI  O  [ADDRESS_1009720] a  w  d es cri b e d  a b o v e ( 0. 3   m L  s er u  m) will  b e  us e d f or   BI  O  3 0 0  p h ar  m a c o d y n a  mi c   m ar k er   a n al ysis; t h e t u b e   will  b e  s hi p p e d t o t h e s p o ns or-d esi g n at e d l a b f or  a n al ysis.  Bl o o d  s er u  m   will  b e  a n al y z e d f or   P  D  bi o  m ar k er 
e x pr essi o n   l e v el s.    P  D     Bi o  m ar k ers   m a y   i n cl u d e     I L 6,   I L- 1α,  I L- 1β,     I L-8,   I L - [ADDRESS_1009721] e d  for  C  B  C,   bl o o d  c h e  mistri es  a n d BI  O  3 0 0  p h ar  m a c o d y n a  mi c   ( P  D)  b as eli n e v al u e.   F or t h os e s u bj e cts   w h o  h a d  a  pr e g n a n c y t est  at V  isit  [ADDRESS_1009722] e d   wit hi n  ± [ADDRESS_1009723] a n d ar d   m e al.    Visit  3 (  D a y    2) Pri or t o t h e  d a ys  BI  O  [ADDRESS_1009724] a  w n  a n d t h e s a  m e  pr o c ess   will  b e f oll o  w e d  as  d es cri b e d  a b o v e i n   Visit  2.    B e c a us e t h er e   will  b e  n o 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009725] a  w n t his  d a y.   BI  O  3 0 0  +   C h e  m o  P  K    Aft er  a n  [ADDRESS_1009726] ati n f or t h os e s u bj e cts i n t h e  P  K  gr o u p.  
Bl o o d  s a  m pli n g  f or   p a clit a x el  ti  m e  p oi nts    will  b e :  pr e -d os e,  2,  3,  4,  8,  a n d  [ADDRESS_1009727] ati n ti  m e  p oi nts   will  b e:   pr e -d os e,  2,  4,  8,  a n d  [ADDRESS_1009728] e d   wit hi n  ±  [ADDRESS_1009729] e d   wit hi n  ±  [ADDRESS_1009730] e d ,  c e ntrif u g e d  at  a p pr o xi  m at el y  4°C   a n d  tr a nsf err e d e q u all y  i nt o t  w o  st eril e t u b es 
a n d   fr o z e n   at    - 8 0°C  .    T h e  t u b e    will   b e   s hi p p e d  t o  t h e   s p o ns or-d esi g n at e d  l a b   f or 
d et er  mi n ati o n  of  p a clit a x el  a n d  c ar b o pl ati n  P  K  p ar a  m et ers.  T h es e ti  m es  ar e r el ati v e t o t h e 
m or ni n g   d os e   of    BI  O   [ADDRESS_1009731] e d ,  c e ntrif u g e d  at  a p pr o xi  m at el y  4°C  a n d   di vi d e d  i nt o t  w o st eril e t u b es  a n d fr o z e n  
at  - 8 0°C.   F or   BI  O  [ADDRESS_1009732] eril e t u b e  an d fr o z e n  i n  a - 8 0°C f  re e z er . 
 
W e e ks   2- [ADDRESS_1009733] ati n,   a n d   t h e    BI  O   3 0 0   p h ar  m a c o d y n a  mi c   m ar k ers    will   b e d et er  mi n e d     w e e kl y    d uri n g    c o n c urr e nt    c h e  m or a di ot h er a p y,    pri or   t o   t h at     w e e k’s c h e  m ot h er a p y tr e at  m e nt  c o urs e  a n d  pri or t o t h at  d a ys   BI  O  [ADDRESS_1009734] e d  i n  a  r e d  t o p  bl o o d c oll e cti o n t u b e . T h e  bl o o d   will  b e  all o  w e d t o  cl ot   2 0-3 0   mi n ut es  a n d t h e n  c e ntrif u g e d  at r o o  m t e  m p er at ur e f or  1 0-1 5   mi n ut es .  Th e s er u  m  fr o  m t h e si n gl e  bl o o d  c oll e cti o n t u b e will b e s e p ar at e d  i nt o t  w o  ali q u ots ( 0. 3  m L f or   BI  O  3 0 0  P  D  a n al ysis  a n d t h e r e  m ai n d er f or   BI  O 
3 0 0  P  K  a n al ysis).  T h e t u b es   will  b e fr o z e n  at - 8 0 °C   a n d s hi p p e d t o t h e s p o ns or -d esi g n at e d 
l a bs f or  a n al ysis.   O n e t u b e   will  b e  s hi p p e d t o t h e s p o ns or-d esi g n at e d  bi o a n al yti c al  l a b f or 
a n al ysis  a n d  d et er  mi n ati o n  of   BI  O  3 0 0 tr o u g h l e v els,  a n d  t h e  s e c o n d t u b e   will  b e s hi p p e d t o t h e s p o ns or-d esi g n at e d l a b f or   BI  O  3 0 0  p h ar  m a c o d y n a  mi c   m ar k er  a n al ysis.   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009735] e d,  c e ntrif u g e d  at  a p pr o xi  m at el y  4°C  a n d  di vi d e d   i nt o t  w o 
st eril e t u b es  a n d fr o z e n  at  - 8 0°C.    T h e t u b e   will  b e  s hi p p e d t o t h e  s p o ns or -d esi g n at e d l a b 
f or  d et er  mi n ati o n  of  p a clit a x el  a n d  c ar b o pl ati n tr o u g h l e v els. 
  Visit    S All s u bj e cts   will  h a v e  a  C  B  C  a n d  bl o o d  c h e  mistri es  dr a  w n f or s af et y   m o nit ori n g.    N o  ot h er bl o o d s a  m pli n g r e q uir e d.   Visits   [ADDRESS_1009736] eril e t u b e a n d fr o z e n  at  - 8 0°C  .   T h e t u b e 
will  b e   s hi p p e d t o t h e s p o ns or- d esi g n at e d l a b f or  a n al ysis.  
 Visit   [ADDRESS_1009737] eril e t u b e a n d fr o z e n   at - 8 0°C  .   T h e t u b e 
will  b e   s hi p p e d t o t h e s p o ns or- d esi g n at e d l a b f or  a n al ysis.  
 Visit   [ADDRESS_1009738] eril e t u b e a n d fr o z e n  at - 8 0°C  .  T h e t u b e   will  b e s hi p p e d 
t o t h e s p o ns or-d esi g n at e d l a b f or  a n al ysis.  
 F or  all  ot h er  visits,  n o  pr ot o c ol  bl o o d  c oll e cti o n is r e q uir e d.  ( S e e s e cti o n  7. 0  S c h e d ul e  of   Ass ess  m e nts f or  a d diti o n al i nf or  m ati o n.)   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009739] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   5 9  8. 0   S  A F  E  T  Y   R  E P  O  R  TI  N  G  
8. 1   D efi niti o ns   8. 1. 1   A d v e rs e   E v e nts   
A n y   u nf a v or a bl e   a n d   u ni nt e n d e d   si g n   (i n cl u di n g   a n   a b n or  m al   l a b or at or y   fi n di n g), 
s y  m pt o  m,  or  dis e as e t e  m p or all y ass o ci at e d   wit h t h e  us e  of a   m e di c al tr e at  m e nt  or  pr o c e d ur e r e g ar dl ess  of    w h et h er  it  is  c o nsi d er e d  r el at e d  t o  t h e    m e di c al  tr e at  m e nt  or  pr o c e d ur e ( attri b uti o n  of  u nr el at e d,  u nli k el y,  p ossi bl e,  pr o b a bl e,  or  d efi nit e).  
8. 1. [ADDRESS_1009740]  b e  r e p o rt e d t o 
t h e S p o ns o r   wit hi n  2 4  h o u rs  of  a  w a r e n ess  of t h e  e v e nt.   D efi niti o n  of  a n  S  A  E:   A n y  a d v ers e  dr u g  e x p eri e n c e  o c c urri n g  at  a n y  d os e t h at r es ults i n a n y  of t h e f oll o  wi n g  o ut c o  m es: 
•    D e at h;   
•    A lif e  -t hr e at e ni n g  a d v ers e  dr u g  e x p eri e n c e; •    I n p ati e nt  h os pit ali z ati o n  or  pr ol o n g ati o n  of  e xisti n g  h os pit ali z ati o n; •    A  p ersist e nt  or si g nifi c a nt  dis a bilit y/i n c a p a cit y;   •    A  c o n g e nit al  a n o  m al y/ birt h  d ef e ct.   
 
I  m p ort a nt    m e di c al  e v e nts  t h at    m a y  n ot  r es ult  i n  d e at h,  b e  lif e  t hr e at e ni n g,  or  r e q uir e 
h os pit ali z ati o n   m a y  b e  c o nsi d er e d  a n  S  A E  dr u g  e x p eri e n c e,   w h e n,  b as e d  u p o n   m e di c al j u d g  m e nt, t h e y   m a y j e o p ar di z e t h e  p ati e nt  a n d   m a y r e q uir e   m e di c al  or s ur gi c al i nt er v e nti o n t o  pr e v e nt  o n e  of t h e  out c o  m es list e d i n t h e  d efi niti o n.   
8. 1. [ADDRESS_1009741] e d   A d v e rs e   E v e nts   
A n y  a d v ers e  e x p eri e n c e t h at ( a) is  n ot i d e ntifi e d i n  n at ur e  or  s e v erit y,  or fr e q u e n c y i n t h e 
c urr e nt i n v esti g at or  br o c h ur e; ( b) t h at is  n ot i d e ntifi e d i n  n at ur e,  s e v erit y,  or fr e q u e n c y i n th e ris k i nf or  m ati o n  d es cri b e d i n t h e  g e n er al i n v esti g ati o n al  pl a n  or els e  w h er e i n t h e c urr e nt a p pli c ati o n  as  a  m e n d e d; ( c)  or t h at  h as  n ot  b e e n  pr e vi o usl y  o bs er v e d. 
8. [ADDRESS_1009742] e d i n t h e 
sit es  s o ur c e  d o c u  m e nt  a n d  r e p ort e d o n t h e   A E  c as e r e p ort f or  m (  C  R F)  fr o  m t h e ti  m e t h e 
s u bj e ct  is  e nr oll e d i n t h e  st u d y u ntil  [ADDRESS_1009743] u g .   Do c u  m e nt ati o n  of t h e s eri o us  e v e nt  will  b e r e p ort e d  o n t h e  S  eri o us   A d v ers e E v e nt  C  R F    a n d s u b  mitt e d t o t h e s p o ns or   wit hi n  2 4  h o urs  of  a  w ar e n ess.    
8. 2. 1   A d v e rs e   E v e nt   D at a   E  l e  m e nts 
•    Ass ess  m e nt  p eri o d  
•    A d v ers e  e v e nt t er  m   C T  C  A E  v ersi o n  4. 0 3 
•    S e v erit y   Gr a d e ( 0 - 5)   C T  C  A E  v ersi o n  4. 0 3 •    Attri b uti o n t o st u d y  a g e nt (r el at e d n ess)   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009744] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   6 0  •    D at e   A E  o c c urr e d    
•    D at e   A E r es ol v e d    •    W h et h er  or  n ot t h e  e v e nt   w as r e p ort e d  as  a n  S  A E 
•    W h et h er  or  n ot t h e  p arti ci p a nt  dr o p p e d  d u e t o t h e  e v e nt 
•    A cti o n t a k e n   wit h st u d y  a g e nt •    O ut c o  m e  of t h e  e v e nt   •    C o  m  m e nts   
8. 2. 2   S e v e rit y  of   A Es 
I d e ntif y  t h e  a d v ers e  e v e nt  usi n g  t h e    N  CI    C o  m  m o n   T er  mi n ol o g y    Crit eri a  f or    A d v ers e 
E v e nts (  C T  C  A E)  v ersi o n  4. [ADDRESS_1009745] e d.   A li n k t o t h e   N  CI  C o  m  m o n  T er  mi n ol o g y  Crit eri a f or   A d v ers e E v e nts (  C T  C  A E)  v ersi o n  4. 0 3  c a n  b e f o u n d i n   A p p e n di x  5.  
T a bl e   8 . 2. 2. 1   Gr a di n g  a n d   D es c ri pti o n  of   A d v e rs e   E v e nts  
Gr a d e     D es cri pti o n   
0    N o   A E  or   wit hi n  n or  m al li  mits   1    Mil d   A E;  a s y  m pt o  m ati c  or   mil d s y  m pt o  ms;  cli ni c al  or  di a g n osti c  o bs er v ati o ns  o nl y; i nt er v e nti o n 
n ot i n di c at e d  
2    M o d er at e    A E;    mi ni  m al,  l o c al  or  n o ni n v asi v e  i nt er v  e nti o n  ( e. g.,  p a c ki n g,  c a ut er y)  i n di c at e d; 
li  miti n g  a g e-a p pr o pri at e i nstr u  m e nt al  a cti viti es  of  d ail y li vi n g (  A  D L)  
3    S e v er e   or     m e di c all y   si g nifi c a nt   b ut   n ot   i  m  m e di at el y   lif e -t hr e at e ni n g;   h os pit ali z ati o n   or 
pr ol o n g ati o n  of  h os pit ali z ati o n i n di c at e d;  dis a bli n g; li  miti n g s elf -c ar e   A  D L  
4    Lif e -t hr e at e ni n g  c o ns e q u e n c es;  ur g e nt i nt er v e nti o n i n di c at e d 5    D e at h r el at e d t o   A E   
 
N  O T E:   A  s e v er e   A E,  as  d efi n e d  b y t h e  a b o v e  gr a di n g  s c al e, is   N  O T t h e  s a  m e  as  s eri o us A E,   w hi c h is  d efi n e d  a b o v e i n s e cti o n  7. 1. 2. 
8. 2. [ADDRESS_1009746] u d y  a g e nt   will  b e  cl assifi e d  as  o n e 
of t h e f oll o  wi n g:  u nr el at e d,  u nli k el y,  p ossi bl e,  pr o b a bl e,  d efi nit e.  T h e i n v esti g at or   will  b e r es p o nsi bl e f or  d et er  mi ni n g t h e r el at e d n ess  of t h e   A E t o t h e st u d y  a g e nt. 
8. 2. [ADDRESS_1009747]  b e r e p ort e d t o t h e I R  B: 
•    A si n gl e  o c c urr e n c e  of  a s eri o us,  u n e x p e ct e d  e v e nt t h at is  u n c o  m  m o n  a n d str o n gl y 
ass o ci at e d   wit h  dr u g  e x p os ur e. 
•    A si n gl e  o c c urr e n c e,  or   m or e  oft e n  a s  m all  n u  m b er  of  o c c urr e n c es,  of  a s eri o us, 
u n e x p e ct e d  e v e nt t h at is  n ot  c o  m  m o nl y  ass o ci at e d   wit h  dr u g  e x p os ur e,  b ut u n c o  m  m o n i n t h e st u d y  p o p ul ati o n. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009748] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   6 1  •    M ulti pl e  o c c urr e n c es  of  a n   A E t h at,  b as e d  o n  a n  a g gr e g at e  a n al ysis, is  d et er  mi n e d 
t o  b e  a n  u n a nti ci p at e d  pr o bl e  m.  T h er e s h o ul d  b e  a  d et er  mi n ati o n t h at t h e seri es  of 
A E  s r e pr es e nts  a si g n al t h at t h e   A Es   w er e  n ot j ust is ol at e d  o c c urr e n c es  a n d i n v ol v e ris k t o  h u  m a n s u bj e cts. 
•    A n   A E t h at is  d es cri b e d  or  a d dr ess e d i n t h e i n v esti g at or’s  br o c h ur e,  pr ot o c ol,  or 
i nf or  m e d  c o ns e nt  d o c u  m e nts,  b ut  o c c urs  at  a s p e cifi cit y  or s e v erit y t h at is i n c o nsist e nt   wit h  pri or  o bs er v ati o ns. 
•    A s eri o us   A E t h at is  d es cri b e d  or  a d dr ess e d i n t h e i n v esti g at or’s  br o c h ur e, 
pr ot o c ol,  or i nf or  m e d  c o ns e nt  d o c u  m e nts,  b ut f or   w hi c h t h e r at e  of  o c c urr e n c e i n t h e st u d y r e pr es e nts  a  cli ni c all y si g nifi c a nt i n cr e as e i n t h e  e x p e ct e d r at e  of o c c urr e n c e.  
•    A n y  ot h er   A E  or s af et y fi n di n g ( e. g.,  b as e d  o n  a ni  m al  or  e pi d e  mi ol o gi c  d at a) t h at 
w o ul d  c a us e t h e s p o ns or t o   m o dif y t h e i n v esti g at or’s  br o c h ur e, st u d y  pr ot o c ol,  or i nf or  m e d  c o ns e nt  d o c u  m e nts,  or   w o ul d  pr o  m pt  ot h er  a cti o n  b y t h e I R  B t o  e ns ur e t h e  pr ot e cti o n  of  h u  m a n s u bj e cts. 
8. [ADDRESS_1009749] e d  a d v ers e  r e a cti o ns will  b e  r e p ort e d t o t h e  F  D  A  n o   l at er t h a n  7  c al e n d ar  d a ys  aft er  t h e  s p o ns or’s  i niti al  r e c ei pt  of  t h e  i nf or  m ati o n.  If  t h e  F  D  A r e q u ests  a n y  a d diti o n al  d at a  or  i nf or  m ati o n,  t h e  s p o ns or   will  s u b  mit  it  t o  F  D  A  as  s o o n as   p ossi bl e,  b ut  n o l at er t h a n  [ADDRESS_1009750]. 
8. 5   D os e   Li  miti n g   T o xi citi es (  D  L  Ts)   Bl o o d s a  m pli n g f or t h e l a b or at or y  p ar a  m et ers   will  b e  p erf or  m e d  d uri n g t h e st u d y a c c or di n g 
t o   t h e   ti  m e   t o   e v e nt   s c h e d ul e   i n   t his   pr ot o c ol.     L a b or at or y   p ar a  m et ers   i n cl u d e C  B  C/ diff er e nti al, c  h e  mistr y  pr ofil e (  C  M P),  p h os p h or us,  p a n cr e ati c li p as e   & a  m yl as e.  E  C  G a n d  vit al  si g ns   will  als o  b e  p erf or  m e d  a c c or di n g t o t h e  T i  m e t o E v e nt  t a bl e ( T a bl e  7. 1. 1). T o xi citi es    will  b e  gr a d e d  a c c or di n g  t o  t h e    V ersi o n  4. 0 3   ( v 4. 0 3)  of  t h e    N  CI   C o  m  m o n T er  mi n ol o g y   Cr it eri a f or  A d v ers e  E v e nts (  C T  C A E).    A d v ers e  e v e nt r e p orti n g  a n d  s eri o us a d v ers e    e v e nt   r e p orti n g     will   f oll o  w   t h e    g ui d eli n es    d efi n e d    b y    F  D  A    St at ut es. Dis c o nti n u ati o n  of  a s u bj e ct  a n d  e arl y st o p pi n g  of  o n e  of t h e tri al  c o h orts   will  b e  b as e d  o n t h e   f oll o  wi n g   un a c c e pt a bl e   a d v ers e   e v e nts   (  A E s)   a n d     m ust   b e   attri b ut a bl e   t o   t h e i n v esti g ati o n al  dr u g   BI  O  3 0 0   Or al s us p e nsi o n (i. e.  p ossi bl y,  pr o b a bl y  or  d efi nit el y r el at e d t o  t h e  st u d y  dr u g)  t o  c o nstit ut e  a   D os e-Li  miti n g   T o xi cit y  (  D L T).     O nl y  a d v ers e  e v e nts w hi c h  o c c ur  b ef or e  or  d uri n g  c o n c urr e nt  c h e  m or a di ati o n   will  b e  c o u nt e d  as   D L Ts. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009751] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   6 2  •    T o xi citi es   m ust  b e  attri b ut a bl e t o t h e st u d y r e gi  m e n (i. e.  p ossi bl y,  pr o b a bl y  or 
d efi nit el y r el at e d t o t h e i n v esti g ati o n al st u d y  dr u g) t o  c o nstit ut e  a   D os e -Li  miti n g 
T o xi cit y (  D L T).    
•    D os e l  i  miti n g t o xi citi es  ar e t o  b e  d efi n e d  as f oll o  ws: 
1)    R a di ati o n  es o p h a gitis   Gr a d e  3 t h at l asts  >  7    c o ns e c uti v e  d a ys  or   Gr a d e  4. 2)    Gr a d e  4  n e utr o p e ni a f or   m or e t h a n  7  d a ys  or  n e utr o p e ni a f e v er ( d efi n e d  as 
A  N  C  <  5 0 0  a n d  a t e  m p er at ur e  of  3 8. 5°   C  or  a b o v e).   
3)    Gr a d e  3 t  hr o  m b o c yt o p e ni a   wit h  cli ni c all y si g nifi c a nt  bl e e di n g  4)    Gr a d e  4 t hr o  m b o c yt o p e ni a  >  7  d a ys.   5)    Gr a d e  4  n a us e a/ v o  miti n g  d es pit e  a p pr o pri at e  a nti e  m eti c t h er a p y.   6)    Gr a d e  3   A S T/  A L T   el e v ati o ns   >  7  d a ys 7)    D el a ys  i n  r a di ot h er a p y  or  c h e  m ot h er a p y  d u e  t o  t o xi cit y  of    m or e  t h a n   [ADDRESS_1009752]  o n  p ati e nt  o ut c o  m e  a n d t h us  ar e t o  b e  d esi g n at e d  as  a   D L T.  
8)    All   ot h er   n o n  -h e  m at ol o gi c  t o xi citi es   of    Gr a d e   3   or   hi g h er,    wit h  t h e 
f oll o  wi n g  e x c e pti o ns: a)    a n or e xi a  b)   f ati g u e c)    i nf e cti o n   wit h o ut  n e utr o p e ni a d)   Gr a d e  3   A S T/  A L T  el e v ati o ns  ≤  7  d a ys   e)    I nf usi o n  r e a cti o ns.   P ati e nts   wit h   Gr a d e  [ADDRESS_1009753] a c e d  a n d   will  n ot  b e  c o nsi d er e d e v al u a bl e f or   D L T.  
f)   Gr a d e  [ADDRESS_1009754] et e d  c o n c urr e nt  c h e  m or a di ot h er a p y   wit h  l ess t h a n 3 3  %   D L Ts.  If o n e  or f e  w er D L Ts   o c c ur , th e  d os e   will  b e  es c al at e d  t o t h e  n e xt  c o h ort  of  6  s u bj e cts. If  2   D L Ts o c c ur  ( 2/ 6  s u bj e cts),  a n  a d diti o n al  2  s u bj e cts   will  b e  tr e at e d   wit h  t h e  s a  m e  d os e.  If  n o a d diti o n al   D L Ts  o c c ur  ( 2/ 8  s u bj e cts),  d os e  es c al ati o n   m a y  pr o c e e d.  If  1  a d diti o n al  D L T o c c urs  ( 3/8 s u bj e cts),  a n  a d diti o n al  2 s u bj e cts   will  b e tr e at e d  at t h e s a  m e  d os e f or  a t ot al  of 1 0 s u bj e cts.  If  n o  a d diti o n al   D L Ts  o c c ur ( 3/ 1 0 s u bj e cts),  d os e  es c al ati o n   m a y  pr o c e e d.  T h e st u d y s p o ns or   will t e  m p or aril y  c e as e  e nr oll  m e nt   i n  a n y  gi v e n  c o h ort  if  4 s u bj e cts ( o ut of  a t ot al  of  1 0),  e x p eri e n c e   D L Ts  attri b ut a bl e t o   BI  O  3 0 0   Or al  S us p e nsi o n  as t h e   M T  D will  h a v e  b e e n  e x c e e d e d.    T h e  s p o ns or’s    m e di c al    m o nit or    will  ass ess  t h e  s af et y  d at a c oll e ct e d t o  d at e t o  d et er  mi n e if  e nr oll  m e nt  s h o ul d  p er  m a n e ntl y  c e as e  at t h at  d os e.  If t h e d e cisi o n  is    m a d e  t o  c e as e  e nr oll  m e nt,  t h e  s p o ns or  a n d  t h e  pri n ci p al  i n v esti g at or    will d et er  mi n e if t h e  d os e  s h o ul d  c e as e  or  b e   m o difi e d  f or t h os e  s u bj e cts i n t h at  c o h ort   w h o 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009755] I  D #. T h e first  n u  m b er i n t h e  S u bj e ct  I  D #  is  t h e  sit e  n u  m b er.    Sit e  n u  m b ers will  st art    wit h  1 0 0  a n d  i n cr e as e  b y i n cr e  m e nts  of  1 0 0 (i. e.,  1 0 0,  2 0 0,  3 0 0),  as  n e e d e d.  T h e  s e c o n d  n u  m b er   will  b e t h at  of t h e s u bj e ct i n t h e  or d er t h e y  ar e  s cr e e n e d  st arti n g   wit h  0 1;  a d diti o n al  n u  m b ers  b ei n g  assi g n e d s e q u e nti all y ( 1 0 1,  1 0 2,  1 0 3,  et c.).  I n a d diti o n,  o nl y t h e s u bj e ct i niti als (first,   mi d dl e   & l ast) will  b e  us e d  o n st u d y  d o c u  m e nts.   All   m e di c al r e c or ds  ar e r e q uir e d t o  b e  d e  -i d e ntifi e d  pri or t o  s u b  missi o n t o t h e  s p o ns or.  St u d y r e c or ds   will  b e  st or e d i n  a l o c k e d  a n d  s e c ur e  st or a g e ar e a  at t h e  st u d y  a n d  s p o ns or  f a ciliti es.  T h e i n v esti g at or(s)/i nstit uti o n(s)   will  p er  mit tri al-r el at e d    m o nit ori n g,  a u dits,  I R  B/I E  C  r e vi e  w,  a n d  r e g ul at or y  i ns p e cti o n(s)  b y  pr o vi di n g dir e ct  a c c ess t o  all  s o ur c e  d at a/ d o c u  m e nts  i n cl u di n g  el e ctr o ni c   m e di c al r e c or ds.   T h er e   will  b e  n o i  m p ut ati o n f or   missi n g   Q  O L  o bs er v ati o ns.   T h e  c a us e  of   missi n g  d at a is ass u  m e d t o  b e   missi n g  c o  m pl et el y  at r a n d o  m.   D  at a  r e q uir e d  f or  t h e  I nt eri  m   A n al ysis   will  b e   m o nit or e d a n d  cl e a n e d  pri or  t o  d at a b as e fr e e z e  a n d  n o  n e  w  d at a    will  b e  a d d e d  t o  t h e   d at a b as e  u ntil  t h e   Pr oj e ct    M a n a g er   or St atisti ci a n   gi v es  a p pr o v al.   T h e  tri al   d at a b as e    will   b e  a u dit e d,  cl e a n e d  a n d   l o c k e d  aft er  c o  m pl eti o n  of  t h e  tri al  a c c or di n g  t o  t h e  st u d y  s p e cifi c    D at a    M a n a g e  m e nt  Pl a n  (  D  M P) .    A  c o p y  of  t his  l o c k e d d at a b as e   will  b e  b u r n e d  o nt o  a   C  D-R  O  M  a n d   m a d e  a v ail a bl e f or  st atisti c al  a n al ysis.   D at a will  b e  a n al y z e d f or  a d v ers e  e v e nts,  pri  m ar y  o ut c o  m es,  a n d s e c o n d ar y  o ut c o  m es.    
9. [ADDRESS_1009756] et e t h e  C  R F  s   will  b e  d eri v e d fr o  m t h e  s u bj e cts  s o ur c e 
d o c u  m e nts   ( E  M  R  a n d/ or  p a p er  d o c u  m e nts).     T h e  r es e ar c h  sit e’s  st u d y  p ers o n n el   will c o  m pl et e  t h e   C  R Fs  a n d r et ai n t h e  m f or   m o nit ori n g  b y t h e  s p o ns or. O n c e   m o nit ori n g  h as b e e n  c o  m pl et e d  a n d t h e  C  R Fs  h a v e  b e e n r e vi e  w e d  a n d si g n e d  b y t h e i n v esti g at or, t h e y   will b e  s u b  mitt e d t o t h e  s p o ns or.   D at a  e ntr y  ,  v erifi c ati o n  a n d  cl e a ni n g will  b e  d o n e   a c c or di n g t o t h e s p o ns or’s st u d y s p e cifi c   D at a  M  a n a g e  m e nt  P l a n.   All  p h ar  m a c o ki n eti c  c al c ul ati o ns   will  b e  p erf or  m e d  usi n g  v ali d at e d  s oft  w ar e   as  arr a n g e d b y  t h e  S p o ns or .  I n di vi d u al  ti  m e-c o n c e ntr ati o n  d at a   will  b e  us e d  i n  all  p h ar  m a c o ki n eti c a n al ys es.   T h e ar e a  u n d er t h e s er u  m ( or  pl as  m a) c o n c e ntr ati o n -ti  m e c ur v e,   will  b e esti  m at e d usi n g t h e li n e ar tr a p e z oi d al r ul e.  T
m a x,  h alf-lif e  a n d r ati os   will  b e list e d t o t  w o  si g nific a nt 
fi g ur es.    All  ot h er  p ar a  m et ers   will  b e list e d t o t hr e e si g nifi c a nt fi g ur es. 
9. 2     D at a  q u alit y  ass u r a n c e 
Q u alit y  c o ntr ol  a n d  q u alit y  ass ur a n c e   will  b e  pr o vi d e d  as s p e cifi e d i n t h e s p o ns or’s  S  O P’s 
t o  e ns ur e  a p pr o pri at e  cli ni c al  c ar e  a n d  d at a i nt e grit y. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009757] e  si z e  of   6  p ati e nts  p er  c o h ort ,  wit h t h e  o pti o n t o  e nr oll  u p t o   a n 
a d diti o n al  1 2  at  a  si n gl e  d os e l e v el  ( o pti  m al  bi ol o gi c al d os e) .   T his is  a  s uffi ci e nt  n u  m b er 
of  p ati e nts t o i d e ntif y   D L Ts.   
9. [ADDRESS_1009758] et e d t o  ass ess  BI  O 
3 0 0 s af et y  a n d t o r e vi e  w s e c o n d ar y  o ut c o  m e   m e as ur es.  D at a   tr e n ds   will  b e  us e d t o  c h o os e a  si n gl e   BI  O  3 0 0  d os e ( 5 0 0,  1 0 0 0  or  1 5 0 0  m g/ d)  as t h e  o pti  m al  b i ol o gic al  d os e.    U p t o  a n a d diti o n al  1 2  s u bj e cts  will  b e  e nr oll e d  at t h e   o pti  m al  b i ol o gi c al  d os e t o f urt h er  e v al u at e BI  O  3 0 0  ’s  s af et y  a n d effi c a c y.   T h e   m a xi  m u  m t ol er at e d  d os e   will  b e  us e d  f or  c o h ort  [ADDRESS_1009759] atisti cs  (  m e a n/  m e di a ns  a n d st a n d ar d  err ors/ c o nfi d e n c e  i nt er v als  f or  c o nti n u o us  r es p o ns e  v ari a bl es  a n d  distri b uti o n t a bl es  or  hist o gr a  ms  f or  dis cr et e  r es p o ns e  v ari a bl es).  I n  a d diti o n,  r el ati o ns hi ps  b et  w e e n t h es e r es p o ns e  v ari a bl es   will  b e e x pl or e d  usi n g  no n -p ar a  m etri c  a p pr o a c h es ( e. g.,  S p e ar  m a n r a n k  c orr el ati o n),  p ar a  m etri c  c orr el ati o n  a n al ysis   m et h o ds ( e. g.,  c orr el ati o n  c o effi ci e nt),  or a p pr o pri at e   st atisti c al   t ests   ( e. g.,   t h e     C hi -s q u ar e   tr e n d   t est   f or   c at e g ori c al   d at a). F urt h er  m or e,  a p pr o pri at e r e gr essi o n t e c h ni q u es f or t h es e r es p o ns e  v ari a bl es ( e. g.,  a n al ysis of   v ari a n c e/ c o v ari a n c e  (  A  N  O  V  A/  A  N  C  O  V  A)),  li n e ar  r e gr essi o n,   pr o p orti o n al   h a z ar ds r e gr essi o n, l o gisti c r e gr essi o n,   G E E  a n d   mi x e d  eff e cts   m o d els)   will  b e  e  m pl o y e d t o f urt h er e x a  mi n e t h eir r el ati o ns hi p  wit h  o n e  a n ot h er.  C o nfi d e n c e i nt er v als   will  b e  c al c ul at e d f or t h e diff er e n c es.   T h e  c o  m p ut e d  c h a n g e  fr o  m  b as eli n e    will  b e  c al c ul at e d  f or  all    m e as ur e d v ari a bl es  a n d  e x pr ess e d  as t h e   m e a n  c h a n g e fr o  m  b as eli n e  + st a n d ar d  d e vi ati o n ( S  D)  of t h e c h a n g e fr o  m  b as el i n e.    A t  w o-s a  m pl e t-t est   will  b e  us e d t o t est t h e t u  m or si z e r e d u cti o n  a n d a l o g -r a n k t est   will  b e  us e d t o  c o  m p ar e ti  m e t o  e v e nt  o ut c o  m es.  St atisti c al a n al ys es  of t h e  F  A  C T -T  OI  d at a   will  b e  p erf or  m e d   wit h t h e  us e  of  S P S S s oft  w ar e, v ersi o n  1 6. 0 ;  e a c h  p ati ent    will  b e  us e d  as  his/ h er  o  w n  c o ntr ol.   A n al ysis  of  v ari a n c e (  A  N  O  V  A)   will  b e  us e d t o  c o  m p ar e   m e a n   U  C S  D-S  O  B  c h a n g e s c or es l o n git u di n all y (fr o  m b as eli n e t o f oll o  w -u p  visits).   T h e   A  N  O  V  As  c a n  b e f oll o  w e d   wit h  p - v al u e-a dj ust e d,  p air -wis e ( p ar a  m etri c  a n d t h e n  n o  n- p ar a  m etri c)  c o  m p aris o ns  of t h e   m e a n   U  C S  D -S  O  B  c h a n g e s c or es.   M ulti v ari at e li n e ar r e gr essi o n  a n al ys es,  a dj ust e d f or  b as eli n e s c or es,   will  b e  us e d t o e x a  mi n e t h e  p ati e nt  r e p ort e d  o ut c o  m es  ( P  R  O).  T h e  s  w all o  wi n g  di ar y   will  b e  s c or e d  a n d a n al y z e d  as  pr e vi o usl y  d es cri b e d  [ 2 6].  Usi n g  k n o  w n  p h ar  m a c o ki n eti c  p ar a  m et ers  of  p a clit a x el  a n d  c ar b o pl ati n, t h e  ar e a  u n d er t h e s er u  m  ( or  pl as  m a)  c o n c e ntr ati o n -ti  m e  c ur v e  (  A  U  C  i n   m g *  mi n/  m L)  will  b e  us e d   b y  t h e s p o ns or t o  ass ess t h e  effe ct  of   BI  O  [ADDRESS_1009760] ati n  o n t h e  p h ar  m a c o ki n eti cs  of  BI  O  3 0 0   Or al  S us p e nsi o n.   F oll o  wi n g a  si n gl e  d os e  of   BI  O  3 0 0   Or al  s us p e nsi o n  (t h e  first   w e e k  of t h e  st u d y) t h e   A  U  C   will  b e d et er  mi n e d.  T h e f oll o  wi n g   w e e k  c h e  m ot h er a p y   will  b e  a d d e d t o t h e tr e at  m e nt r e gi  m e n  a n d 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009761] u gs ( p a clit a x el,  c ar b o pl ati n,  a n d  BI  O  3 0 0 
Or al  S  us p e nsi o n).  T h e   A  U  C  v al u es  at t his ti  m e p oi nt   will  b e  c o  m p ar e d t o t h at  o bt ai n e d aft er a   BI  O  [ADDRESS_1009762] or  (  G -C S F),    C  -r e a cti v e  pr ot ei n,  a n d  pr ost a gl a n di n    E 2.  Fi n all y, p ul  m o n ar y f u n cti o n ( b y  s pir o  m etr y)   will  b e   m e as ur e d i n t h e  st u d y.  F or c e d   Vit al   C a p a cit y ( F  V  C)   a n d   F or c e d    E x pir at or y    V ol u  m e  i n  t h e   first   s e c o n d   ( F E  V 1)    will   b e   s c or e d l o n git u di n all y f or i n di vi d u al s u bj e cts i n t h e st u d y  as  d es cri b e d  a b o v e. 
[ADDRESS_1009763] u d y, h e/s h e    will  b e  as k e d  t o  s i g n  t h e  I nf or  m e d    C o ns e nt  d o c u  m e nt.    A  c o p y  of  t h e  si g n e d I nf or  m e d   C o ns e nt   will  b e  gi v e n t o t h e st u d y  p arti ci p a nt  a n d t h e  ori gi n al I nf or  m e d   C o ns e nt d o c u  m e nt  will  b e  k e pt  o n fil e  .  T h e st u d y  a g e nt(s)   will  n ot  b e r el e as e d t o  a  p arti ci p a nt   w h o h as  n ot  si g n e d t h e  I nf or  m e d   C o ns e nt  d o c u  m e nt.  P ati e nts   w h o r ef us e t o  p arti ci p at e  or   w h o wit h dr a  w fr o  m t h e st u d y   will  b e tr e at e d   wit h o ut  pr ej u di c e.    
T h e i nf or  m e d  c o ns e nt  d o c u  m e nt   m ust  b e r e vi e  w e d  a n d  a p pr o v e d  b y t h e I  R  B,  a n y  c h a n g es 
t o t h e i nf or  m e d  c o ns e nt   m ust  b e s u b  mitt e d t o t h e I  R  B f or  a p pr o v al  pri or t o i niti ati o n.   
[ADDRESS_1009764] u d y    will  b e  p erf or  m e d  as  o utli n e d  u n d er  I  N  D  1 1 9 3 2 2  i n  c o  m pli a n c e    wit h  t his pr ot o c ol   a n d   all   a p pli c a bl e  r e g ul ati o ns   a n d   g ui d eli n es  ( e. g.    G o o d    Cli ni c al   Pr a cti c e 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009765] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
 C  O  N FI  D  E  N  TI  A  L  I  N F  O  R  M  A  TI  O  N   O F   H  U  M  A  N  E  TI  C S   C  O  R P  O  R  A  TI  O  N   6 6  G ui d eli n es, t h e   D e cl ar ati o n  of   H elsi n ki,  2 1   C F  R 5 0  – Pr ot e cti o n  of   H u  m a n  S u bj e cts,  a n d  2 1 
C  F  R 5 6 –I nstit uti o n al   R e vi e  w   B o ar ds).   
[ADDRESS_1009766] u d y,  s u bj e cts’ ri g hts  a n d  s af et y ar e  pr ot e ct e d  a n d  t o  c o nfir  m  d at a  i nt e grit y  a n d  q u alit y.   Aft er  t h e  r es e ar c h  sit e  h as  b e e n q u alifi e d, r e c ei v es I  R  B  a p pr o v al  a n d  h as  b e e n tr ai n e d  a n d i nti at e d t h e   m o nit or   will  p er f or  m r o uti n e i nt eri  m  visits. I nt eri  m  visits   will o c c ur  o n  a n  o n g oi n g  b asis,  as  d es cri b e d   b el o  w.  At a   mi ni  m u  m,  p eri o di c   m o nit ori n g   will  o c c ur  o n  a n  a n n u al  b asis f or  a n y  i n v esti g ati o n al sit e wit h  at l e ast  [ADDRESS_1009767]  1  or  2 s u bj e cts at e a c h 
sit e.   
Tr e at  m e nt   &  F oll o  w -u p  E v er y   [ADDRESS_1009768] eti o n   (l ess   t h a n   3 3  % 
D L T s) i n t h e  c o n c urr e nt  c h e  m or a di ati o n  p eri o d    
E n d  of  f oll o  w u p Aft er l ast  s u bj e ct l ast  visit i n  e a c h   sit e  
Cl os e  -o ut  Aft er  all  d at a  q u eri es  h a v e  b e e n  cl os e d   
 
I n  a d diti o n t o t h e   m o nit ori n g fr e q u e n c y list e d  a b o v e, i nt eri  m  visits   m a y  n e e d t o  b e   m or e 
fr e q u e nt if t h er e is 
1)    A  c h a n g e i n st u d y  p ers o n n el (t o  all o  w f or tr ai ni n g  a n d  a d diti o n al s p o ns or 
o v ersi g ht) 
2)    A  pr ot o c ol  a  m e n d  m e nt/s af et y iss u e t h at si g nifi c a ntl y  aff e cts st u d y  pr o c e d ur  es 
or  d esi g n 
3)    A  d o c u  m e nt e d  or s us p e ct e d l a c k  of st u d y  c o  m pli a n c e  or i n v esti g at or  o v ersi g ht 4)    A n iss u e   wit h r e cr uit  m e nt  or  e nr oll  m e nt   
 If t h e  st u d y  s p o ns or  dis c o v ers t h at  a  p arti ci p ati n g  i n v esti g at or is  n ot  c o  m pl yi n g   wit h t h e si g n e d   a gr e e  m e nt   ( F or  m    F  D  A - 1 5 7 2),   t h e    g e n er al   i n v esti g ati o n al    pl a n,    or   ot h er r e q uir e  m e nts t h e st u d y s p o ns or s h all  pr o  m ptl y  eit h er s e c ur e  c o  m pli a n c e  or  dis c o nti n u e t h e i n v esti g at or’s  p arti ci p ati o n i n t h e i n v esti g ati o n.  
[ADDRESS_1009769] u g  as it is  o bt ai n e d fr o  m t h e  p arti ci p ati n g  i n v esti g at or. F or r e vi e  wi n g  a n d r e p orti n g 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009770] u g.  If  t h e A  d v ers e  E v e nt   (  A E) m e ets t h e   S eri o us   A d v ers e  E v e nt   ( S  A E) crit eri a, t h e i n v esti g at or is r e q uir e d t o r e p ort t h e  e v e nt t o t h e s p o ns or   wit hi n  2 4  h o urs  of a  w ar e n ess .    
T o   R e p o rt  a  S  A  E   c all t h e  H u  m a n eti cs   A d v e rs e   E v e nt   R e p o rti n g    li n e: 
 or  b y  c o nt a cti n g t h e   m e di c al   m o nit or  
 
M e di c al   M o nit o r   
Mi c h a el   K ur  m a n,   M  D   
 
 
 
 
Pr o  m pt  r e vi e  w  of t h e  S  A E  b y t h e   m e di c al   m o nit or   will  b e  c o  m pl et e d t o  d et er  mi n e if t h e e v e nt   m e ets  a n y  of t h e  crit eri a f or  r e p orti n g t o t h e  F  D  A , I n v esti g at ors,  a n d/ or I nstit uti o n al R e vi e  w   B o ar ds (I R  B).    S h o ul d  a n  S  A E  b e  d et er  mi n e d t o   m e et t h e  crit eri a f or  a  [ADDRESS_1009771] u g.  
N o   D at a  S af et y   M o nit ori n g   B o ar d (  D S  M  B) is r e q uir e d f or t his st u d y  h o  w e v er, s af et y  d at a 
will  b e r e vi e  w e d  b y t h e s p o ns or  o n  a n  o n g oi n g  b asis  a n d  q u art erl y f or tr e n di n g  of  a d v ers e e v e nts  a n d  cli ni c all y r el e v a nt  s af et y  d at a  o v er ti  m e t o i d e ntif y  p ot e nti al  s af et y  si g n als  a n d t h e n  d et er  mi n e if  a n y  a cti o n is  n e e d e d t o  e ns ur e t h e s af et y  of s u bj e cts.  
T h e  s p o ns or   will  n otif y  t h e  PIs  at  e a c h  sit e  r e g ar di n g  a n y  d os e  li  miti n g  t o xi cit y  (  D L T) 
a n d/ or  S  A E r el at e d t o   BI  O  [ADDRESS_1009772] a n di n g,  a n d  f ur nis h  F  D  A   wit h  a f ull r e port  of t h e s p o ns or’s  a cti o ns.  
 [ADDRESS_1009773] a n n e d.  Pr ot o c ol  d e vi ati o ns   m a y b e i d e ntifi e d  d uri n g   m o nit ori n g  visits  or  b y t h e sit e  eit h er i n  a nti ci p ati o n  of  a  d e v ai ati o n  or 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009774]  o n  a n al ysis  a n d t o  d et er  mi n e if  a n y  a cti o ns  n e e d t o  b e t a k e n  pr e v e nt  c o nti n u e d d e vi ati o ns.  
1 0. 7   R e c o r ds  r et e nti o n   
Cli ni c al  r e c or ds  f or   all   p arti ci p a nts,  i n cl u di n g   all  s o ur c e   d o c u  m e nt ati o n  ( c o nt ai ni n g 
e vi d e n c e  t o  st u d y  eli gi bilit y,  hist or y  a n d  p h ysi c a l  fi n di n gs,  l a b or at or y  d at a,  r es ults  of c o ns ult ati o ns,  et c.),  as   w ell  as  I R  B  r e c or ds  a n d  ot h er  r e g ul at or y  d o c u  m e nt ati o n   will  b e r et ai n e d  b y t h e  Pr ot o c ol  L e a d I n v esti g at or i n  a  s e c ur e  st or a g e f a cilit y i n  c o  m pli a n c e   wit h HI P  A  A,   O  H  R P,  F  D  A  r e g ul ati o ns  a n d  g ui d  a n c e,  u nl ess  t h e  st a n d ar d  at  t h e  sit e  is    m or e stri n g e nt.   T h e  r e c or ds  f or  all  st u di es  p erf or  m e d  u n d er  a n  I  N  D   will  b e    m ai nt ai n e d,  at  a mi ni  m u  m,  f or t  w o  ( 2)  y e ars  aft er t h e  a p pr o v al  of  a n   N  D  A.   T h e  s p o ns or   will  b e  n otifi e d pri or  t o  t h e  pl a n n e d  d estr u cti o n  of  a n y    m at eri als.   T h e  r e c or ds  s h o ul d  b e  a c c essi bl e  f or i ns p e cti o n  a n d  c o p yi n g  b y  a ut h ori z e d  p ers o ns  of t h e  F o o d  a n d   Dr u g   A d  mi nistr ati o n.    
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009775]  S h e ets .   2 0 1 7- 0 6-2 1];   A v ail a bl e 
fr o  m: htt p://s e er. c a n c er. g o v/st atf a cts/ ht  ml/l u n g b. ht  ml . 
2.   C a n c er     F a cts    a n d     Fi g ur es    2 0 1 4  .    2 0 1 4;     A v ail a bl e    fr o  m: 
htt p://  w  w  w. c a n c er. or g/r es e ar c h/ c a n c erf a ctsst atisti cs/ c a n c erf a ctsfi g ur es 2 0 1 4/ . 
3.   P ol k o  ws ki,   K.  a n d   A. P.   M a z ur e k,  Bi ol o gi c al  pr o p erti es  of  g e nist ei n.  A r e vi e  w  of i n 
vitr o  a n d i n  vi v o  d at a.    A ct a  P ol  P h ar  m,  2 0 0 0. 5 7 ( 2):  p.  [ADDRESS_1009776] asis   R e v,  2 0 1 0. 2 9 ( 3):  p.  [ADDRESS_1009777] e  m.   M ol   G e n et    M et a b, 
2 0 1 3.  1 0 9 ( 4):  p.  [ADDRESS_1009778] eristi cs  a n d  p h ar  m a c o ki n eti cs  of  p urifi e d  s o y 
is ofl a v o n es:    m ulti pl e-d os e  a d  mi nistr ati o n  t o    m e n    wit h  pr ost at e  n e o pl asi a.   N utr C a n c er,  2 0 0 4.   4 8 ( 2):  p.  [ADDRESS_1009779]  m e n o p a us al   w o  m e n:  a  p h as e I cli ni c al tri al.    M e n o p a us e,  2 0 0 8. 1 5 ( 4  Pt  1):  p.  [ADDRESS_1009780] ass  m a n n,  S.,  R o  2 4 -2 0 7 6/ 0 0 0  S e g  m e nt II:   Or al  st u d y f or  eff e cts  o n  e  m br y o -f et al  
d e v el o p  m e nt i n t h e r at.   1 9 9 7,   H off  m a n - L a   R o c h e  Lt d.,   B asl e (  C  H).  
9.   W ol z,   E.  R.,   D.;  S c h  mi d,   H.;   H o  w al d,   M.;   K n u p p e,   C.,   R o  2 4 -2 0 7 6/ 0 0 0:  1 3 -W e e k 
or al t o xi cit y  (f e e d  a d  mi x)  st u d y i n t h e  r at.   2 0 01,   H off  m a n -L a   R o c h e,   B asl e (  C  H) ( T esti n g I nstit uti o n:   R  C  C  Lt d., Iti n g e n,  S  wit z erl a n d). 
[ADDRESS_1009781]  (  M L/ T  K)  ( 2 1 3    M 0 0).    2 0 0 0, 
H off  m a n   - L a   R o c h e  Lt d.,   B asl e (  C  H).  
[ADDRESS_1009782] er,    W.,   R o  2 4 -2 0 7 6/ 0 0 0:    Mi cr o n u cl e us  T est  (  M  N T)  i n   P eri p h er al   Bl o o d  of 
Mi c e  aft er  R e p e at e d   Or al  A d  mi nistr ati o n (  G a v a g e) ( 1 3 8  M 9 6)  .  1 9 9 9,   H off  m a n - L a R o c h e  Lt d.,   B asl e (  C  H).   
1 2.   W ol z,  E.  D.,   B.;   C h et el at,   A.;   M att h es,   B.;  Fl a d e,   D.,   R o  2 4 -2 0 7 6/ 0 0 0 (  G e nist ei n): 
Mi cr o n u cl e us   Ass a y i n   B o n e   M arr o  w   C ells  of t  h e   R at  aft er   Or al   A d  mi nistr ati o n (  G a v a g e).  2 0 0 4,   R o c h e   Vit a  mi ns   Lt d.,   B asl e  (  C  H)    ( T esti n g  F a cilit y:   R  C  C   Lt d., Iti n g e n,  S  wit z erl a n d). 
1 3.   Milt y k,    W.,  et  al.,   L a c k  of  si g nifi c a nt  g e n ot o xi cit y  of  p urifi e d  s o y  is ofl a v o n es 
( g e nist ei n,  d ai dz ei n,  a n d  gl y cit ei n) i n  [ADDRESS_1009783] at e  c a n c er. A  m  J   Cli n N utr,  2 0 0 3.   7 7 ( 4):  p.  8 7 5- 8 2. 
1 4.   S c h  mitt,    G.,   T h e  t er at o g e ni c  p ot e nti al  of   R o  2 4 -2 0 7 6/ 0 0 0  (    G e nist ei n):    W h ol e 
e  m br y o  c ult ur e  ass a y.   1 9 9 7,   H off  m a n -  L a   R o c h e  Lt d.,   B asl e (  C  H). 
[ADDRESS_1009784] ei n i n  d o gs.  
F o o d   C h e  m  T o xi c ol,  2 0 0 5.  4 3 ( 1 0):  p.  1 4 6 1- 8 2. 
1 6.   H u  m a n eti cs,   BI  O  3 0 0:  [ADDRESS_1009785] u d y i n   M al e  a n d 
F e  m al e  B e a gl e   D o gs  R e p ort .  2 0 1 3.  p.  7 1 1. 
1 7.   H u  m a n eti cs,   BI  O  3 0 0:   A  I ntr a  m us c ul ar  Si n gl e   M a xi  m u  m  T ol er at e d   D os e  a n d  [ADDRESS_1009786] u d y i n   B e a gl e   D o gs   R e p ort .  2 0 1 3.  p. 1 7 9. 
1 8.   H u  m a n eti cs,   BI  O  3 0 0:   A  [ADDRESS_1009787] u d y  i n   B e a gl e 
D o gs  R e p ort  .  2 0 1 3.  p.  2 0 5. 
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009788] at us.    Cli n   M e d I nsi g hts   O n c ol,  2 0 1 4. 8 :  p.  1 2 1- 8. 
2 1.    S e ki n e, I.,  et  al.,  Q u alit y  of lif e  a n d  dis e as e  -r el at e d s y  m pt o  ms i n  pr e vi o usl y tr e at e d 
J a p a n es e  p ati e nts   wit h  n o n -s  m all-c ell l u n g  c a n c er:  r es ults  of  a  r a n d o  miz e d  p h as e III st u d y ( V- 1 5- 3 2)  of  g efiti ni b  v ers us  d o c et a x el.   A n n   O n c ol,  2 0 0 9. 2 0 ( 9):  p.  1 4 8 3-8. 
2 2.   C ell a,    D.,   et   al.,   W h at  is   a   cli ni c all y    m e a ni n gf ul   c h a n g e   o n  t h e    F u n cti o n al 
Ass ess  m e nt   of    C a n c er   T h er a p y -L u n g  ( F A  C T -L)    Q u esti o n n air e ?    R es ults  fr o  m E ast er n    C o o p er ati v e    O n c ol o g y    Gr o u p  ( E  C  O  G)  St u d y  5 5 9 2.    J    Cli n    E pi d e  mi ol, 2 0 0 2.  5 5 ( 3):  p.  2 8 5- 9 5. 
2 3.   C ell a,   D. F.,  et  al.,   R eli a bilit y  a n d  v ali dit y  of t h e  F u n cti o n al  Ass ess  m e nt  of   C a n c er 
T h er a p y- L u n g  ( F A  C T -L)  q u alit y  of lif e i nstr u  m e nt.  L u n g   C a n c er,  1 9 9 5.   1 2 ( 3):  p. [ADDRESS_1009789]  v ali dit y i n i di o p at hi c  p ul  m o n ar y fi br osis.  R es pir   M e d,  2 0 1 2.   1 0 6 ( 1 0):  p. 1 4 4 7- 5 5. 
2 5.   F a y ers,  P.  M.,  et  al.,  Ass ess  m e nt  of  q u alit y  of lif e i n  s  m all -c ell l u n g  c a n c er  usi n g  a 
D ail y    Di ar y    C ar d  d e v el o p e d  b y  t h e    M e di c al    R es e ar c h    C o u n cil   L u n g    C a n c er W or ki n g  P art y.     Br J   C a n c er,  1 9 9 1. 6 4 ( 2):  p.  2 9 9- 3 0 6. 
2 6.   M o vs as,   B.,  et  al.,   R a n d o  miz e d tri al  of  a  mif osti n e i n l o c all y  a d v a n c e d  n o n -s  m all-
c ell l u n g  c a n c er  p ati e nts r e c ei vi n g  c h e m ot h er a p y  a n d  h y p erfr a cti o n at e d r a di ati o n: r a di ati o n t h er a p y  o n c ol o g y  gr o u p tri al  9 8 - 0 1. J  Cli n   O n c ol,  2 0 0 5. 2 3 ( 1 0):  p.  2 1 4 5-5 4. 
  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009790] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 0  A p p e n di x  2  : D r u gs   t h at   m a y  p r ol o n g   Q  T c 
T o  d et er  m i n e if  a  dr u g   m a y  pr ol o n g t h e   Q T  C i nt er val,  a c c ess  t h e f oll o  wi n g li n k f or  a 
c urr e nt listi n g  of  dr u gs   wit h  a  k n o  w n  or  p ossi bl e ris k  of  pr ol o n gi n g t h e   Q T c i nt er v al  or i n d u ci n g  T ors a d es  d e  P oi nt es ( T d P),   or  c o nt a ct t h e st u d y s p o ns or. T h e  us e  of t h es e  dr u gs s h o ul d  b e  c ar ef ull y  e v al u at e d f or t his st u d y.  
htt ps:// cr e di bl e  m e ds. or g/  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009791] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 2  A p p e n di x   4 :   R  E  CI S  T   C rit e ri a 
R es p o ns  e   Ass ess  m e nt (  R  E  CI S  T   C rit e ri a)  
 M e as ur e  m e nt  of  R es p o ns e T h e  r at e  of  pr o gr essi v e  dis e as e   will  b e  e v al u at e d  i n  t his  st u d y  usi n g  t h e  i nt er n ati o n al crit e ri a   pr o p os e d   b y  t h e    R es p o ns e    E v al u ati o n    Crit eri a  i n   S oli d    T u  m ors   (  R E  CI S T) C o  m  mitt e e [ ]  S e e  htt p:// ct e p.i nf o. ni h. g o v/ g ui d eli n es/r e cist. ht  ml 
f or f urt h er  d et ails. 
R es p o ns e   C rit e ri a:   E v al u ati o n  of t a r g et l esi o ns   
*  C o  m pl et e   R es p o ns e ( C  R):   Dis a p p e ar a n c e  of  all t ar g et l esi o ns
* P arti al   R es p o ns e ( P  R):   At l e ast  a  3 0  %  d e cr e as e i n t h e s u  m  of t h e  L  D  of t ar g et l esi o ns,
t a ki n g  as r ef er e n c e t h e  b as eli n e s u  m  L  D
* Pr o gr essi v e    Dis e as e  ( P  D):    At  l e ast  a  2 0  %  i n cr e as e  i n  t h e  s u  m  of  t h e   L  D  of  t ar g et
l esi o ns, t a ki n g  as r ef er e n c e t h e s  m all est s u  m  L  D r e c or d e d si n c e t h e tr e at  m e nt st art e d  ort h e  a p p e ar a n c e  of  o n e  or   m or e  n e  w
L esi o ns
* St a bl e    Dis e as e  ( S  D):    N eit h er  s uffi ci e nt  s hri n k a g e  t o  q u alif y  f or  P  R  n or  s uffi ci e nt
i n cr e as e t o  q u alif y f or  P  D, t a ki n g  as r ef er e n c e t h e  s  m all est  s u  m  L  D  si n c e t h e tr e at  m e ntst art e d
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009792] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 3  A p p e n di x   5:   C  T  C  A  E  v e rsi o n  4. 0 3 
C o  m  m o n  T er  mi n ol o g y   Crit eri a f or   A d v ers e  E v e nts (  C T  C  A E) 
T h e    m ost  r e c e nt  v ersi o n  of  t h e    C T  C  A E  ( v 4. 0 3)  c a n  b e  f o u n d  a n d  d o  w nl o a d e d  at  t h e 
f oll o  wi n g li n k. 
htt p:// e vs. n ci. ni h. g o v/ft p 1/  C T  C  A E/  C T  C  A E _ 4. 0 3 _ 2 0 1 0- 0 6-
1 4 _  Q ui c k  R ef er e n c e _ 8. 5 x 1 1. p df  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009793] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 4  A p p e n di x   6 :   E  C  O  G  P e rf o r  m a n c e st at us 
T o   m o nit or  a n d  f oll o  w t h e  p ati e nt’s  g e n er al   w ell - bei n g  a n d  a cti viti es  of  n or  m al lif e t h e 
E  C  O  G/ Z u br o d  p erf or  m a n c e st at us   will  b e  d et er  mi n e d t hr o u g h o ut t h e  c o urs e  of t h e  cli ni c al st u d y.  T h e  p erf or  m a n c e st at us s c or e   will  b e r e c or d e d  at  b as eli n e,   w e e kl y  d uri n g t h e  [ADDRESS_1009794] f oll o  w -u p ( 3   m o nt hs), a n d  at  [ADDRESS_1009795] e d i n  p h ysi c all y str e n u o us  a cti vit y  b ut  a  m b ul at  or y  a n d  a bl e t o  c arr y  o ut 
w or k  of  a li g ht  or s e d e nt ar y  n at ur e,  e. g., li g ht  h o us e   w or k,  offi c e   w or k   
2    A  m b ul at or y  a n d  c a p a bl e  of  all  s elf c ar e  b ut  u n a bl e  t o  c arr y  o ut  a n y    w or k 
a cti viti es.   U p  a n d  a b o ut   m or e t h a n  5 0  %  of   w a ki n g  h o urs  
3    C a p a bl e  of  o nl y  li  mit e d   s elf c ar e,  c o nfi n e d  t o  b e d  or  c h air   m or e  t h a n  5 0  %  of 
w a ki n g  h o urs   
[ADDRESS_1009796] et el y  dis a bl e d.   C a n n ot  c arr y  o n  a n y  s elf c ar e.   T ot all y  c o nfi n e d t o  b e d  or 
c h air  
5    D e a d   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009797] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 5  
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009798] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 6  A p p e n di x   8:  S o y   Ri c h  F o o ds 
T h e f oll  o  wi n g is  a list  of s o y  ri c h f o o ds t h at st u d y  p a rti ci p a nts s h o ul d  b e  c o u ns el e d t o 
a v oi d   w hil e  p a rti ci p ati n g i n t h e st u d y:  
E d a  m a  m e  
M e at     Alt er n ati v es  c o nt ai ni n g s o y  pr ot ei n  or t of u,  e. g. n o   m e at  h ot  d o gs Mis o   N att o   N utriti o n al  dri n ks  a n d  b ars   wit h  a d d e d s o y  pr ot ei n S o y  mil k  S o y  c h e es e  S o y i c e  cr e a  m  S o y  y o g urt  S o y   N uts  T e  m p e h  T e xt ur e d  S o y  Pr ot ei n  T of u  W h ol e  S o y b e a ns   
Us e t o t h e   f oll o  wi n g li n ks f or  a d diti o n al i nf or  m ati o n  o n s o y ri c h f o o ds: 
htt p://  w w  w. u csf h e alt h. or g/ e d u c ati o n/ a _ g ui d e _t o _f o o ds _ri c h _i n _s o y/   htt p://  w w  w. ars. us d a. g o v/ S P 2  Us er Fil es/ Pl a c e/ 8 0 4 0 0 5 2 5/  D at a/is ofl a v/Is ofl a v    R 2. p df   
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009799] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 8  A p p e n di x   1 0:   C rit e ri a  f o r    P at h ol o gi c    R es p o ns e  of    T a r g et    L esi o ns    a n d   E xt e nt  of 
S u r gi c al   R es e cti o n  
C rit e ri a f o r  P at h ol o gi c   R es p o ns e  of   T a r g et   L esi o ns   
•  P at h ol o gi c   C o  m pl et e   R es p o ns e ( P  C  R):   C o  m pl et e r es e cti o n (  R 0 r es e cti o n)
a c hi e v e d  a n d  n o  e vi d e n c e  of  vi a bl e t u  m or i n t h e  e ntir e r es e cti o n s p e ci  m e n;
•  M e di asti n al  P at h ol o gi c   C o  m pl et e   R es p o ns e (  M  C  R) (t o  b e  ass ess e d  o nl y if t h er e
w er e   m e di asti n al  L  Ns (  N 2  dis e as e)  pr es e nt  at  di a g n osis):   C o  m pl et e r es e cti o n
a c hi e v e d   wit h  n o  e vi d e n c e  of r esi d u al  vi a bl e t u  m or i n t h e   m e di asti n al l y  m p hn o d es, r e g ar dl ess  of t h e  pri  m ar y t u  m or st at us;
•  Pr o gr essi v e   Dis e as e ( P  D):   N e  w sit es  of  dis e as e i d e ntifi e d  p at h ol o gi c all y ( e. g.,
m ali g n a nt  pl e ur al st u d di n g,   m ulti pl e  p ul  m o n ar y   m et ast as es,  et c.);
•  St a bl e   Dis e as e ( S  D):   N ot   m e eti n g t h e  crit eri a  of  a n y  of t h e t hr e e  c at e g ori es  a b o v e.
E xt e nt  of  S u r gi c al   R es e cti o n   
•  R 0:   C o  m pl et e r es e cti o n  of  all  dis e as e   wit h  n e g ati v e   m ar gi ns  a n d t h e  hi g h est
l y  m p h  n o d e r es e ct e d  n e g ati v e f or r esi d u al t u  m or;
•  R 1:   C o  m pl et e r es e cti o n  of  all  gr oss  d  is e as e   wit h  p at h ol o gi c all y  p ositi v e   m ar gi ns
a n d/ or  p at h ol o gi c  e vi d e n c e  of t u  m or  c ells i n t h e  hi g h est l y  m p h  n o d e r es e ct e d i nt h e   m e di asti n u  m  a n d/ or  e xtr a c a ps ul ar  n o d al s pr e a d;
•  R 2:   Gr oss r esi d u al  dis e as e l eft  b e hi n d  aft er s ur gi c al r es e cti o n.
P r ot o c ol  #  C  L 0 1 0 1 -0 1  P h as e I/II   BI  O  [ADDRESS_1009800] u d y    V e rsi o n  8. 0,   2 6  F e b  2 0 1 8  
8 9  A p p e n di x  1  1:   R a di ati o n  P n e u  m o nitis  q u a ntifi c ati o n  vi a   C  T  c h a n g es 
Q u a ntif yi n g   C  T   C h a n g es   
S c o r e    D es c ri pti o n   
0    N o  c h a n g e   
1    Sli g ht  h o  m o g e n e o us i n cr e as e i n r a di o gr a p hi c  d e nsit y ( e g,  gr o u n d  gl ass  a p p e ar a n c e)  
2    P at c h y   or     m ultif o c al   c o ns oli d ati o n   t h at   d o es   n ot   c o nf or  m   t o   i rr a di at e d   ar e a 
( pr es u  m a bl y  as t o o  p at c h y) 
3    S e v er e  c o nfl u e nt  c o ns oli d ati o n t h at  c o nf or  ms t o s h a p e  of irr a di at e d  ar e a  b ut  d o es  n ot 
u nif or  ml y i n v ol v e it  
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P P a g e  [ADDRESS_1009801] a n 
( S  A P) 
P  R  O T  O  C  O L   N  U  M  B E  R: C L 0 1 0 1- 0 1 
S  A P   V E  R SI  O  N: Dr aft  6 
S  A P   D  A T E: 9- O ct  - 2 0 1 7
P  R  O T  O  C  O L   D  A T E: Ori gi n al:  7   A pr  2 0 1 5 
V ersi o n  3. 0:  1 8   A u g  2 0 1 5 
V ersi o n  3. 0:  1 6  F e b  2 0 1 6 
V ersi o n  4. 0:  2   M a y  2 0 1 6 
V ersi o n  5. 0:  1 5   A u g  2 0 1 6 
V ersi o n  6. 0:  2 0   D e c  2 0 1 6 V ersi o n  7. 0:  1 5   A u g  2 0 1 7 
S P  O  N S  O  R: H u  m a n eti cs 
P  R E P  A  R E  D   B  Y: H u  m a n eti cs 
A  U T  H  O  R( S): M eliss a I n gr a  m,  P h.  D. 
A P P  R  O  V E  D: 
N a  m e   
Titl e,   C o  m p a n y  D at e   
N a  m e   Titl e,   C o  m p a n y  D at e   
Pr ot o c ol   C L [ADDRESS_1009802] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009803]   Attriti o n .....................................................................  8  3. 3. 2    Crit eri a f or   Dis c o nti n u ati o n  of  S u bj e cts fr o  m t h e  Tri al ............................................  9   
3. 4    S  C  H E  D  U L E   O F  S T  U  D  Y   A S S E S S  M E  N T S ....................................................................  9  
4    S  A  M P L E  SI Z E   C  O  N SI  D E  R  A TI  O  N S ..................................................................................  1 5  
5    A  N  A L  Y SI S  P  O P  U L  A TI  O  N S ...............................................................................................  1 5   
5. 1    F  U L L   A  N  A L  Y SI S  S E T .................................................................................................  1 5  5. 2    E F FI  C  A  C  Y   A  N  A L  Y SI S  S E T ........................................................................................  1 5  
5. 3    P  H  A  R  M  A  C  O  KI  N E TI  C ( P  K)  P  O P  U L  A TI  O  N ..............................................................  1 5  
5. 4    P  H  A  R  M  A  C  O  D  Y  N  A  MI  C S ( P  D)  P  O P  U L  A TI  O  N .........................................................  1 5  
6    C  O  N SI  D E  R  A TI  O  N S  F  O  R   D  A T  A   A  N  A L  Y SI S ...................................................................  1 5   
6. 1    P  R  O  G  R  A  M  MI  N  G  E  N  VI  R  O  N  M E  N T ...........................................................................  1 5  
6. 2    S T  R  A T  A   A  N  D   C  O  V  A  RI  A T E S ....................................................................................  1 5  6. 3    S  U  B  G  R  O  U P S ................................................................................................................  1 5  
6. 4    M  U L TI P L E   C  O  M P  A  RI S  O  N S   A  N  D   M  U L TI P LI  C T  Y .................................................  1 5   
6. 5    SI  G  NI FI  C  A  N  C E  L E  V E L ..............................................................................................  1 6  
6. 6    S T  A TI S TI  C  A L   N  O T  AI  O  N   A  N  D   M E T  H  O  D  O L  O  G  Y ..................................................  1 6  
7    D  A T  A   H  A  N  D LI  N  G   M E T  H  O  D S ..........................................................................................  1 6   
7. 1    MI S SI  N  G   D  A T  A ...........................................................................................................  1 6   
7. 1. 1    F  A  C T- T  OI   H a n dli n g  of   Missi n g It e  ms ..................................................................  1 6  
7. 2    VI SI T   WI  N  D  O  W S .........................................................................................................  1 7   7. 3    D  A T  A   D E  RI  V  A TI  O  N S   A  N  D   D E FI  NI TI  O  N S .............................................................  1 7   
8    S T  U  D  Y  P  O P  U L  A TI  O  N ........................................................................................................  1 7  
8. 1    A  N  A L  Y SI S  P  O P  U L  A TI  O  N ..........................................................................................  1 7   
8. 2    S  U  BJ E  C T   DI S P  O S TI TI  O  N ...........................................................................................  1 8  
8. 3    I  N  C L  U SI  O  N/ E  X  C L  U SI  O  N   C  RI T E  RI  A .......................................................................  [ADDRESS_1009804] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3  of  4 3 9. 1    O  BJ E  C TI  V E   R E S P  O  N S E S ...........................................................................................  1 8   
9. 2    D  U  R  A TI  O  N   O F   R E S P  O  N S E (  D  O  R) ............................................................................  1 9   
9. 3    P  R  O  G  R E S SI  O  N  F  R E E  S  U  R  VI  V  A L ............................................................................  1 9  
9. 4    P  U L  M  O  N  A  R  Y  F  U  N  C TI  O  N  T E S T ...............................................................................  2 0  
9. 5    S  W  A L L  O  WI  N  G   DI  A  R  Y ...............................................................................................  2 0  
9. 6    S  O  B  Q .............................................................................................................................  2 0  
9. 7    F  A  C T- T  OI  ......................................................................................................................  2 0 
1 0    S  A F E T  Y  ................................................................................................................................  2 0 
1 0. 1    E  X P  O S  U  R E  T  O  S T  U  D  Y   D  R  U  G ..................................................................................  2 0  
1 0. 2    D L T   A  N  D   M T  D .............................................................................................................  2 1   
1 0. 3    A  D  V E  R S E  E  V E  N T S .....................................................................................................  2 1   
1 0. 4    S E  RI  O  U S   A  D  V E  R S E  E  V E  N T S   A  N  D   D E  A T  H ...........................................................  2 1  
1 0. 5    L  A  B  O  R  A T  O  R  Y  E  V  A L  U  A TI  O  N S ...............................................................................  2 1  
1 0. 6    P  R E  G  N  A  N  C  Y  T E S T .....................................................................................................  2 1  
1 0. 7    P  H  Y SI  C  A L  E  X  A  MI  N  A TI  O  N S .....................................................................................  2 2  
1 0. 8    E L E  C T  R  O  C  A  R  DI  O  G  R  A  M S ........................................................................................  2 2  
1 0. 9    E  C  O  G .............................................................................................................................  2 2  
1 0. 1 0    VI T  A L  SI  G  N S ............................................................................................................  2 2   
1 1    P  H  A  R  M  A  C  O  KI  N E TI  C S   A  N  A L  Y S E S ................................................................................  2 2  1 2    P  H  A  R  M  A  C  O  D  Y  N  A  MI  C   A  N  A L  Y S E S ...............................................................................  2 2  
1 3    I  N T E  RI  M   A  N  A L  Y SI S ..........................................................................................................  2 2 
1 4    E  N  D -O F  - S T  U  D  Y   A  N  A L  Y SI S .............................................................................................  2 2 
1 5    T  A  B L E   O F   C  O  N T E  N T S  F  O  R   D  A T  A   DI S P L  A  Y S .............................................................  2 4  
1 5. 1    D E  M  O  G  R  A P  HI S  C  S  U  M  M  A  R  Y  FI  G  U  R E S   A  N  D  T  A  B L E S .......................................  2 4   1 5. 2    E F FI  C  A  C  Y  S  U  M  M  A  R  Y  FI  G  U  R E S   A  N  D  T  A  B L E S ...................................................  2 4  
1 5. 3    S  A F E T  Y  S  U  M  M  A  R  Y  FI  G  U  R E S   A  N  D  T  A  B L E S ........................................................  2 5  
1 5. 3. 1    A d v ers e  E v e nts .......................................................................................................  2 5   1 5. 3. 2    S eri o us   A d v ers e  E v e nts,   D e at hs  a n d   Ot h er  Si g nifi c a nt   A d v ers e  E v e nts  ................  2 5 
1 5. 3. 3    N arr ati v es ................................................................................................................  2 5   
1 5. 3. 4    L a b or at or y   R es ults ..................................................................................................  2 5  
1 5. 3. 5    Ot h er  S af et y   R es ults ...............................................................................................  2 5   
1 5. 4    LI S TI  N  G S ......................................................................................................................  2 6  
1 5. 4. 1    Dis c o nti n u e d  P ati e nts ..............................................................................................  2 6   
1 5. 4. 2    Pr ot o c ol   D e vi ati o ns .................................................................................................  2 6  
1 5. 4. 3    S u bj e cts  E x cl u d e d fr o  m t h e  Effi c a c y   A n al ysis .......................................................  2 6  
1 5. 4. 4    D e  m o gr a p hi c   D at a ..................................................................................................  2 6   
1 5. 4. 5    C o  m pli a n c e  a n d/ or   Dr u g   C o n c e ntr ati o n   D at a .........................................................  [ADDRESS_1009805] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009806] er   C o o p er ati v e   O n c ol o g y   Gr o u p 
F  A  C T- T  OI     F u n cti o n al   Ass ess  m e nt  of   C a n c er  T h er a p y- Tri al   O ut c o  m e I n d e x (l u n g  c a n c er) 
F  A S         F ull   A n al ysis  S et 
F E  V [ADDRESS_1009807] a n d ar d   D e vi ati o n 
T 1/ [ADDRESS_1009808] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009809] u d y  pr ot o c ol  a n d  c as e r e p ort 
f or  ms (  C  R Fs) f or  d et ails  of st u d y  c o n d u ct  a n d  d at a  c oll e cti o n. 
2    S  T  U  D  Y  O  B J  E  C  TI  V  E S,   T  R  E  A  T  M  E  N  T S   A  N  D   E  N  D P  OI  N  T S   
2. 1    S  T  U  D  Y   O  B J  E  C  TI  V  E S 
2. 1. 1    P ri  m a r y   O bj e cti v es 
T h e  pri  m ar y  o bj e cti v e is t o  d es cri b e  a n y  d os e li  miti n g t o xi citi es  of t h e  c o  m bi n ati o n  of   BI  O  3 0 0 
wit h  c h e  m or a di ot h er a p y i n  s u bj e cts   wit h  n o n-s  m all  c ell l u n g  c a n c er (  N S  C L  C)  a n d t o  d et er  mi n e t h e r e c o  m  m e n d e d  d os e (t h e  o pti  m al  d os e)  of t his  c o  m bi n ati o n.  
2. 1. [ADDRESS_1009810] u d y  ar e: 
•    T o   d es cri b e  t h e   o v er all   a d v ers e   e v e nt   pr ofil e   of  t h e   c o  m bi n ati o n   of    BI  O   3 0 0   a n d 
c h e  m or a di ot h er a p y i n t h e t ar g et  p ati e nt  p o p ul ati o n 
•    T o  d et er  mi n e t h e  p h ar  m a c o ki n eti cs  of   BI  O  3 0 0  a n d t h e  c h e  m ot h er a p y  c o  m p o n e nts  of t h e 
r e gi  m e n ( p a clit a x el  a n d  c ar b o pl ati n)   w h e n  gi v e n i n  c o  m bi n ati o n 
•    T o    d et er  mi n e   t h e    p h ar  m a c o d y n a  mi c    eff e cts    of     BI  O    3 0 0   i n    c o  m bi n ati o n     wit h 
c h e  m or a di ot h er a p y  b y t h e  d et er  mi n ati o n  of  c ert ai n s er u  m  pr ot ei n  a n d  c yt o ki n e l e v els  
•    T o r e p ort l o c al  pr o gr essi o n r at e as  d efi n e d  p er  R E  CI S T ( 1. 1) crit eri a  or f or s ur gi c al  p ati e nts 
p at h ol o gi c al r es p o ns e. 
•    P ul  m o n ar y  f u n cti o n t est  ( P F T)  a n d  q u alit y  of lif e  (  Q  O L)   m e as ur es  ( F  A  C T- T  OI,   U S  C  D-
S  O  B,  a n d s  w all o  wi n g  di ar y) 
•    T o  st u d y  t h e   eff e ct   of    BI  O   3 0 0   o n  t h e  i n ci d e n c e   of   p ul  m o n ar y  fi br osis  f oll o  wi n g 
c h e  m or a di ot h er a p y i n t h e t ar g et  p o p ul ati o n  as  ass ess e d  b y  4  D   C T s c a n ni n g  
•    T o  d et er  mi n e  o v er all  s ur vi v al  (  O S)  a n d  pr o gr essi o n  fr e e  s ur vi v al  ( P F S)  i n  t h e  st u d y 
p o p ul ati o n 
2. [ADDRESS_1009811] er e d  d ail y f or t h e  e ntir e  c o urs e  of  c o n c urr e nt  c h e  m or a di ot h er a p y,  a   mi ni  m u  m  of  6   w e e ks; 
c h e  m ot h er a p y   will  b e  a d  mi nist er e d   w e e kl y  f or  [ADDRESS_1009812] er e d 
d ail y (  M- F) f or  a  p eri o d  of  6   w e e ks.    T h e i niti al  d os e  of   BI  O  3 0 0   will  b e  5 0 0   m g/ d;  s u bs e q u e nt 
d os es    will  b e  1 0 0 0    m g/ d  a n d  1 5 0 0    m g/ d.     P a clit a x el  a n d  c ar b o pl ati n    will  b e  a d  mi nist er e d 
i ntr a v e n o usl y   w e e kl y,  p a clit a x el  i n  a  d os e  of  4 5   m g/  m
[ADDRESS_1009813] ati n  i n  a  d os e  s uffi ci e nt  t o 
a c hi e v e  a n   A  U  C  of  2   m g *  mi n/  m L.    R a di ot h er a p y   will  b e  a d  mi nist er e d  5  d a ys  a   w e e k (  M- F) f or  [ADDRESS_1009814] et e d  c o n c urr e nt  c h e  m or a di ot h er a p y   wit h  f e  w er t h a n  3 3  %   D L Ts  attri b ut e d t o 
BI  O  [ADDRESS_1009815] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009816] e as e r ef er t o 
S e cti o n  3. 1 f or  d et ails i n t h e  d et er  mi n ati o n  of t h e  o pti  m al  d os e.  
 
2. 3. 2    S e c o n d a r y   E n d p oi nts 
A d v ers e  e v e nts  a n d  s eri o us  a d v ers e  e v e nts  c o d e d  a c c or di n g  t o   C o  m  m o n   T o xi cit y   Crit eri a  f or 
A d v ers e  E v e nts (  C T  C  A E)  v ersi o n  4. 0 3. 
P n e u  m o nitis/fi br osis i n ci d e n c e  a c c or di n g t o  d o c u  m e nt e d   A Es  a n d  q u a ntifi c ati o n  vi a   C T.  
•    P h ar  m a c o ki n eti c  e n d p oi nts f or   BI  O  [ADDRESS_1009817] ati n  ar e: 
o    M a xi  m u  m  c o n c e ntr ati o n (  C m a x) 
o    Ti  m e  at   m a x  c o n c e ntr ati o n ( T m a x) 
o    Ar e a  u n d er t h e  c o n c e ntr ati o n-ti  m e  c ur v e (  A  U  C)   
o    H alf  -lif e ( T 1/ 2) 
o    Cl e ar a n c e (  Cl) 
•    P h ar  m a c o d y n a  mi c  e n d p oi nts  ar e: 
o    C yt o ki n es I L- 6, I L- [ADDRESS_1009818] or (  G-  C S F) 
o    C-r e a cti v e  pr ot ei n,  a n d  
o    Pr ost a gl a n di n  E 2 
•    Dis e as e  pr o gr essi o n/ T u  m or r es p o ns e: 
o    O bj e cti v e t u  m or r es p o ns e  T u  m or  di a  m et er 
o    O bj e cti v e t u  m or r es p o ns e  a c c or di n g t o   R E  CI S T  1. 1   Crit eri a 
o    Pr o gr essi o n  Fr e e  S ur vi v al  
•    Q u alit y  of  Lif e   M e as ur es: 
o    S  O  B  Q o    F  A  C T- T  OI  
o    S  w all o  wi n g  di ar y 
•    P ul  m o n ar y  F u n cti o n: 
o    F  V  C/ F E  V [ADDRESS_1009819] u d y is  a n  o p e n l a b el,  d os e  es c al ati o n tri al   wit h s e q u e nti al  c o h orts  of s u bj e cts r e c ei vi n g   BI  O 
3 0 0   Or al  S us p e nsi o n  a n d  c h e  m or a di ati o n t h er a p y.  T hr e e  d os es  of   BI  O  3 0 0   Or al  S us p e nsi o n ( 5 0 0 
m g/ d,   1 0 0 0    m g/ d,   a n d   1 5 0 0    m g/ d)    will   b e   a d  mi nist er e d   d uri n g  t h e   c o urs e   of   c o n c urr e nt 
c h e  m or a di ati o n t h er a p y.  E a c h  c o h ort   will  b e gi n   wit h  a st u d y  of t h e  p h ar  m a c o ki n eti cs  of   BI  O  [ADDRESS_1009820] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009821] et e  si x  ( 6)    w e e ks   of 
c o n c urr e nt  c h e  m or a di ati o n  t h er a p y    w hil e  c o nti n ui n g  d ail y    BI  O  [ADDRESS_1009822] er e d  d ail y f or t h e  e ntir e  c o urs e  of  c o n c urr e nt  c h e  m or a di ot h er a p y,  a   mi ni  m u  m  of  6   w e e ks; 
c h e  m ot h er a p y   will  b e  a d  mi nist er e d   w e e kl y  f or  [ADDRESS_1009823] er e d 
d ail y (  M- F) f or  a  p eri o d  of  6   w e e ks.    T h e i niti al  d os e  of   BI  O  3 0 0   will  b e  5 0 0   m g/ d;  s u bs e q u e nt 
d os es    will  b e  1 0 0 0    m g/ d  a n d  1 5 0 0    m g/ d.     P a clit a x el  a n d  c ar b o pl ati n    will  b e  a d  mi nist er e d 
i ntr a v e n o usl y   w e e kl y,  p a clit a x el  i n  a  d os e  of  4 5   m g/  m
[ADDRESS_1009824] ati n  i n  a  d os e  s uffi ci e nt  t o 
a c hi e v e  a n   A  U  C  of  2   m g *  mi n/  m L.    R a di ot h er a p y   will  b e  a d  mi nist er e d  5  d a ys  a   w e e k (  M- F) f or  [ADDRESS_1009825] er e d  o n   D a y  1,   Visit  2, i n   w hi c h  s af et y  d at a ( a d v ers e 
e v e nts,     E  C  Gs,   r es ults    of   s af et y   l a b or at or y    d et er  mi n ati o ns),    p h ar  m a c o ki n eti c   ( P  K)    a n d 
p h ar  m a c o d y n a  mi c ( P  D)  d at a   will  b e  c oll e ct e d.   P  K  d at a   will  b e  c oll e ct e d fr o  m  a   mi ni  m u  m  of  si x 
( 6)  st u d y  p arti ci p a nts  fr o  m  e a c h  st u d y  c o h ort.    Bl o o d  s a  m pl es  f or  P  D  d at a  c oll e cti o n    will  b e 
c oll e ct e d  pri or t o  a n d  p ost   BI  O  3 0 0  d osi n g ( 2  hr) fr o  m  all s u bj e cts i n  e a c h st u d y  c o h ort.   
D a y  [ADDRESS_1009826] er e d  i n 
c o  m bi n ati o n     wit h   t h e   c h e  m ot h er a p y   c o  m p o n e nts   of   t h e   pr ot o c ol   t h er a p y   ( p a clit a x el   a n d 
c ar b o pl ati n).   D uri n g t h e  first  or  s e c o n d  c h e  m ot h er a p y i nf usi o n,  as  b ef or e,  a d diti o n al  s af et y,  P  K 
a n d  P  D  d at a   will  b e  c oll e ct e d.   Bl o o d s a  m pl es f or  P  D  d at a  c oll e cti o n   will  b e  c oll e ct e d  pri or t o  a n d 
p ost   BI  O  3 0 0  d osi n g ( 2  hr) fr o  m  all s u bj e cts i n  e a c h st u d y  c o h ort.  
D a y  1  of   r a di ati o n t h er a p y  (  R T)   m a y  b e  s c h e d ul e d  at t h e  dis cr eti o n  of t h e i n v esti g at or  pr o vi d e d 
t h e  s u bj e ct  h as  c o  m pl et e d  a   mi ni  m u  m  of  [ADDRESS_1009827] er e d  d ail y;  p a clit a x el  a n d  c ar b o pl ati n   will  b e  a d  mi nist er e d   w e e kl y  a n d r a di ot h er a p y   will 
b e a d  mi nist er e d  d ail y as  d es cri b e d a b o v e  u ntil a t ot al  d os e  of  [ADDRESS_1009828] er e d.    D uri n g 
t h e  p eri o d  of  c o  m bi n e d   BI  O  3 0 0  a n d  c h e  m or a di ot h er a p y ( 6   w e e ks),  a d diti o n al s af et y,  P  K  a n d  P  D 
d at a    will  b e  c oll e ct e d    w e e kl y.   Tr o u g h  l e v els  f or   BI  O  [ADDRESS_1009829]  pri or 
t o t h at   w e e k’s  c h e  m ot h er a p y tr e at  m e nt  a n d t h at  d a ys’   BI  O  [ADDRESS_1009830] et e d  c o n c urr e nt  c h e  m or a di ot h er a p y   wit h  f e  w er t h a n  3 3  %   D L Ts  attri b ut e d t o 
BI  O  [ADDRESS_1009831] e d i n t h e   A E   C  R Fs:  
Pr ot o c ol   C L [ADDRESS_1009832] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  8  of  4 3 1)    R a di ati o n  es o p h a gitis   Gr a d e  3 t h at l asts  >  7  c o ns e c uti v e  d a ys  or   Gr a d e  4. 
2)    Gr a d e  4  n e utr o p e ni a f or   m or e t h a n  7  d a ys  or  n e utr o p e ni a f e v er ( d efi n e d  as   A  N  C  <  5 0 0  a n d 
a t e  m p er at ur e  of  3 8. 5°   C  or  a b o v e). 
3)    Gr a d e  3 t hr o  m b o c yt o p e ni a   wit h  cli ni c all y si g nifi c a nt  bl e e di n g 
4)    Gr a d e  4 t hr o  m b o c yt o p e ni a  >  7  d a ys. 
5)    Gr a d e  4  n a us e a/ v o  miti n g  d es pit e  a p pr o pri at e  a nti e  m eti c t h er a p y. 
6)    Gr a d e  3   A S T/  A L T  el e v ati o ns  >  7  d a ys 
7)    D el a ys i n r a di ot h er a p y  or  c h e  m ot h er a p y  d u e t o t o xi cit y  of   m or e t h a n  [ADDRESS_1009833]  o n  p ati e nt  o ut c o  m e a n d t h us  ar e t o  b e  d esi g n at e d  as  a   D L T. 
8)    All  ot h er  n o n- h e  m at ol o gi c t o xi citi es  of   Gr a d e  3  or  hi g h er,   wit h t h e f oll o  wi n g  e x c e pti o ns:   
a.    a n or e xi a 
b.    f ati g u e 
c.    i nf e cti o n   wit h o ut  n e utr o p e ni a 
d.    Gr a d e  3   A S T/  A L T  el e v ati o ns  ≤  [ADDRESS_1009834] u d y   m e as ur e  m e nts   will  b e  p erf or  m e d  at t h e ti  m e 
of  d e p art ur e ( or  as s h ortl y t h er e aft er  as  p ossi bl e).  
1)    Dr u g-  R el at e d   R e as o ns 
a.    S u bj e ct  e x p eri e n c es  a n  a d v ers e r e a cti o n  a n d  d o es  n ot   wis h t o r e  m ai n i n t h e tri al.  b.    S u bj e ct  e x p eri e n c es  a  s eri o us  a d v ers e  r e a cti o n  or  a  s p e cifi c  a d v ers e  r e a cti o n t h at 
r e q uir es    dis c o nti n u ati o n   a c c or di n g   t o   t h e    pr ot o c ol   as    d et er  mi n e d    b y   t h e i n v esti g at or. 
c.    Cli ni c al  tri al  is  t er  mi n at e d  pr e  m at ur el y  b e c a us e  of  u n a c c e pt a bl e  s af et y  c o n c er ns 
(ris ks)  of t h e s u p pl e  m e nt  b ei n g t est e d. 
2)    Cli ni c al- Tri al-  R el at e d   R e as o ns 
a.    S u bj e ct i n di c at es t h e r e q uir e  m e nts  ar e t o o  o n er o us,  or t o o l o n g,  or l os es i nt er est;  or 
r ef us es t o  p arti ci p at e. 
b.    Cli ni c al tri al is t er  mi n at e d  at  a  pr es et  d at e  a n d s o  m e s u bj e cts  ar e  n ot  c o  m pl et e d.   
3)    S u bj e ct-  R el at e d   R e as o ns   D et er  mi n e d  b y t h e I n v esti g at or 
a.    S u bj e ct  f ails  t o    m ai nt ai n  a d e q u at e  c o  m pli a n c e    wit h  o n e  or    m or e  as p e cts  of  t h e 
pr ot o c ol  or s u bj e ct f ails t o  c o o p er at e  a d e q u at el y  d uri n g  cli ni c al  visits.  
b.    S u bj e ct f o u n d  n ot t o   m e et  or  n o l o n g er   m e ets t h e  ori gi n al  e ntr y r e q uir e  m e nts.  
c.    S u bj e ct  h as  us e d  a  n o n- a p pr o v e d   m e di ci n e  or tr e at  m e nt  d uri n g t h e tri al.  
d.    S u bj e ct   w h o  at t h e I n v esti g at or’s  dis cr eti o n f e els t h at  c o nti n ui n g i n t h e st u d y   w o ul d 
n ot  b e i n t h eir  b est i nt er est.  
e.    S u bj e ct   b e c o  m es   pr e g n a nt   ( o bs er v ati o n   a n d   f oll o  w- u p   pr o c e d ur es     m ust   b e 
i niti at e d). 
f.   S u bj e ct   wit h dr a  ws i nf or  m e d  c o ns e nt. 
Pr ot o c ol   C L [ADDRESS_1009835] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  9  of  4 3 4)    Ot h er   R e as o ns 
a.    S u bj e ct r ef us es t o st at e r e as o ns f or  dr o p pi n g  o ut. 
b.    S u bj e ct  d e v el o ps  a n i nt er c urr e nt ill n ess  a n d is  u n a bl e  or  u n  willi n g t o  c o nti n u e i n  a 
cli ni c al tri al;  h o  w e v er, I n v esti g at or  di d  n ot   wis h t o  dis c o nti n u e t h e s u bj e ct.  
c.    S u bj e ct’s  p ers o n al sit u ati o n  c h a n g es:  e. g.   m or e   w or k r es p o nsi bilit y/tr a v el  or  h o  m e 
c h a n g es   (  m o v es,     m arri es,   f a  mil y)   a n d   s u bj e ct   h as   l ess   ti  m e/  m oti v ati o n   t o p arti ci p at e. 
d.    Ot h er iss u es r e q uiri n g   wit h dr a  w al  of t h e s u bj e ct fr o  m t h e tri al.   
5)    L ost t o  F oll o  w- u p 
6)    D e at h   
 
3. 3. 2    C rit e ri a f o r   Dis c o nti n u ati o n  of  S u bj e cts f r o  m t h e   T ri al 
Pr ot o c ol tr e at  m e nt   m a y  b e  dis c o nti n u e d f or  a n y  of t h e f oll o  wi n g r e as o ns:  
1)    At t h e  dis cr eti o n  of t h e I n v esti g at or,  at y pi c al  pr o gr essi o n  of  dis e as e;   
2)    If  4 0  %  or   m or e  of s u bj e cts ( 4  o ut  of  a t ot al  of  1 0) i n  a  c o h ort  e x p eri e n c e  a   D L T  attri b ut a bl e 
t o   BI  O  3 0 0   Or al  S us p e nsi o n, t h e   M T  D   will  h a v e  b e e n  e x c e e d e d  a n d  e nr oll  m e nt i nt o t h at c o h ort  a n d  a n y  hi g h er- d os e  c o h ort  c urr e ntl y  o p e n t o  e nr oll  m e nt   will  c e as e (s e e s e cti o n  8. 5, 
D os e  Li  miti n g  T o xi citi es (  D L Ts).  
3)    A  d el a y i n  pr ot o c ol tr e at  m e nt  of  gr e at er t h a n  3   w e e ks  d uri n g t h e c o n c urr e nt  p h as e a n d   m or e 
t h a n  4   w e e ks i n t h e  c o ns oli d ati o n  c h e  m ot h er a p y  p h as e. 
4)    A n y  o n e  of t h e   D os e   Li  miti n g   T o xi citi es list e d i n  s e cti o n  8. 5,   D os e   Li  miti n g   T o xi citi es 
(  D L Ts).  
5)    If  pr ot o c ol tr e at  m e nt is  dis c o nti n u e d  d u e t o  d el a y  or  d os e li  miti n g t o xi cit y (  D L T),  at t h e 
dis c o nti n u ati o n  visit,   C  B  C   wit h  diff er e nti al  a n d  s er u  m  c h e  mistri es   will  b e  c o  m pl et e d f or 
s af et y r e p orti n g.   At t h e  dis cr eti o n  of t h e I n v esti g at or, a d diti o n al f oll o  w- u p  bl o o d   w or k   m a y 
b e r e q u est e d.  
6)    If   pr ot o c ol  tr e at  m e nt  is   dis c o nti n u e d  f or   a n y   ot h er  r e as o n,   at  t h e   dis cr eti o n   of  t h e 
I n v esti g at or,   C  B  C   wit h  diff er e nti al  a n d  s er u  m  c h e  mistri es    m a y  b e  r e q u est e d  f or  s af et y 
r e p orti n g  p ur p os es.  
 
3. 4    S  C  H  E  D  U  L  E   O F  S  T  U  D  Y   A S S  E S S  M  E  N  T S 
T a bl e   3- 1 :   Ti  m e t o   E v e nt f o r  n o n s u r gi c al s u bj e cts 
VI SI  T  #   [ADDRESS_1009836] eti o n   3   m o  6   m o  
9   m o  
1 1   m o  
1 3  m o   
I nf or  m e d 
C o ns e nt   X     
     
                    
R e vi e  w    I/ E 
Crit eri a   X   X  
     
                    
Pr ot o c ol   C L [ADDRESS_1009837] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009838] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  1 1  of  4 3 Di et 
C o u ns eli n g8 X Xb Xb   Xb                  
 
aO pti o n al  visit  5 b   as  n e e d e d,  bw e e kl y, cbi -w e e kl y   ( e v er y  ot h er   w e e k), dvisit  2 0  o nl y;  visit   wi n d o  w  all o  w a n c e  of  +/ - [ADDRESS_1009839]  is    m e di c all y  fit  f or  s ur g er y  us e  t a bl e  7. 1. 2, f BI  O 3 0 0  + c  h e  m o   P  K 
s c h e d uli n g  all o  w e d   w e e k  1  or  2,  S e e  T a bl e  7. 1. 3 f or  d et ails  
 T a bl e   3- 2 :   Ti  m e t o   E v e nt f o r s u r gi c al s u bj e cts 
VI SI  T  #   [ADDRESS_1009840]  C o ns oli d ati o n   3   m o  
6   m o  
9   m o  
1 2  m o   
I nf or  m e d 
C o ns e nt   X     
     
                 
R e vi e  w    I/ E Crit eri a   X   X  
     
                 
M e di c al 
Hist or y   X     
     
                 
P h ysi c al 
E x a  m1  X Xb Xb Xb X   X X X   X X   X 
E  C  O  G  S c or e  X Xb Xb   Xb X   X   X   X   X   X   X 
Vit al  Si g ns X Xb Xb   Xb X   X   X   X   X   X   X 
W ei g ht   X Xb Xb   Xb X   X   X   X   X   X   X 
H ei g ht   X                           
E  C  G X2 X3   X4 b X4 c                  
C  B  C X   X   Xb   Xb    X   X   X      
S er u  m 
C h e  mistr y5 X   X  
 Xb   Xb    X   X   X     
 
Uri n al ysis6 X                             
Pr e g n a n c y 
T est7 X   X  
                       
 
E xt e nt    of Dis e as e   X     
    Xd X          X   X   X   X 
P  K s a  m pli n g     X X Xf X Xb                  
P  D s a  m pli n g    X  Xf X Xb       X   X   X     
BI  O    [ADDRESS_1009841] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009842]  X     
         X            X      X 
Di a g.     C T S c a n  X     
         X         X   X   X   X 
4  D -C T  S c a n   X                           
S  w all o  wi n g Di ar y   X Xb Xb   Xb          X   X  
 
Di et 
C o u ns eli n g8 X Xb Xb   Xb               
 
aO pti o n al  visit  5 b   as  n e e d e d,  bw e e kl y, cbi -w e e kl y   ( e v er y  ot h er   w e e k), dvisit  2 0  o nl y;  visit   wi n d o  w  all o  w a n c e  of  +/ - 7 
d a ys , f BI  O 3 0 0  + c  h e  m o  P  K s c h e d uli n g  all o  w e d   w e e k  [ADDRESS_1009843].  
5.    T o  i n cl u d e  s o di u  m,  p ot assi u  m,  c hl ori d e,  bi c ar b o n at e,    B  U  N,  cr e ati ni n e,  gl u c os e,    A S T, 
A L T,  al k ali n e  p h os p h at as e,  t ot al  bilir u bi n,  al b u  mi n,  t ot al  pr ot ei n,    m a g n esi u  m,  c al ci u  m, 
p h os p h or o us  a n d  uri c  a ci d.   A n al ysis  of  p a n cr e ati c  e n z y  m es  als o t o  b e i n cl u d e d i n  p a n el 
( a  m yl as e  a n d li p as e). 
6.    Uri n al ysis  t o  i n cl u d e  p  H,  s p e cifi c  gr a vit y,  di psti c k  d et er  mi n ati o ns  of  gl u c os e,  k et o n es, 
pr ot ei n,  h e  m o gl o bi n,  bilir u bi n. 
7.    Pr e g n a n c y t est   m a y  b e  uri n e  or s er u  m  d et er  mi n ati o n  of  β-  H  C  G.   Visit  [ADDRESS_1009844] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  1 3  of  4 3 h a v e  a   mi ni  m u  m  of  3 2  visits t hr o u g h t h e  c o n cl usi o n  of  c o n c urr e nt  c h e  m or a di ot h er a p y ( 6 
w e e ks  of  c h e  m ot h er a p y  a n d  d ail y   R T fr a cti o ns  of  2. 0   G y, t ot al  d os e  of  6 0   G y). 
[ADDRESS_1009845] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009846] a n d ar d  of  c ar e s h o ul d b e f oll o  w e d.  
BI  O  3 0 0  + C h e  m o  P  K   BI  O  3 0 0  +   C h e  m o  p h ar  m a c o ki n eti cs   m a y  b e s c h e d ul e d   w e e k  [ADDRESS_1009847] e d   wit hi n  ±  [ADDRESS_1009848] e d   wit hi n  ±  [ADDRESS_1009849] er e d
  
Visit  S,  S ur gi c al E v al u ati o n  +/ - 7 d   
Visit  3 6  -3 7, 
C o ns oli d ati o n C h e  m ot h er a p y
 +/ - 7 d  +/ - 1 4 d f or   C T  
Visit  3 8  -3 9,  3  a n d 
6   m o nt h f oll o  w u p  +/ - 1 4 d   
Visit  4 0  -4 2,  9 -1 3 
m o nt h f oll o  w  u p   +/ - 2 1 d  F or s ur gi c al s u bj e cts visit  4 1,  1 2   m o nt h f oll o  w u p ( e n d  of st u d y)  
 
 
Pr ot o c ol   C L [ADDRESS_1009850] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009851] u d y  is    m e a nt  t o  b e  h y p ot h esis 
g e n er ati n g. 
5    A  N  A  L  Y SI S  P  O P  U  L  A  TI  O  N S   
5. 1    F  U  L  L   A  N  A  L  Y SI S  S  E  T 
T h e  F ull   A n al ysis  S et ( F  A S)   will i n cl u d e  all  s u bj e cts   w h o r e c ei v e  at l e ast  o n e  d os e  of   BI  O  3 0 0. 
T his  a n al ysis s et   will  b e  us e d t o s u  m  m ari z e  all s af et y  e n d p oi nts.  
5. 2    E F FI  C  A  C  Y   A  N  A  L  Y SI S  S  E  T 
T h e   Effi c a c y   A n al ysis  S et ( E  A S)   will i n cl u d e  all  s u bj e cts   w h o r e c ei v e  at l e ast  o n e  d os e  of   BI  O 
[ADDRESS_1009852]  o n e  e xt e nt  of  dis e as e  ass ess  m e nt  f oll o  wi n g  t h e  c o n cl usi o n  of  c o n c urr e nt 
t h er a p y. 
5. 3    P  H  A  R  M  A  C  O  KI  N  E  TI  C ( P  K)  P  O P  U  L  A  TI  O  N 
T h e  P  K  P o p ul ati o n   will  i n cl u d e  all  s u bj e cts   w h o  r e c ei v e  at  l e ast  [ADDRESS_1009853]  1  of t h e  d a ys  of s a  m pli n g.  P  K 
s u  m  m ari es   will  b e  b as e d  o n t h e  P  K  p o p ul ati o n. 
5. 4    P  H  A  R  M  A  C  O  D  Y  N  A  MI  C S ( P  D)  P  O P  U  L  A  TI  O  N 
T h e  P  D  P o p ul ati o n   will  i n cl u d e  all  s u bj e cts   w h o  r e c ei v e  at  l e ast  [ADDRESS_1009854] atisti c al  c o  m p uti n g  a n d  gr a p hi cs  g e n er ati o n [ 1]. 
6. [ADDRESS_1009855] u di es    will  i n cl u d e  s u b gr o u p  a n al ys es, 
s u b gr o u ps   m a y i n cl u d e: 
•    G e n d er 
•    C a n c er st a g e  at  e nr oll  m e nt 
•    Hist ol o g y ( e. g. s u bt y p e  of   N S  C L  C) 
•    T u  m or l o c ati o n 
 
6. [ADDRESS_1009856] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009857] at e d  ot h er  wis e, t h e t er  m “ d es cri pti v e st atisti cs ” r ef ers t o t h e  n u  m b er  of s u bj e cts ( n),   m e a n, 
m e di a n,   st a n d ar d   d e vi ati o n   ( S T  D),     mi ni  m u  m   (  mi n),   a n d     m a xi  m u  m   (  m a x)   a n d   st a n d ar d 
err ors/ c o nfi d e n c e i nt er v als f or  c o nti n u o us r es p o ns e  v ari a bl es  a n d  distri b uti o n t a bl es  or  hist o gr a  ms 
f or  dis cr et e r es p o ns e  v ari a bl es.   Mi n  a n d   m a x  v al u es   will  b e r o u n d e d t o t h e  pr e cisi o n  of t h e  ori gi n al 
v al u e,   m e a ns  a n d   m e di a ns   will  b e  r o u n d e d t o  [ADDRESS_1009858]   w h ol e  n u  m b er ( z er os  ar e  n ot  dis pl a y e d) 
wit h  v al u es  of  “ <  1  % ”  a n d  “ >  9 9  % ” s h o  w n  as  n e c ess ar y f or  v al u es f alli n g  n e ar t h e  b o u n d ari es.   
I n  a d diti o n, r el ati o ns hi ps  b et  w e e n t h es e r es p o ns e  v ari a bl es   will  b e  e x pl or e d  usi n g  n o n- p ar a  m etri c 
a p pr o a c h es  ( e. g.,   S p e ar  m a n  r a n k  c orr el ati o n),   p ar a  m etri c  c orr el ati o n  a n al ysis    m et h o ds  ( e. g., 
c orr el ati o n   c o effi ci e nt),   or   a p pr o pri at e   st atisti c al  t ests   ( e. g.,  t h e    C hi-s q u ar e  tr e n d  t est   f or 
c at e g ori c al  d at a).  F urt h er  m or e,  a p pr o pri at e  r e gr essi o n  t e c h ni q u es  f or  t h es e  r es p o ns e  v ari a bl es 
( e. g.,  a n al ysis  of  c o v ari a n c e  (  A  N  C  O  V  A)),  li n e ar  r e gr essi o n,  pr o p orti o n al  h a z ar ds  r e gr essi o n, 
l o gisti c  r e gr essi o n,  g e n er ali z e d  esti  m ati n g  e q u ati o n  (  G E E)  a n d    mi x e d  eff e cts    m o d els)    will  b e 
e  m pl o y e d  t o  f urt h er  e x a  mi n e  t h eir  r el ati o ns hi p   wit h  o n e  a n ot h er.   C o nfi d e n c e  i nt er v als   will  b e 
c al c ul at e d  f or  t h e  diff er e n c es.   T h e  c o  m p ut e d  c h a n g e  fr o  m  b as eli n e    will  b e  c al c ul at e d  f or  all 
m e as ur e d  v ari a bl es  a n d  e x pr ess e d  as t h e   m e a n  c h a n g e fr o  m  b as eli n e  +  st a n d ar d  d e vi ati o n ( S T  D) 
of t h e  c h a n g e fr o  m  b as eli n e.    A t  w o-s a  m pl e t-t est   will  b e  us e d t o t est t h e t u  m or si z e r e d u cti o n  a n d 
a l o g-r a n k t est   will  b e  us e d t o  c o  m p ar e ti  m e t o  e v e nt  o ut c o  m es.    A n al ysis  of  c o v ari a n c e   will  b e 
us e d t o  c o  m p ar e  d os a g e  gr o u ps  o n  “ c h a n g e fr o  m  b as eli n e ”   m e as ur es (  wit h  b as eli n e   m e as ur e  m e nt c o nsi d er e d  as  a n  a dj ust  m e nt  c o v ari at e).  
U nl ess  ot h er  wis e  n ot e,  all  d at a  c oll e ct e d  d uri n g t h e st u d y   will  b e i n cl u d e d i n  d at a listi n gs  a n d   will 
b e s ort e d  b y tr e at  m e nt  gr o u p, s u bj e ct  n u  m b er  a n d t h e n  b y  visit f or  e a c h s u bj e ct  n u  m b er. 
[ADDRESS_1009859] u all y  a ns  w er e d.   T his  c a n  b e  d o n e  o n t h e s c ori n g g ui d e  or  b y  usi n g t h e f or  m ul a  b el o  w: 
P r o r at e d  s u bs c al e  s c o r e   =   [ S u  m  of  it e  m  s c or es]  x   [  N  of  it e  ms  i n  s u bs c al e]  ÷   [  N  of  it e  ms 
a ns  w er e d] 
Pr ot o c ol   C L [ADDRESS_1009860] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  1 7  of  4 3 W h e n t h er e  ar e   missi n g  d at a,  pr or ati n g  b y s u bs c al e i n t his   w a y is  a c c e pt a bl e  as l o n g  as     m o r e t h a n 
5 0  %  of t h e it e  ms   w er e  a ns  w er e d ( e. g.,  a   mi ni  m u  m  of  4  of  7 it e  ms,  4  of  6 it e  ms,  et c. ).    T h e t ot al 
s c or e  is  t h e n  c al c ul at e d  as  t h e  s u  m  of  t h e  u n-  w ei g ht e d  s u bs c al e  s c or es.     T h e  F  A  C T  s c al e  is 
c o nsi d er e d t o  b e  a n  a c c e pt a bl e i n di c at or  of  p ati e nt  q u alit y  of lif e  as l o n g  as  o v e r all it e  m  r es p o ns e 
r at e   is  gr e at er  t h a n  8 0  %  ( e. g.,  at  l e ast  [ADDRESS_1009861] et e d).     T his  is  n ot  t o  b e 
c o nf us e d   wit h i n di vi d u al s u bs c al e it e  m r es p o ns e r at e,   w hi c h  all o  ws  a s u bs c al e s c or e t o  b e  pr or at e d 
f or   missi n g it e  ms if  gr e at er t h a n  5 0  %  of it e  ms  ar e  a ns  w er e d. I n  a d diti o n,  a t ot al s c or e s h o ul d  o nl y b e  c al c ul at e d if   A L L  of t h e  c o  m p o n e nt s u bs c al es  h a v e  v ali d s c or es.    
7. [ADDRESS_1009862] u d y  visits  a c c or di n g t o t h e  n o  mi n al  v al u e  o bt ai n e d 
fr o  m  t h e   C  R F.  If  a n  u ns c h e d ul e d  visit  f alls  i n  a  visit    wi n d o  w    wit h  a n  e xisti n g  n o  mi n al  visit 
ass ess  m e nt, t h e  n o  mi n al  ass ess  m e nt   will  b e  us e d  f or  s u  m  m ar y  pr es e nt ati o n.  If  n o  n o  mi n al  visit 
ass ess  m e nt  e xists f or  a  visit   wi n d o  w   wit h  u ns c h e d ul e d  visit(s), t h e n t h e l at est  u ns c h e d ul e d  visit 
wit hi n  t h e  visit   wi n d o  w   will  b e  us e d.  If   m ulti pl e  n o  mi n al  ass ess  m e nts  ar e  c oll e ct e d   wit hi n  t h e s a  m e  visit, t h e l at est  v al u e  a n d  c orr es p o n di n g  d at e   will  b e  us e d f or s u  m  m ar y  pr es e nt ati o n. 
7. [ADDRESS_1009863] e  d at es  o c c ur f or t h e s cr e e ni n g  visit, t h e  c o n v e nti o n  as  d es cri b e d  at t h e  e n d  of  S e cti o n  7. 2 
will  b e  us e d. 
T h e f oll o  wi n g   will  d efi n e  pri or   m e di c ati o n  us e  v ers us  c o n c o  mit a nt   m e di c ati o n  us e:   
•    Pri or  us e  e n d e d  b ef or e t h e first  a d  mi nistr ati o n  of   BI  O  3 0 0 
•    C o n c o  mit a nt  us e is  o n  or  aft er t h e first  a d  mi nistr ati o n  of  BI  O  [ADDRESS_1009864] u d y  p o p ul ati o n  a n al ys es   will  b e  p erf or  m e d  o n t h e  F ull   A n al ysis  S et 
( F  A S). 
8. [ADDRESS_1009865] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009866] atisti cs.  R e as o ns f or  dis c o nti n u ati o n   will  b e  pr es e nt 
wit h  fr e q u e n ci es  a n d  p er c e nt a g es  f or  all  c at e g ori es.   A  c o  m pr e h e nsi v e  d at a  listi n g   will  als o  b e 
i n cl u d e d. 
8. 3    I  N  C  L  U SI  O  N/  E  X  C  L  U SI  O  N   C  RI  T  E  RI  A 
I n cl usi o n  a n d  e x cl usi o n  crit eri a f ail ur es   will  b e i n cl u d e d i n  a  d at a listi n g. 
8. 4    P  R  O  T  O  C  O  L   D  E  VI  A  TI  O  N S 
Pr ot o c ol  d e vi ati o ns   will  b e  s u  m  m ari z e d  b y tr e at  m e nt  gr o u p  a n d  c at e g or y  a n d i n cl u d e d i n  a  d at a 
listi n g. 
M aj or  pr ot o c ol  d e vi ati o ns i n cl u d e,  b ut  ar e  n ot li  mit e d t o t h e f oll o  wi n g:   
•    N o n-f ulfill  m e nt  of  all i n cl usi o n  crit eri a  or f ulfill  m e nt  of  at l e ast  o n e  e x cl usi o n  crit eri a;   
•    I  m pr o p er I nf or  m e d   C o ns e nt  pr o c ess; •    N o n- d el e g at e d st u d y  p ers o n n el  dis p e nsi n g i n v esti g ati o n al  pr o d u ct; •    Ot h er r el e v a nt  vi ol ati o ns, t o  b e j u d g e d  o n  a n i n di vi d u al  b asis. 
 
Mi n or  pr ot o c ol  d e vi ati o ns i n cl u d e,  b ut  ar e  n ot li  mit e d t o: 
•    M e as ur e  m e nts  o bt ai n e d  o utsi d e t h e  visit   wi n d o  w t o  a li  mit e d  d e gr e e;   •    Miss e d  visit  ass ess  m e nts; •    L a c k  of s o ur c e  d o c u  m e nt ati o n; •    Ot h er  d e vi ati o ns   will  b e j u d g e d  o n  a n i n di vi d u al  b asis. 
 
8. [ADDRESS_1009867] or y   will    b e i n cl u d e d. 
9    E F FI  C  A  C  Y   A  N  A  L  Y SI S   
9. 1    O  B J  E  C  TI  V  E   R  E S P  O  N S  E S O bj e cti v e  r es p o ns es  of  t h e  t ar g et  l esi o n  b as e d  o n   m e as ur e  m e nts  fr o  m  a  c o n v e nti o n al   C T  s c a n, 
P E T/  C T,  4  D-  C T  or  ot h er   will  b e  d et er  mi n e d i n  all  s u bj e cts  at  b as eli n e  a c c or di n g t o t h e   R E  CI S T 
1. 1  crit eri a (s e e   A p p e n di x  4  of t h e  pr ot o c ol).  T h e  pr o p orti o n  of  p ati e nts  e x p eri e n ci n g  pr o gr essi v e 
Pr ot o c ol   C L [ADDRESS_1009868] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009869] a bl e   dis e as e   ( S  D),   p arti al   r es p o ns es   ( P  R)   or   c o  m pl et e   r es p o ns es   (  C  R)    will   b e 
s u  m  m ari z e d i n t a b ul ar f or  m at. 
P er   R E  CI S T  1. 1,  o v er all r es p o ns e r at e (  O  R  R)   will  b e  c al c ul at e d  usi n g  b est  o v er all r es p o ns e   wit h 
c o nfir  m ati o n  of   C  R  a n d  P  R.  T h e  c orr es p o n di n g  9 5  %  e x a ct  c o nfi d e n c e i nt er v al   will  b e  c al c ul at e d 
b as e d  o n t h e  bi n o  mi al  distri b uti o n. 
B est  o v er all r es p o ns e ( pr o gr essi v e  dis e as e, st a bl e  dis e as e,  P  R,  C  R,  or  n ot a p pli c a bl e/ n ot e v al u a bl e) 
will  b e  t a b ul at e d.  If  S  D  is  b eli e v e d  t o  b e  b est  r es p o ns e,    m e as ur e  m e nts    m ust  h a v e    m et  t h e  S  D 
crit eri a  at l e ast  o n c e  aft er  st u d y  e ntr y  at  a   mi ni  m u  m i nt er v al  of  [ADDRESS_1009870]  ti  m e  p oi nt  r es p o ns e,  t h e  p ati e nt’s  b est  r es p o ns e  d e p e n ds  o n  t h e s u bs e q u e nt  ass ess  m e nts ( a c c or di n g t o   R E  CI S T  1. 1). 
T u  m or  di a  m et er    m e as ur e  m e nts  a n d  c h a n g e  fr o  m  b as eli n e   will  b e  s u  m  m ari z e d   wit h  d es cri pti v e 
st atisti cs  b y  visit   wit h r es p e ct t o tr e at  m e nt  gr o u p.   A  pl ot  of t u  m or  di a  m et er  o v er ti  m e   will  als o  b e 
i n cl u d e d. 
9. 2    D  U  R  A  TI  O  N   O F   R  E S P  O  N S  E (  D  O  R) 
D ur ati o n  of r es p o ns e (  D  O  R) is  d efi n e d  as t h e ti  m e fr o  m t h e first t u  m or r es p o ns e  of   C  R  or  P  R t o 
d o c u  m e nt e d t u  m or  pr o gr essi o n  or  d e at h,   w hi c h e v er is t h e  e arli est.  
D  O  R   will  b e s u  m  m ari z e d f or t h e r es p o n d ers  o nl y.  R es p o n d er is  d efi n e d  as t h os e s u bj e cts   w h o  h a d 
t u  m or r es p o ns e  of   C  R  or  P  R. 
A   K a pl a n-  M ei er  a n al ysis  of   D  O  R   will  b e  p erf or  m e d t o g et h er   wit h its  9 5  %  c o nfi d e n c e i nt er v al.   
T h e   D  O  R   will  b e  c e ns or e d i n t h e f oll o  wi n g s c e n ari os: 
1)    S u bj e cts   w h o  g o  off tr e at  m e nt f or r e as o ns  ot h er t h a n  pr o gr essi o n  a n d  b e gi n tr e at  m e nt   wit h 
ot h er  a nti- n e o pl asti c t h er a pi [INVESTIGATOR_738887] o  b e  c e ns or e d  at t h e  d at e  of l ast t u  m or  ass ess  m e nt 
b ef or e st arti n g  ot h er  a nti- n e o pl asti c t h er a pi [INVESTIGATOR_014]. 
2)    If s u bj e ct  h a d  pr o gr essi v e  dis e as e  or  d e at h  o c c urr e d  aft er   missi n g t  w o t u  m or  ass ess  m e nts, 
t h e  p ati e nt   will  b e  c e ns or e d  at t h e  d at e  of t h e  pr e vi o us t u  m or  ass ess  m e nt   wit h   C  R,  P  R  or S  D.  
3)    If s u bj e ct  d o es  n ot  h a v e  p ost  b as eli n e t u  m or  ass ess  m e nt  or   wit h  n o  P  D  or  d e at h   wit hi n t  w o 
ass ess  m e nts aft er e nr oll  m e nt, t h e   D  O  R   will  b e c e ns or e d at t h e  d at e  of t h e first  d os e  of st u d y 
dr u g. 
4)    If   a   s u bj e ct    wit h dr a  ws  fr o  m  t h e   st u d y   pr e  m at ur el y  f or  r e as o ns   ot h er  t h a n   dis e as e 
pr o gr essi o n  or  d e at h,   D  O  R   will  b e  c e ns or e d  at t h e  s u bj e ct’s l ast  d at e  k n o  w n  ali v e  a n d  n ot P  D.  
D  O  R   will  b e  pr es e nt e d i n  a  b y-s u bj e ct listi n g. 
9. 3    P  R  O  G  R  E S SI  O  N  F  R  E  E  S  U  R  VI  V  A  L 
Pr o gr essi o n fr e e  s ur vi v al ( P F S)   will  b e  c al c ul at e d fr o  m t h e first  a d  mi nistr ati o n  of   BI  O  3 0 0  u ntil 
d e at h  or  u ntil  t h e  crit eri a  f or  dis e as e  pr o gr essi o n  ar e    m et  ( a c c or di n g  t o   R E  CI S T  1. 1  or  i n  t h e 
o pi [INVESTIGATOR_9384] o n  of t h e tr e ati n g  p h ysi ci a n).   A   K a pl a n-  M ei er  a n al ysis  of  P F S   will  b e  p erf or  m e d  a n d   m e di a n 
s ur vi v al ti  m e  a n d its  9 5  %  c o nfi d e n c e i nt er v al   will  b e  c o  m p ut e d  b y tr e at  m e nt  c o h ort  a n d  o v er all. A   K a pl a n-  M ei er  c ur v e   will  b e  pr es e nt e d. 
Pr ot o c ol   C L [ADDRESS_1009871] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009872]  h as  n ot  pr o gr ess e d  or  di es  at t h e ti  m e  of t h e fi n al  d at a  c ut off,  P F S   will  b e  c e ns or e d 
usi n g t h e s a  m e r ul es  d es cri b e d i n  9. 2. 
P F S (i n  d a ys) is  c al c ul at e d  as: 
(  D at e  of  d e at h  of  d o c u  m e nt e d  pr o gr essi o n)  – (  D at e  of first  a d  mi nistr ati o n  of  BI  O  3 0 0)  +  1, if  e v e nt (  D at e  of l ast t u  m or  ass ess  m e nt   wit h   C  R,  P  R,  or  S  D)  – (  D at e  of first  a d  mi nistr ati o n  of   BI  O  3 0 0)  + 
1, if  c e ns or 
A  c o  m pr e h e nsi v e  d at a listi n g   will  als o  b e i n cl u d e d. 
9. 4    P  U  L  M  O  N  A  R  Y  F  U  N  C  TI  O  N   T  E S  T 
T h e    m e as ur e  m e nts  of  P F T  i n cl u di n g  f or c e d  vit al  c a p a cit y  ( F  V  C),  f or c e d  e x pir at or y  v ol u  m e 
( FE  V
1),  F E  V 1/ F  V  C,  diff usi o n  c a p a cit y  (  D L  C  O)  a n d  c h a n g e  fr o  m  b as eli n e   will  b e  s u  m  m ari z e d 
wit h  d es cri pti v e st atisti cs  b y ti  m e  p oi nt   wit h r es p e ct t o tr e at  m e nt  gr o u p.   
A  d at a listi n g  of  all r es ults   will  als o  b e i n cl u d e d. 
9. 5    S  W  A  L  L  O  WI  N  G   DI  A  R  Y 
T h e  p ati e nt s elf- ass ess e d  d ail y s  w all o  wi n g s c or e (t h e s  w all o  wi n g  q u esti o n n air e) fr o  m  0 t o  5,  1    n o 
pr o bl e  ms s  w all o  wi n g;  2   mil d s or e n ess  o nl y;  3 s o  m e  diffi c ult y s  w all o  wi n g s oli ds;  4 c a n n ot s  w all o  w 
s oli ds;  a n d  5  c a n n ot  s  w all o  w li q ui ds.   T h e   m e as ur e  m e nts   will  b e  a n al y z e d  usi n g  ar e a  u n d er t h e 
c ur v e (  A  U  C)   m et h o d ol o g y,   w hi c h i n c or p or at es  b ot h t h e  gr a d e  a n d  d ur ati o n  of t h e   m e as ur e d  e n d 
p oi nt.  T h e  a v er a g e s c or e fr o  m t h e s  w all o  wi n g  di ar y   will  b e  pl ott e d  b y tr e at  m e nt  gr o u p.  
A  c o  m pr e h e nsi v e  d at a listi n g   will  als o  b e i n cl u d e d. 
9. [ADDRESS_1009873] t o tr e at  m e nt  gr o u p. 
1 0    S  A F  E  T  Y  
T h e f ull  a n al ysis  s et   will  b e  us e d f or  all t h e  a n al ys es  of  s af et y  d at a.  S af et y  d at a   will i n cl u d e   A Es, 
s af et y   l a b or at or y   (  C  B  C/ h e  m at ol o g y,   s er u  m   c h e  mistr y   a n d   uri n al ysis),   pr e g n a n c y   t est   (if 
a p pli c a bl e),  p h ysi c al  e x a  m,  E  C  G,  E  C  O  G  a n d  vit al si g ns.  T h e  pr o p orti o n  of s u bj e cts  e x p eri e n ci n g 
a d v ers e  e v e nts,  s eri o us  a d v ers e  e v e nts,  a n d  d os e li  miti n g t o xi citi es   will  b e  s u  m  m ari z e d f or  e a c h d osi n g  c o h ort.   A  d at a listi n g  of s u bj e cts  e x p eri e n ci n g tr e at  m e nt  d el a ys   will  als o  b e i n cl u d e d.  
[ADDRESS_1009874] er e d  (  m g),  d ur ati o n  of  e x p os ur e  (  w e e ks)  a n d  st u d y tr e at  m e nt  d osi n g 
Pr ot o c ol   C L [ADDRESS_1009875] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009876] u d y is t o  d es cri b e  a n y  d os e li  miti n g t o xi citi es  a n d t o  d et er  mi n e t h e 
r e c o  m  m e n d e d  d os e (t h e  o pti  m al  d os e)  of t his  c o  m bi n ati o n.  
T h e  d efi niti o n  of    D L T  is  s p e cifi e d  i n  S e cti o n  3. 2.    M et h o d ol o g y  f or  d et er  mi ni n g  t h e    M T  D  is 
s p e cifi e d i n  S e cti o n  3. 1. 
T h e  d os e s el e ct e d  as t h e   M T  D  or t h e  o pti  m al  d os e  of   BI  O  [ADDRESS_1009877] e  m  or g a n  cl assifi c ati o n ( S  O  C)  a n d  pr ef err e d t er  m. 
A d diti o n all y,   A E s u  m  m ari es   will  b e  pr o vi d e d f or t h e f oll o  wi n g: 
•    D L T   
•    A Es   
•    A Es l e a di n g t o  dis c o nti n u ati o n fr o  m t h e st u d y 
•    A Es  b y r el ati o ns hi p t o   BI  O  3 0 0 •    A Es  b y s e v erit y  usi n g   C T  C  A E  gr a d e •    A Es   wit h  1 0  %  or  hi g h er i n ci d e n c e r at es 
F or  all   A E s u  m  m ari es,  e v e nts   will  b e  c o u nt e d  o nl y  o n c e  p er s u bj e ct  b y  pri  m ar y  S  O  C  a n d  pr ef err e d 
t er  m.   W h e n  a n   A E  o c c urs   m or e t h a n  o n c e f or  a  s u bj e ct, t h e   m a xi  m u  m  s e v erit y  a n d  c a us alit y will 
b e  us e d. 
All   A Es   will  b e i n cl u d e d i n  c o  m pr e h e nsi v e  d at a listi n gs.  S e p ar at e listi n gs   will  b e  pr o vi d e d f or   A Es 
of   D L Ts,  all   A Es r el at e d t o   BI  O  [ADDRESS_1009878] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009879] at us is  a  p h ysi ci a n  assi g n e d r ati n g  s c al e  us e d t o  ass ess  h o  w  a  p ati e nt’s 
dis e as e is  pr o gr essi n g i n  a d diti o n t o  h o  w t h e  dis e as e  aff e cts t h e  d ail y li vi n g  a biliti es  of t h e  p ati e nt. 
T h e  s c or e  v al u es  ar e  0  t o  5,    w h er e  0  i n di c at es  “f ull y  a cti v e,  a bl e  t o  c arr y  o n  all  pr e- dis e as e 
p erf or  m a n c e    wit h o ut  r estri cti o n ”  a n d  [ADDRESS_1009880] at us   will 
b e  pr o vi d e d. 
1 0. 1 0  VI  T  A  L  SI  G  N S 
T h e r es ults  of  vit al si g ns (i n cl u di n g t e  m p er at ur e, r es pir at or y r at e,  h e art r at e, s yst oli c  a n d  di ast oli c 
bl o o d  pr ess ur e,  h ei g ht  a n d   w ei g ht)   will  b e  s u  m  m ari z e d   wit h  d es cri pti v e  st atisti cs  b y  tr e at  m e nt gr o u p.   A  d at a listi n g  of  all  vit al si g ns  d at a   will  b e i n cl u d e d. 
[ADDRESS_1009881] or (  G-  C S F),   C-r e a cti v e  pr ot ei n,  a n d  pr ost a gl a n di n  E 2.  T h e  P  D r es ults  a n d  c h a n g e fr o  m  b as eli n e   will  b e  s u  m  m ari z e d   wit h  d es cri pti v e  st atisti cs,  b y t est  a n d ti  m e 
p oi nt   wit h r es p e ct t o tr e at  m e nt  gr o u p.   A  d at a listi n g   will  dis pl a y  all  P  D r es ults.  
[ADDRESS_1009882] et e d t o  ass ess   BI  O  3 0 0  s af et y  a n d t o r e vi e  w  s e c o n d ar y  o ut c o  m e   m e as ur es.   D at a tr e n ds   will 
b e  us e d t o  c h o os e  a si n gl e   BI  O  3 0 0  d os e ( 5 0 0,  1 0 0 0  or  1 5 0 0  m g/ d)  as t h e  o pti  m al  bi ol o gi c al  d os e.  
U p t o  a n  a d diti o n al  1 2  s u bj e cts   will  b e  e nr oll e d  at t h e  o pti  m al  bi ol o gi c al  d os e t o f urt h er  e v al u at e 
BI  O  3 0 0’s s af et y  a n d  effi c a c y.  T h e   m a xi  m u  m t ol er at e d  d os e   will  b e  us e d f or  c o h ort  [ADDRESS_1009883] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009884] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009885] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009886] u d y    F  A S  
1 4. 3. 1. 5    S u  m  m ar y  of   A d v ers e  E v e nts  b y   R el ati o ns hi p t o   BI  O  3 0 0  F  A S  
1 4. 3. 1. 6    S u  m  m ar y  of   A d v ers e  E v e nts  b y  S e v erit y   Usi n g   C T  C  A E   Gr a d e  F  A S  
1 4. 3. 1. 7    S u  m  m ar y  of   A d v ers e  E v e nts   wit h  1 0  %  or   Hi g h er I n ci d e nt   R at e  F  A S  
 
1 5. 3. 2   S e ri o us   A d v e rs e   E v e nts,   D e at hs  a n d   Ot h e r  Si g nifi c a nt   A d v e rs e   E v e nts 
T a bl e     Titl e   P o p ul ati o n  
1 4. 3. 2. 1    S u  m  m ar y  of  S eri o us   A d v ers e  E v e nts  F  A S  
1 4. 3. 2. 2    S u  m  m ar y  of  S eri o us   A d v ers e  E v e nts  b y r el ati o ns hi p t o   BI  O  3 0 0  F  A S  
1 4. 3. 2. 3    S u  m  m ar y  of   D e at hs  F  A S  
 
1 5. 3. 3   N a r r ati v es 
N ot  a p pli c a bl e. 
 
1 5. 3. 4   L a b o r at o r y   R es ults 
T a bl e     Titl e   P o p ul ati o n  
1 4. 3. 4. 1    S u  m  m ar y  of  Cli ni c al  L a b or at or y   R es ults   F  A S  
1 4. 3. 4. 2    S u  m  m ar y  of   A b n or  m al  Cli ni c al  L a b or at or y   R es ults   F  A S  
1 4. 3. 4. 3   S u  m  m ar y  of   Uri n al ysis/ Pr e g n a n c y   R es ults  F  A S  
 
[ADDRESS_1009887] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009888]   Dis p ositi o n 
 
1 5. 4. 2   P r ot o c ol   D e vi ati o ns 
1 5. 4. 2. 1  I n cl usi o n/ E x cl usi o n   Crit eri a   D e vi ati o ns 
[ADDRESS_1009889] or y 
 
1 5. 4. 5   C o  m pli a n c e  a n d/ o r   D r u g   C o n c e nt r ati o n   D at a 
[ADDRESS_1009890] as  m a   C o n c e ntr ati o n 
 
1 5. 4. 6   I n di vi d u al   Effi c a c y   R es p o ns e   D at a 
1 5. 4. 6. 1  T u  m or   R es p o ns es  P er   R E  CI S T  1. 1 
1 5. 4. 6. 2  T u  m or   Di a  m et er  Fi n di n gs 1 5. 4. 6. 3  R es p o ns e   Crit eri a:  E v al u ati o n  of  T ar g et  L esi o ns  Fi n di n gs 1 5. 4. 6. 4  P at h ol o gi c   R es p o ns e  of  T ar g et  L esi o ns  a n d  E xt e nt  of  S ur gi c al   R es e cti o n   Fi n di n gs 1 5. 4. 6. 5  U ni v ersit y  of  S a n   Di e g o  S h ort n ess  of   Br e at h   Q u esti o n n air e (  U  C S  D- S  O  B)   R es ults 
[ADDRESS_1009891] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009892] u d y 1 5. 4. 7. 5  S eri o us   A d v ers e  E v e nts 
1 5. 4. 7. 6  A d v ers e  E v e nts   R el at e d t o   BI  O  3 0 0 
1 5. 4. 7. 7  C T  C  A E   Gr a d e  3  or  4   A d v ers e  E v e nts 1 5. 4. 7. 8  D e at hs 
 
1 5. 4. 8   Listi n gs  of I n di vi d u al   L a b o r at o r y   M e as u r e  m e nts 
1 5. 4. 8. 1  D efi niti o ns  of   N or  m al   R a n g es f or  L a b or at or y   V al u es 
1 5. 4. 8. 2  Cli ni c al  L a b or at or y   R es ults 1 5. 4. 8. 3  Uri n al ysis/ Pr e g n a n c y   R es ults  
[ADDRESS_1009893] er n   C o o p er ati v e   O n c ol o g y   Gr o u p ( E  C  O  G)  P erf or  m a n c e  St at us [ADDRESS_1009894] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  2 8  of  4 3 1 6    R  E F  E  R  E  N  C  E S   
1.     R    C or e    T e a  m,   R:    A  l a n g u a g e   a n d   e n vir o n  m e nt  f or  st atisti c al   c o  m p uti n g.    [ADDRESS_1009895] atisti c al   C o  m p uti n g:   Vi e n n a,   A ustri a. 
2.     M o vs as,   B.,  et  al.,  R a n d o  miz e d tri al  of  a  mif osti n e i n l o c all y  a d v a n c e d  n o n-s  m all- c ell l u n g 
c a n c er   p ati e nts   r e c ei vi n g   c h e  m ot h er a p y   a n d   h y p erfr a cti o n at e d   r a di ati o n:   r a di ati o n 
t h er a p y  o n c ol o g y  gr o u p tri al  9 8- 0 1. J   Cli n   O n c ol,  2 0 0 5. 2 3 ( 1 0):  p.  [ADDRESS_1009896] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  2 9  of  4 3 S h ell   T a bl es  a n d  Fi g u r es 
T a bl e  1 4. 1. 1  S u  m  m ar y  of   A n al ysis  P o p ul ati o n 
A n al ysis  S et   All     5 0 0   m g     1 0 0 0   m g     1 5 0 0   m g   
F ull   A n al ysis  S et ( F  A S)    N     N     N     N   
Effi c a c y   A n al ysis  S et ( E  A S)    N     N     N     N   P  K  P o p ul ati o n  N     N     N     N   
P  D  P o p ul ati o n  N     N     N     N   
 
T a bl e  [ADDRESS_1009897] e risti c  All (  N)     5 0 0   m g (  N)    1 0 0 0   m g (  N)    1 5 0 0   m g (  N)  
M/ F       
M e di a n  a g e (r a n g e)       
R a c e       
A  m eri c a n I n di a n  or  Al as k a n   N ati v e        
Asi a n      
Bl a c k  or  Afri c a n  A  m eri c a n      
N ati v e   H a  w aii a n  or   Ot h er  P a cifi c 
Isl a n d er     
W hit e  or   C a u c asi a n       
U n k n o  w n  or   N ot  R e p ort e d       
Et h ni cit y      
His p a ni c       
N o n  -His p a ni c       
U n k n o  w n  or   N ot  R e p ort e d       
I niti al  St a g e     
II     
III     
I V     
Hist ol o g y       
S q u a  m o us      
A d e n o c ar ci n o  m a      
L ar g e   C ell      
Mi x e d       
Ot h er       
Pri  m ar y t u  m or l o c ati o n      
L eft  u p p er l o b e      
L eft l o  w er l o b e      
L eft li n g ul a      
Ri g ht  u p p er l o b e      
Ri g ht   mi d dl e l o b e      
Ri g ht l o  w er l o b e      
U n k n o  w n       
M arit al st at us       
M arri e d/ ot h er li v e  -i n  p art n er       
Si n gl e/ di v or c e d/  wi d o  w e d/s e p ar at e d        
U n k n o  w n  or   N ot  R e p ort e d       
 
 
Pr ot o c ol   C L [ADDRESS_1009898] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 0  of  4 3 T a bl e  1 4. 1. 3  S u  m  m ar y  of  Pr ot o c ol   D e vi ati o ns 
D e vi ati o n   C at e g o r y   F r e q u e n c y (  M aj o r/  Mi n o r)  
5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g  
C o n c urr e nt   M e di c ati o n   &   Tr e at  m e nt   D e vi ati o n         
Eli gi bilit y       
St u d y   Dr u g   A d  mi nistr ati o n         
Visit   Ass ess  m e nt          
Visit   Wi n d o  w          
Ot h er          
T ot al            
 
T a bl e  1 4. 1. 4  S u  m  m ar y  of  T ot al   D os e  of   BI  O  3 0 0   A d  mi nistr ati o n 
D r u g   E x p os u r e   5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    All   
M e a n   T ot al   D os e ( r a n g e)            
M e a n   D ur ati o n  of  e x p os ur e (  r a n g e)           
Fr e q u e n c y   miss e d  d os es (r a n g e)            
 
  
Pr ot o c ol   C L [ADDRESS_1009899] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009900]   O v er all   R es p o ns e  p er   R E  CI S T  1. 1 
( E  A S) 
R es p o ns e   5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    All   
R es p o ns e  T y p e,   N o. (  %)       
C o  m pl et e          
P arti al        
St a bl e   Dis e as e        
Pr o gr essi v e  dis e as e        
O v er all   R es p o ns e   R at e       
O v er all   R es p o ns e,   N o. (  %)         
9 5  %   CI,   %        
 
T a bl e  [ADDRESS_1009901]   O v er all   R es p o ns e  p er   R E  CI S T  1. 1 
( E v al u a bl e) 
R es p o ns e   5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    All   
R es p o ns e  T y p e,   N o. (  %)       
C o  m pl et e          
P arti al        
St a bl e   Dis e as e        
Pr o gr essi v e  dis e as e        
O v er all   R es p o ns e   R at e       
O v er all   R es p o ns e,   N o. (  %)         
9 5  %   CI,   %        
 
T a bl e  1 4. 2. 3  S u  m  m ar y  of  T u  m or  Di a  m et er   
T u  m o r   Di a  m et e r   5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    All   
B as eli n e       
n         
M e a n         
S T  D        
M e di a n         
R a n g e         
Visit       
n         
M e a n         
S T  D        
M e di a n         
R a n g e         
C h a n g e fr o  m   B as eli n e t o   Visit         
n         
M e a n         
S E        
9 5  %   CI        
  
 
 
Pr ot o c ol   C L [ADDRESS_1009902] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 3  of  4 3 T a bl e  1 4. 2. 4  S u  m  m ar y  of   D ur ati o n  of   R es p o ns e ( E  A S) 
 
S u bj e ct    D os e   D u r ati o n  of   R es p o ns e (  m o nt hs)   
#    5 0 0   m g   
#    5 0 0   m g   
M e di a n   D  O  R,   m o nt hs ( 9 5  %   CI)      
#    1 0 0 0   m g   
#    1 0 0 0   m g   
M e di a n   D  O  R,   m o nt hs ( 9 5  %   CI)      #    1 5 0 0   m g   
 
T a bl e  1 4. 2. 5  S u  m  m ar y  of   D ur ati o n  of   R es p o ns e ( E v al u a bl e)  
S u bj e ct    D os e   D u r ati o n  of   R es p o ns e (  m o nt hs)   
#    5 0 0   m g   
#    5 0 0   m g   
M e di a n   D  O  R,   m o nt hs ( 9 5  %   CI)      
#    1 0 0 0   m g   
#    1 0 0 0   m g   
M e di a n   D  O  R,   m o nt hs ( 9 5  %   CI)      #    1 5 0 0   m g   
#    1 5 0 0   m g   
M e di a n   D  O  R,   m o nt hs ( 9 5  %   CI)      
 
T a bl e  1 4. 2. 6  S u  m  m ar y  of  Pr o gr essi o n  Fr e e  S ur vi v al ( F  A S) 
 5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  All   
M e di a n  Pr o gr essi o n 
Fr e e  S ur vi v al  (  M o nt hs)     
9 5  %   CI      
 
T a bl e  1 4. 2. 7  S u  m  m ar y  of  Pr o gr essi o n  Fr e e  S ur vi v al ( E v al u a bl e) 
 5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  All   
M e di a n  Pr o gr essi o n 
Fr e e  S ur vi v al  (  M o nt hs)     
9 5  %   CI      
 
 
 
 
 
 
Pr ot o c ol   C L [ADDRESS_1009903] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 4  of  4 3 T a bl e  1 4. 2. 8  S u  m  m ar y  of    A bs ol ut e    V al u e  a n d  c h a n g e  fr o  m  b as eli n e  i n  P ul  m o n ar y  F u n cti o n 
M e as ur e  m e nts 
V a ri a bl es   5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    p- v al u e  
B as eli n e   
F E  V 1 ( L)    X   ±  S T  D       
F  V  C ( L)        
F E  V 1/ F  V  C        
D L  C  O   (m L/  m  m  H g/  mi n  )       
Visit   X,   m o nt h   X   
F E  V 1 ( L)    X   ±  S T  D       
F  V  C ( L)        
F E  V 1/ F  V  C        
D L  C  O   (m L/  m  m  H g/  mi n  )       
P F T  c h a n g es  aft er   X   m o nt hs  
F E  V 1  c h a n g e  ( L)   X   ±  S T  D       
F  V  C  c h a n g e  ( L)       
F E  V 1/ F  V  C  c h a n g e        
D L  C  O   (m L/  m  m  H g/  mi n  ) 
c h a n g e      
 
T a bl e  1 4. 2. 9  S u  m  m ar y  of  S  w all o  wi n g   Di ar y  Fi n di n gs 
 5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  p- v al u e  
S  w all o  wi n g     Di ar y 
A  U  C   X   ±  S T  D     
 
 
T a bl e  1 4. 2. 1 0  S u  m  m ar y  of  S  O  B  Q  Fi n di n gs 
S  O  B  Q  5 0 0   m g    1 0 0 0   m g    1 5 0 0   m g    All   
B as eli n e       
n         
M e a n         
S T  D        
M e di a n         
R a n g e         
Visit       
n         
M e a n         
S T  D        
M e di a n         
R a n g e         
C h a n g e fr o  m   B as eli n e t o   Visit         
n         
M e a n         
S E        
9 5  %   CI        
  
Pr ot o c ol   C L [ADDRESS_1009904] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 7  of  4 3 T a bl e  1 4. 3. 1. 3  S u  m  m ar y  of   A d v ers e  E v e nts 
C  T  C  A  E  v 4  S  O  C/  A  E   N u  m b e r  of  S u bj e cts   E x p e ri e n ci n g   E v e nt   (  %) 
[ADDRESS_1009905] ati o ns      
     L u n g I nf e cti o n      
     Ot h er, s p e cif y:   Or al   C a n di di asis       
     S ki n I nf e cti o n      
     Uri n ar y tr a ct i nf e cti o n       
     U p p er r es pir at or y i nf e cti o n       
I nj u r y,  p ois o ni n g,  a n d  p r o c e d u r al c o  m pli c ati o ns      
     Br uisi n g       
     Ot h er, s p e cif y:  S ki n  a br asi o n       
I n v esti g ati o ns     
     A n e  mi a       
     N e utr o p hil  c o u nt  d e cr e as e d       
     Ot h er, s p e cif y:   H e  m at o crit 
d e cr e as e d      
     Pl at el et  c o u nt  d e cr e as e d      
     W hit e  bl o o d  c ell  d e cr e as e d       
M et a b olis  m  a n d  n ut riti o n  dis o r d e rs         
     A n or e xi a       
     H y p o  m a g n es e  mi a       
     H y p o n atr e  mi a       
     H y p o k al e  mi a       
M us c ul os k el et al  a n d  c o n n e cti v e 
tiss u e  dis o r d e rs     
     B a c k  P ai n       
     B o n e  p ai n       
     M y al gi a       
     Ot h er, s p e cif y:   G e n er ali z e d   m us cl e w e a k n ess       
Pr ot o c ol   C L [ADDRESS_1009906] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 8  of  4 3 C  T  C  A  E  v 4  S  O  C/  A  E   N u  m b e r  of  S u bj e cts   E x p e ri e n ci n g   E v e nt   (  %) 
5 0 0  m g     1 0 0   m g    1 5 0 0   m g    T ot al   
     Ot h er, s p e cif y: J oi nt  p ai n i n  hi ps       
N e r v o us s yst e  m  dis o r d e rs       
     Di z zi n ess       
     P ar est h esi a      
     P eri p h er al  S e ns or y   N e ur o p at h y      
R es pi r at o r y,    t h o r a ci c    a n d 
m e di asti n al  dis o r d e rs       
     C o u g h       
     D ys p n e a       
     E pi[INVESTIGATOR_541] a xis      
     L ar y n g e al i nfl a  m  m ati o n      
     N as al   C o n g esti o n       
     Ot h er,    s p e cif y:     R a di ati o n p n e u  m o nitis      
V as c ul a r  dis o r d e rs       
     H y p ot e nsi o n       
     T hr o  m b o e  m b oli c  e v e nt      
 
T a bl e  [ADDRESS_1009907] u d y 
   
 P r ef e r r e d   T e r  m  5 0 0   m g  
(  N  =   X  X)  
n (  %)  1 0 0 0   m g  
(  N  =   X  X)  
n (  %)  1 5 0 0   m g  
(  N  =   X  X)  
n (  %)    P- v al u e  
N u  m b er  of  S u bj e cts r e p orti n g  a d v ers e  e v e nts l e a di n g t o  dis c o nti n u ati o n     x x ( x x x)    x x ( x x x)    x x ( x x x)    x x   [ S yst e  m   Or g a n   Cl ass   Cl ass  # 1]           
  [ Pr ef err e d  T er  m  # 1] x x ( x x x)    x x ( x x x)    x x ( x x x)    x x   
  [ Pr ef err e d  T er  m  # 2] x x ( x x x)    x x ( x x x)    x x ( x x x)    x x   
…           
           
 
  
Pr ot o c ol   C L [ADDRESS_1009908] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  3 9  of  4 3 T a bl e  1 4. 3. 1. 5  S u  m  m ar y  of   A d v ers e  E v e nts  b y   R el ati o ns hi p t o   BI  O  3 0 0 
 
 P r ef e r r e d   T e r  m  R el ati o ns hi p     5 0 0   m g  
(  N  =   X  X)  
n (  %)  1 0 0 0   m g  
(  N  =   X  X)  
n (  %)  1 5 0 0   m g  
(  N  =   X  X)  
n (  %)  
N u  m b er  of s u bj e cts r e p orti n g  a d v ers e  e v e nts     P ossi bl e  
Pr o b a bl e  D efi nit el y   
T ot al  x x ( x x x)  
x x ( x x x)  x x ( x x x)  
x x ( x x x)  x x ( x x x)  
x x ( x x x)  x x ( x x x)  
x x ( x x x)  x x ( x x. x)  
x x ( x x. x)  x x ( x x. x)  
x x ( x x. x)  
 [ S yst e  m   Or g a n   Cl ass   Cl ass  # 1]     
  [ Pr ef err e d  T er  m  # 1]  P ossi bl e  
Pr o b a bl e  D efi nit el y   T ot al  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  
  [ Pr ef err e d  T er  m  # 2] P ossi bl e  Pr o b a bl e  D efi nit el y   
T ot al  x x ( x x x)  
x x ( x x x)  x x ( x x x)  
x x ( x x.)  x x ( x x x)  x x ( x x x)  x x ( x x x)  
x x ( x x.)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  
x x ( x x.)  
 
T a bl e  1 4. 3. 1. 6  S u  m  m ar y  of   A d v ers e  E v e nts  b y  S e v erit y   Usi n g   C T  C  A E   Gr a d e 
   
 P r ef e r r e d   T e r  m  M a xi  m u  m 
G r a d e   5 0 0   m g  
(  N  = 
X  X)    
n (  %)  1 0 0 0   m g  
(  N  = 
X  X)    
n (  %)  1 5 0 0   m g  
(  N  = 
X  X)    
n (  %)  P-
v al u e  
N u  m b er    of    s u bj e cts    r e p orti n g    tr e at  m e nt  -e  m er g e nt 
a d v ers e  e v e nts  Mil d   
M o d er at e   
S e v er e  T ot al  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  x x ( x x x)  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  x x ( x x x)  x x ( x x. x)  
x x ( x x. x)  
x x ( x x. x)  x x ( x x. x)  -- 
-- 
x x  
x x  
 [ S yst e  m   Or g a n   Cl ass   Cl ass  # 1]            
  [ Pr ef err e d  T er  m  # 1]  Mil d   M o d er at e   S e v er e  T ot al  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  --  -- 
x x  x x  
  [ Pr ef err e d  T er  m  # 2] Mil d   M o d er at e   S e v er e  T ot al  x x ( x x x)  x x ( x x x)  x x ( x x x)  
x x ( x x.)  x x ( x x x)  x x ( x x x)  x x ( x x x)  
x x ( x x.)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  
x x ( x x .) --  -- 
x x  x x  
Pr ot o c ol   C L [ADDRESS_1009909] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  4 0  of  4 3 T a bl e  1 4. 3. 1. 7  S u  m  m ar y  of   A d v ers e  E v e nts   wit h  1 0  %  or   Hi g h er I n ci d e nt   R at e 
S u bj e ct  
I  D C  T  C  A  E  v 4  S  O  C     A  E   T e r  m     D os e (  m g)      S e v e rit y 
       
       
       
       
T a bl e  1 4. 3. 2. 1  S u  m  m ar y  of  S eri o us   A d v ers e  E v e nts 
   
 P r ef e r r e d   T e r  m  5 0 0   m g  
(  N  =   X  X)  
n (  %)  1 0 0 0   m g  
(  N  =   X  X)  
n (  %)  1 5 0 0   m g  
(  N  =   X  X)  
n (  %)    P- v al u e  
N u  m b er  of s u bj e cts r e p orti n g s eri o us  a d v ers e  e v e nts     x x ( x x. x)    x x ( x x x)       x x   [ S yst e  m   Or g a n   Cl ass   Cl ass  # 1]           
  [ Pr ef err e d  T er  m  # 1] x x ( x x. x)    x x ( x x x)       x x   
  [ Pr ef err e d  T er  m  # 2] x x ( x x. x)    x x ( x x x)       x x   
…           
           
 
T a bl e  1 4. 3. 2. 2  S u  m  m ar y  of  S eri o us   A d v ers e  E v e nts  b y   R el ati o ns hi p t o   BI  O  3 0 0 
 
 P r ef e r r e d   T e r  m  R el ati o ns hi p     5 0 0   m g  
(  N  =   X  X)  
n (  %)  1 0 0 0   m g  
(  N  =   X  X)  
n (  %)  1 5 0 0   m g  
(  N  =   X  X)  
n (  %)  
N u  m b er  of s u bj e cts r e p orti n g   S eri o us  a d v ers e  e v e nts    P ossi bl e  
Pr o b a bl e  
D efi nit el y   
T ot al  x x ( x x x)  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  x x ( x x x)  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  x x ( x x. x)  x x ( x x. x)  
x x ( x x. x)  
x x ( x x. x)  
 [ S yst e  m   Or g a n   Cl ass   Cl ass  # 1]       
  [ Pr ef err e d  T er  m  # 1]  P ossi bl e  Pr o b a bl e  D efi nit el y   T ot al  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  x x ( x x. x)  
  [ Pr ef err e d  T er  m  # 2] P ossi bl e  
Pr o b a bl e  
D efi nit el y   T ot al  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  
x x ( x x.)  x x ( x x x)  
x x ( x x x)  
x x ( x x x)  
x x ( x x.)  x x ( x x. x)  
x x ( x x. x)  
x x ( x x. x)  
x x ( x x.)  
 
Pr ot o c ol   C L [ADDRESS_1009910] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009911] u d y 
D r u g/  D os e (  m g)  PI 
[INVESTIGATOR_738888] b uti o n   M e di c al   M o nit o r 
Att ri b uti o n   
         
         
         
         
 
T a bl e  [ADDRESS_1009912]   5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  P- v al u e  M e a n     Mi n     M a x     M e a n     Mi n     M a x     M e a n     Mi n     M a x   
H  G  B ( g/ d L)                             
H  C T ( v ol   %)                             
R  B  C (  M/ u L)                             
W  B  C   (  K/ u L)                           
N E # (  K/ u L)                             
L  Y # (  K/ u L)                            
M  O # (  K/ u L)                             
E  O # (  K/ u L)                            
B  A # (  K/ u L)                             
P L T (  K/ u L)                            
Pr ot ei n,  T ot al ( g/ d L)                            
Al b u  mi n ( g/ d L)                             
C  A2 + (  m g/ d L)                           
P  O4 (  m g/ d L)                           
C h ol est er ol (  m g/ d L)                             
T  G (  m g/ d L)                            
Gl u c os e (  m g/ d L)                             
U  A (  m g/ d L)                             
B  U  N (  m g/ d L)                             
Cr e ati ni n e (  m g/ d L)                             
Bilir u bi n, t ot al (  m g/ d L)                             
Al k ali n e  p h os p h at as e (I  U/ L)                             
N a+ (  m  m ol/ L)                           
K+ (  m  m ol/ L)                           
Cl- (  m  m ol/ L)                           
C  O2 (  m  m ol/ L)                           
A S T (I  U/ L)                             
A L T (I  U/ L)                             
A  m yl as e (I  U/ L)                             
Li p as e (I  U/ L)                            
 
 
Pr ot o c ol   C L [ADDRESS_1009913] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  4 2  of  4 3 T a bl e  1 4. 3. 4. 2  S u  m  m ar y  of   A b n or  m al (  Gr a d e  3  or   w ors e)   Cli ni c al  L a b or at or y   V al u es 
S u bj e ct  
I  D C  T  C  A  E  v 4  S  O  C     A  E   T e r  m     D os e (  m g)      S e v e rit y 
       
       
       
       
 
T a bl e  1 4. 3. 4. 3  S u  m  m ar y  of   Uri n al ysis/ Pr e g n a n c y   R es ults 
T est   5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  P- v al u e  M e a n     Mi n     M a x     M e a n     Mi n     M a x     M e a n     Mi n     M a x   
S p e cifi c   Gr a vit y                            
p  H                            
Pr ot ei n (  m g/ d L)                            
Gl u c os e 
(  m g/ d L)                             
K e nt o n es (  m g/ d L)                             
Bl o o d (  m g/ d L)                             
H  C  G (  mI  U/  m L)                             
 
  
Pr ot o c ol   C L [ADDRESS_1009914] a n C o nfi d e nti al 
 
  
 
BI  O  3 0 0  P h as e I/II   N S  C L  C  S  A P  P a g e  [ADDRESS_1009915]   BI  O  3 0 0      
n         
M e a n         
S E        
9 5  %   CI        
C h a n g e fr o  m   B as eli n e t o   BI  O  [ADDRESS_1009916] at e     
n         
M e a n         
S E        
9 5  %   CI        
 
T a bl e  1 4. 3. 5. 2  S u  m  m ar y  of   Vit al  Si g ns 
M e as u r e  m e nt   5 0 0   m g  1 0 0 0   m g  1 5 0 0   m g  
M e a n     M a x     Mi n     M e a n     M a x     Mi n     M e a n     M a x     Mi n   
T e  m p er at ur e ( F)                             
R es pir at or y   R at e                              
H e art   R at e                            
S yst oli c   B P                           
Di ast oli c   B P                            
H ei g ht                            
W ei g ht (l bs)                            
 
 